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ABSTRACT 
Background: Opioids are often used in nursing homes to manage non-malignant pain, 
but little is known about their long-term use, initiation, and comparative safety. 
Methods: We used the Minimum Data Set 3.0 from 2011-2013 merged to Medicare and 
facility characteristics data to study opioid use and safety among older, long-stay 
residents. The specific aims were to examine the 1) prevalence of long-term opioid use; 
2) geographic variation in the initiation of commonly used opioids (oxycodone, 
hydrocodone, tramadol); and 3) comparative safety of commonly used opioids and 
fracture hospitalizations.  
Results: One in seven long-stay residents were prescribed opioids long-term. There was 
extensive geographic variation in the initiation of commonly used opioids, with 
oxycodone (9.4%) initiated less frequently than hydrocodone (56.2%) or tramadol 
(34.5%) but varying most extensively across the United States, with the majority of 
variation in prescribing explained by state of residence. Compared to hydrocodone 
initiators (7.9 fracture hospitalizations per 100-person years), those initiating tramadol 
had lower rates of fracture hospitalizations (subdistribution hazard ratio [HRSD] = 0.67, 
95% Confidence Interval [CI]: 0.56-0.80), whereas oxycodone initiators had similar rates 
of fracture hospitalizations (HRSD=1.08, 95% CI: 0.79-1.48).  
Conclusion: The prevalence of long-term opioid use was twice as common in nursing 
homes as community settings, with initiation patterns varying extensively by region and 
being strongly driven by state of residence. Although initiating tramadol was associated 
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with lower rates of fractures than hydrocodone, questions on opioid risks and benefits 
remain and are especially pertinent given the high mortality rates in this population. 
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CHAPTER I:  
INTRODUCTION 
Pain and pharmacologic pain management in United States (US) nursing homes 
 In United States nursing homes, 35 to 49% of long-stay residents experience 
intermittent or persistent pain.
1–4
 Left untreated or undertreated, pain has distressing and 
far-reaching consequences including dependence in activities of daily living,
5,6
 anxiety,
5,7
 
depression,
5,7–9
 aggressive behavior,
10
 decreased involvement in recreational activities,
8,11
 
and increased healthcare costs.
12,13
 Despite this, pain has been historically undertreated in 
US nursing homes. Many residents receive no analgesics including residents with daily 
malignant pain at admission (1992-1995: 26% of residents;
14
 2006-2007: 17.5%),
15
 daily 
nonmalignant pain at admission (1992-1995: 25.1%),
5
 daily pain at the end of life (1992-
1997: 20.2%),
16
 and persistent nonmalignant pain (1998-2000: 24.5%;
3
 2008: 16.7%).
17
 
Although the prevalence of untreated pain appears to be declining over time with recent 
studies documenting encouragingly lower estimates of administration of no analgesics 
among residents with cancer-related pain at the end of life (2011-2012: 4.0%)
18
 and long-
stay residents with persistent pain (2011-2012: 6.4%),
1
 little is known about the overall 
use and safety of commonly-used pharmacologic pain management strategies – including 
opioids.  
Opioid prescribing among older adults – nationwide and in US nursing homes 
Pain management guidelines specific to older adults (persons ≥65 years old) 
recommend that “all patients with moderate to severe pain, pain-related functional 
impairment, or diminished quality of life due to pain should be considered for opioid 
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therapy.”
13
 However, few studies of opioid effectiveness and safety have included 
nursing home residents,
19–22
 highlighting the “geriatric pharmacoparadox” –we know the 
least about the risks and benefits of medications in persons who need and use them the 
most. Guidelines currently recommend opioids for chronic pain based on their short-term 
effectiveness for managing acute pain and the limited availability of safe and effective 
therapeutic alternatives for pain management.
13,23–25
 Although acetaminophen is the 
recommended first-line medication for pain in older adults,
13
 it may be insufficient for 
adequate pain control, has a maximum daily dose of 4 grams, is contraindicated in 
persons with liver failure, and must be used with caution in persons with hepatic 
insufficiency. Nonsteroidal anti-inflammatory drugs (NSAIDS) are not viable alternatives 
for most older adults due to the potential for increased risk of cardiovascular disease, 
kidney failure, and gastrointestinal events.
24
 Many nonpharmacologic approaches (e.g., 
cognitive behavioral therapy, exercise therapy)
26
 may be ineffective due to the high 
burden of cognitive impairment in this population, as well as being potentially  
impractical (e.g., limited staffing and difficulty billing for services). Thus, in many 
circumstances opioids may be prescribed as the only viable option for pain management 
in older adults living in nursing homes.  
Calls for increased opioid use must however be placed in the context of the 
ongoing US opioid epidemic. From 1999 to 2010, the overall nationwide use of 
prescription opioids quadrupled to more than 240 million prescriptions per year.
27
 This 
skyrocketing in prescription opioid use has been accompanied by an alarming rise in 
opioid misuse and abuse, addiction, and fatal and non-fatal overdoses.
28–30
 In 2015, in 
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response to this growing national epidemic, the Department of Health and Human 
Services (HHS) initiated a multifaceted national campaign to address the root causes of 
opioid abuse.
31,32
 HHS efforts include creating clear opioid prescribing guidelines and 
developing and expanding the evidence base to guide the use of opioid medications to 
treat non-cancer pain.
31
 However, recent federal campaigns addressing the opioid abuse 
epidemic
31,32
 and pain management guidelines
33,34
 have largely ignored – with few 
exceptions
13,25
 – the use and safety of opioids in older adults. Older adults have an 
increased prevalence of pain,
35,36
 use more analgesics,
37,38
 and are at heightened risk for 
opioid overdoses and other adverse outcomes in comparison to younger adults.
13,34,39
 
Further, older adults are not immune to the epidemic of drug-related overdoses; between 
2013 and 2014 Americans ≥65 years old had the third highest relative increase in drug 
overdose deaths behind 25-34 and 35-44 years age groups.
28
 Older adults in medically 
supervised settings such as nursing homes may also be at risk for opioid-related adverse 
events due to suspected medication errors
40,41
 and potentially inappropriate prescribing 
(e.g., the initiation of fentanyl in opioid-naïve residents).
42,43
 Yet, little is known about 
opioid use and safety in this care setting despite increased opioid prescribing among 
those in pain.
3,5,44
  
Nearly two decades ago (1998-2000), 38.4% of nursing home residents 
experiencing persistent nonmalignant pain were treated with opioids,
3
 but more recent 
studies from 2007-2009 found that 69.2-73.2% of US residents in persistent 
nonmalignant pain were prescribed opioids.
17,44
 However, these studies have not 
characterized use in the broader nursing home population (i.e., among all residents vs. 
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restricted to residents in pain) and have rarely described drug regimen-related 
characteristics that may increase the risk of adverse drug events (e.g., falls and 
unintentional overdoses)
24,39,45–49
 including length of use (short-, medium-, or long-term 
use), duration of action used (short- vs. long-acting), prescribed dosage strength, and 
concomitant psychopharmacologic medication use. These drug-regimen-related 
characteristics are important to understand because they may increase the risk of adverse 
drug events including falls and unintentional overdoses in this vulnerable 
population.
24,39,45–49
 
 Although the opioid crisis is nationwide, there is extensive geographic variation in 
opioid prescribing and opioid-related mortality among community-dwelling adults,
50–55
 
raising concerns of inconsistent or inappropriate prescribing practices dependent on 
place. These studies have however provided no information on opioids prescribed within 
nursing homes, raising questions on how opioids are initiated and used within this care 
setting. The type of opioids that residents initiate may impact the quality of pain 
management and risk of adverse events due to differing pharmacologic profiles including 
affinity for mu-opioid receptors, elimination half-lives, and bioavailability affecting time 
to onset of effect, potency, and analgesic duration.
56–58
 Beyond specific opioids initiated, 
the prescribed dosage strength modulates and potentially increases both the analgesic 
effect of opioids and the risk of adverse opioid-related events that exhibit a strong dose-
response relationship (e.g., falls and fractures).
34,58–60
 The extent to which specific 
opioids and prescribed dosage strength initiated geographically vary and potentially co-
vary (i.e., the type of opioid initiated is associated with being prescribed high doses) has 
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implications for both pain management and resident safety and provides further context 
for how opioids are initiated and used in this care setting.  
 Commonly prescribed opioids in nursing homes include hydrocodone, 
oxycodone, and tramadol.
3,44
 Understanding which opioids may be safest to prescribe in a 
frail, elderly population with few pharmacological pain management alternatives may 
inform safer prescribing and lead to better pain management. Many prescribers assume 
that the safety profiles of opioids are interchangeable.
61
 However, the unique 
pharmacologic profiles of these commonly used opioids may explain differences in the 
sedating and constipating effects of different opioids
62–64
 and affect the risk of more 
serious adverse events. In the only study that compared commonly used opioids among 
community-dwelling older adults,
58
 the risk of adverse outcomes within 180 days of 
follow-up – such as fractures – varied by specific opioid initiated (hydrocodone: 26 
fractures per 100 person-years; oxycodone: 25 fractures per 100 person-years, adjusted 
rate ratio [vs. hydrocodone] =1.02, 95% CI: 0.86-1.21; tramadol: 7 fractures per 100 
person-years, adjusted rate ratio [vs. hydrocodone]=0.32, 95% CI: 0.25-0.40). This 
suggests that different opioids may have different comparative safety profiles. However, 
this study has not been replicated; had limited information on potential confounders 
including pain frequency and severity, cognitive impairment, and activities of daily 
living; and may not be generalizable to nursing home residents who are on average older 
with more comorbidities, mobility issues, and potentially inappropriate medication use.
65–
70
 Comparative safety studies focusing on commonly initiated opioids among nursing 
home residents are needed.  
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Specific aims 
 This dissertation uses recent (years 2011-2013), comprehensive, national data to 
describe and evaluate opioid use and safety among older adults who were long-stay 
residents living in US nursing homes. The specific aims of this dissertation were: 
Aim 1. To evaluate the prevalence of overall and long-term opioid use: 
 Estimate the prevalence of overall and long-term opioid use 
 Describe and characterize patterns of opioid use, other 
pharmacologic/nonpharmacologic pain management, and potentially 
contraindicated medication use  by length of opioid use 
 Describe variation in long-term opioid use by key resident factors including age, 
gender, race/ethnicity, cognitive impairment, and physical functioning. 
Aim 2. To examine geographic variation in the initiation of commonly used opioids: 
 Describe geographic variability in the initiation of commonly used opioids 
(oxycodone, hydrocodone, tramadol) and prescribed dosage strength 
 Quantify the observed geographic variation in opioid prescribing across hospital 
referral regions after accounting for differences in resident characteristics, facility 
characteristics, and state of residence 
 Examine and contrast the strength of clustering in opioid prescribing practices 
within states versus within hospital referral regions. 
 Estimate the extent to which type of opioid initiated was associated with dosage 
strength prescribed 
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Aim 3. To examine the association between the initiation of commonly used opioids 
(oxycodone, hydrocodone, tramadol) and risk of hospitalization for major fractures. 
Overview of study population and data sources 
 Our study population of interest was Medicare beneficiaries who were long-stay 
residents in Medicare- or Medicaid-certified nursing homes (~96% of US nursing 
homes). We focused on long-stay residents because they generally require long-term 
assistance to manage their chronic comorbidities and declining physical functioning in 
comparison to short-stay residents who primarily receive rehabilitative care.
71
 We 
excluded residents <65 years old because we were specifically interested in describing 
opioid use and safety among older adults.
13
 Additionally, residents with cancer or those 
receiving hospice care were excluded because they have differing pain management 
guidelines in comparison to those with nonmalignant pain.
25,34,72,73
 Additional exclusion 
criteria were applied to each specific aim to increase the validity of our results and are 
detailed in later chapters. 
 This dissertation used routinely-collected, federally-required administrative and 
claims data from Centers for Medicaid and Medicare Services (CMS) during 2011-2013. 
Resident-level data included the Minimum Data Set (MDS) 3.0 merged to Medicare 
enrollment (Master Beneficiary Summary File [MBSF]), hospitalization (Part A), 
outpatient (Part B; available for 2011 only), and pharmacy (Part D) files. Resident data 
were linked using a unique encrypted beneficiary identifier. Facility-level data included 
Certification and Survey Provider Enhanced Reporting (CASPER) data and Nursing 
Home Compare data
74
 were merged to resident data using unique facility provider 
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numbers. Geographic data on hospital referral regions (HRRs) were merged to facility 
and resident data using a publically available ZIP code to HRR crosswalk.
75
 Each of the 
eight data sources is described further below: 
MDS 3.0 (2011-2013): The MDS 3.0 is a federally required clinical assessment of all 
residents in Medicare or Medicaid certified nursing homes. It has been in effect since 
October 2010 and uses measures with documented validity and reliability.
76–78
 
Assessments contain more than 400 items and are administered by registered nurses who 
review resident medical records and interview residents (when possible), resident proxies 
(e.g., family members), and direct care staff to provide a comprehensive picture of 
resident health status including pain, mood, cognitive functioning, physical functioning, 
psychosocial wellbeing, mood state, disease diagnoses, symptoms, health conditions, and 
medication use. Comprehensive assessments occur at admission, annually, and whenever 
there is a significant change in clinical status. Condensed quarterly assessments (with a 
subset of items) are administered at 90 day intervals between full assessments. We used 
the MDS 3.0 for all three study aims.  
MBSF (2011-2013): The MBSF is an annual file with one record per Medicare 
beneficiary that provided detail on beneficiary demographics, date of death during the 
study period (validated by Social Security Administration Files), and monthly indicators 
of whether the resident was enrolled in Medicare Part A/B/D and Medicare Advantage. 
The MBSF was used for all three aims. 
Medicare Part A (2011-2013): Part A provides health services claims for 
hospitalizations and skilled nursing facility stays of eligible Medicare beneficiaries 
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during the study period. Each claim includes dates or periods of service, diagnosis codes, 
and charges and/or payments. Diagnoses and procedures are coded to the International 
Classification of Disease, 9th Revision, clinical modification (ICD-9 CM) and/or to the 
Current Procedural Terminology, 4
th
 edition (CPT-4). We used Part A claims to assess 
fracture and fall hospitalizations and to determine prior skilled nursing facility and 
hospitalization stays for aim 3. 
Medicare Part B (2011): Part B provides outpatient claims of all eligible Medicare 
beneficiaries submitted on CMS-1500 claims. Claims are predominantly submitted from 
non-institutional providers (e.g., physicians, physician assistants, nurse practitioners) and 
free-standing facilities including ambulance providers, laboratories, and emergency 
departments. Claims include information on diagnosis and procedure codes using ICD-9 
CM, CPT-4, or Healthcare Common Procedure Coding System (HCPCS) codes; dates of 
service; and reimbursement amounts. Part B claims were used to characterize resident 
comorbidities and emergency department use for aim 2. 
Medicare Part D (2011-2013): Part D provides information on prescription claims 
submitted to CMS during the study period. Part D claims include information on unique 
National Drug Codes (NDCs), date dispensed, days’ supply, drug name, strength, and 
dosage form. Part D claims were used in all three aims to identify prescribed opioids, 
alternative pain medications and pain adjuvants, and potential confounders (aim 3).  
CASPER (2011-2013): State surveyors conduct federally-required onsite evaluations of 
nursing homes at least every 15 months or when complaints have been filed. CASPER is 
a repository of this survey data and provides information on nursing home characteristics, 
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health inspections, and facility-aggregated patient characteristics. Facility administrators 
provide information about ownership, size, certification, special services, and information 
about the case-mix of residents. For all aims, we used CASPER data to exclude certain 
facilities primarily serving different patient populations (e.g., provider based facilities). 
For aim 2, we used CASPER to characterize facility characteristics.  
Nursing Home Compare (2011): Nursing Home Compare is a quality rating system 
designed for future residents and their caregivers to find and compare different Medicare- 
and Medicaid certified nursing homes. Nursing Home Compare uses aggregated MDS 
and CASPER assessments to rate each nursing home between one (lowest quality) and 
five (highest quality) stars. Facilities have an overall five-star rating but are also 
separately rated on health inspections, staffing, and quality measures. These data were 
used to characterize facility quality for aim 2. 
ZIP code to HRR crosswalk (2011): The ZIP code to HRR crosswalk provided by the 
Dartmouth Atlas Project links geographic data on the hospital referral region in which 
each facility is located to other resident and facility data sources.
75
 A HRR (N=306) is a 
regional healthcare market containing at least one hospital that performs neurosurgery 
and major cardiovascular procedures; HRRs can cross state lines and are commonly used 
in studies of geographic variation in medication prescribing.
54,79,80
 For aim 2, these data 
were used to examine geographic variation across HRRs.
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CHAPTER II:  
PREVALENCE OF LONG-TERM OPIOID USE IN LONG-STAY NURSING 
HOME RESIDENTS 
 
ABSTRACT 
 Background/Objectives: Overall and long-term opioid use among older adults have 
increased since 1999. Less is known about opioid use in older adults in nursing homes 
(NHs). 
Design: Cross-sectional.  
Setting: U.S. NHs (N=13,522) 
Participants: Long-stay NH resident Medicare beneficiaries with a Minimum Data Set 
3.0 (MDS) assessment between April 1, 2012, and June 30, 2012, and 120 days of 
follow-up (N=315,949) 
Measurements: We used Medicare Part D claims to measure length of opioid use in the 
120 days from the index assessment (short-term: ≤30 days, medium-term: >30-89 days, 
long-term: ≥90 days), adjuvants (e.g., anticonvulsants), and other pain medications (e.g., 
corticosteroids). MDS assessments in the follow-up period were used to measure 
nonpharmacologic pain management use. Modified Poisson models were used to estimate 
adjusted prevalence ratios (aPR) and 95% confidence intervals (CI) for age, gender, 
race/ethnicity, cognitive and physical impairment and long-term opioid use. 
Results: Of all long-stay residents, 32.4% were prescribed any opioid, and 15.5% were 
prescribed long-term. Opioid users (versus nonusers) were more commonly prescribed 
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pain adjuvants (32.9% vs. 14.9%), other pain medications (25.5% vs. 11.0%), and 
nonpharmacological pain management (24.5% vs. 9.3%). Long-term opioid use was 
higher in women (vs. men, aPR: 1.21, 95% CI: 1.18-1.23) and lower in racial/ethnic 
minorities (non-Hispanic blacks vs. whites, aPR: 0.93, 95% CI: 0.90-0.94) and those with 
severe cognitive impairment (vs. no or mild impairment, aPR: 0.82, 95% CI: 0.79-0.83). 
Conclusion: One in 7 NH residents was prescribed opioids long-term. Recent guidelines 
on opioid prescribing for pain recommend reducing long-term opioid use, but this is 
challenging in NHs because residents may not benefit from nonpharmacological and 
nonopioid interventions. Studies to address concerns of opioid safety and effectiveness 
(e.g., on pain and functional status) in NHs are needed. 
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INTRODUCTION 
 In the United States, prescription opioid use quadrupled to >240 million 
prescriptions annually from 1999-2010.
27
 At the same time, rates of opioid misuse, abuse, 
addiction, and fatal and non-fatal overdoses increased for both younger and older 
adults.
28,29,81,82
 In response to this epidemic, the Centers for Disease Control and 
Prevention (CDC) released guidelines for managing chronic pain that caution against 
opioid use and warn that the benefits for improving pain and function must outweigh the 
risks when prescribing opioids.
34
 The short-term effectiveness of opioids for pain 
management has been documented.
23,83
 However, no study has demonstrated that long-
term opioid use (≥3 months) is effective while many studies document risks (e.g. falls, 
fractures, overdoses).
20
 Despite this, use of opioids long-term has increased in 
community-dwelling older adults.
38,53
 To our knowledge, no studies have described long-
term opioid use in older adults living in nursing homes. 
 Managing pain in nursing homes is challenging, and this care setting has a 
documented history of undertreating pain.
1,3,15,17
 Prescribers must balance the risks 
associated with untreated/undertreated pain (e.g., dependence in activities of daily living, 
anxiety, depression)
5,6,8
 with potential risks of opioids. Opioids are prescribed to 60% of 
nursing home residents in persistent pain.
17,44
 Elderly nursing home residents may be 
uniquely vulnerable to the sedating side effects of opioids (even at therapeutic doses) and 
adverse drug events due to their older age, frailty, and high burden of comorbidities and 
polypharmacy in comparison to community-dwelling elders.
70,84–86
 Yet, little is known 
about how opioids and concurrent pharmacologic/nonpharmacologic therapies for pain 
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are currently being used in nursing homes despite the potential harms associated with 
long-term opioid use.
20,34
 
 To date, opioid prescribing guidelines and national campaigns have largely 
focused on younger adults and community-dwelling elders and may not be applicable to 
nursing home residents despite the burden of pain and extensive analgesic use in this 
population.
13,32–34
 We conducted a study to: 1) estimate the prevalence of overall and 
long-term opioid use; 2) describe patterns of opioid and other 
pharmacologic/nonpharmacologic pain management by length of opioid use; and 3) 
describe variation in long-term opioid use by key resident factors. 
METHODS 
Study Design and Data Sources 
This cross-sectional study (approved by the University of Massachusetts School 
Internal Review Board) used routinely-collected, federally-required administrative data 
from 2012 of all nursing home residents in Medicare- and/or Medicaid-certified nursing 
homes (the Minimum Data Set [MDS] 3.0; covering ~96% of US nursing homes) merged 
to facility characteristics data (Certification and Survey Provider Enhanced Reporting) 
and pharmacy claims (Medicare Part D). The MDS 3.0 is a standardized assessment 
conducted by trained, registered nurses with 400+ items including medical conditions, 
cognitive/physical functioning, and pain/pain management.
76–78
 Based on medical record 
review and interviews with staff and direct caregivers, assessments are conducted at 
admission and quarterly thereafter. Measures have demonstrated validity and reliability 
(Κ≥0.78 for pain management measures).
76
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Study Sample 
 Our cohort included Medicare beneficiaries who were long-stay residents (>100 
consecutive days in nursing home) and had a MDS assessment between 4/1/2012-
6/30/2012 (n=602,122). The first eligible assessment was selected. Long-stay residents 
were included because they generally require extensive, long-term assistance from 
nursing homes to manage their chronic disabilities.
71
 After restricting to those ≥65 years 
of age without a cancer diagnosis or receiving hospice care, 315,949 residents met 
inclusion/exclusion criteria applied for practical purposes (e.g., missing data; see Figure 
2.1). 
Opioid Use 
We were conceptually interested in opioid use during 120 days of follow-up 
(starting at index date), which we operationalized using Medicare Part D claims. Part D 
claims provided information on the generic drug name (used to identify opioids), 
prescription fill date, days’ supply, dosage form, and dosage strength. Opioids were 
classified by their duration of action (short- vs. long-acting). The number of prescribed 
opioids during the 120 days of follow-up was calculated. Dosage form was categorized as 
oral, injection, transdermal, or other.  
We estimated cumulative days of opioid use during the 120 day study period 
based on opioid prescription fill dates plus days’ supply, assuming that the opioid was 
used on the fill date and daily for as long as the medication was prescribed.
87
 We 
assumed that residents with overlapping opioid prescriptions (e.g., filling a second opioid 
prescription with ≥1 day of opioid use still remaining from the previous prescription) 
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used both medications simultaneously as prescribed. We categorized opioid use as long-
term (≥90 days cumulative use during the 120 days)
45,88
, medium-term (31-89 cumulative 
days), and short-term (1-30 days). We categorized the average daily dose in oral 
morphine equivalents (OME) using recent CDC guidelines as <50 mg, 50-89 mg, and 
≥90 mg OME/day.
34,89
 
Part D claims provide no information on the administration of pain medications. 
Although not specific to opioids, MDS assessments during follow-up (items J0100A and 
J0100B) were used to broadly describe pain management regimens in the preceding five 
days as scheduled and/or pro re nata (PRN). 
Pain Management and Other Medications 
Part D claims provided information on the total number of nonopioid medications 
and alternative analgesics or pain adjuvants prescribed during the 120 day follow-up. 
Nonopioid pharmacotherapies included prescribed nonsteroidal anti-inflammatory agents 
(NSAIDS; excluding aspirin). The American Geriatrics Society (AGS) 2009 guidelines
13
 
were used to identify pain adjuvants and other medications used for pain.  
MDS assessments during the follow-up provided information on potentially 
contraindicated psychopharmacologic medication use in the 7 days preceding the MDS 
(anxiolytics, hypnotics).
34
 We used the MDS because benzodiazepines were not covered 
by Part D in 2012. We also measured the percentage of residents receiving ≥2 
antipsychotics, anxiolytics, and/or hypnotics because concurrent use of ≥2 central 
nervous system-active medications with opioids can increase the risk of falls/fractures 
beyond opioid use alone.
20,24
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Guidelines recommend that persons prescribed opioids receive 
nonpharmacological interventions.
34
 MDS 3.0 item J0100C documented receipt of 
nonpharmacologic pain management in the 5 days before the assessment.
76
 
Resident Characteristics 
Age, gender, race/ethnicity, and cognitive/physical impairment have been 
documented to influence opioid use.
1,3,5,14,15,17
 Age (65-74 years, 76-84 years, ≥85 years), 
gender, race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic/Latino, Asian, 
other), physical impairment, and cognitive impairment came from the MDS. Physical 
impairment was measured using the MDS Activities of Daily Living (ADL) scale.
90
 
Cognitive impairment was classified using CMS definitions.
2
 We also evaluated 
persistent pain (defined as pain with a duration ≥3 months),
13
 and intermittent pain.
1
 We 
considered resident characteristics that may be potential confounders including length of 
nursing home stay (<1 year, 1-2 years, 2-3 years, ≥3 years), marital status (married vs. 
other), comorbidities known to cause pain (e.g., arthritis, fractures), and total comorbidity 
burden (based on MDS 3.0 Section I; categorized into quartiles). 
Analysis 
 Descriptive statistics summarized 1) variation in resident characteristics by age 
group; 2) medication use and characteristics of use by length of opioid use during follow-
up; and 3) length of opioid use by resident characteristics. Modified Poisson models with 
robust variance estimation (using generalized estimating equations and exchangeable 
correlation structure) were used to estimate crude and adjusted prevalence ratios (aPR) 
with 95% confidence intervals (CI) for key resident characteristics and long-term opioid 
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use.
91
 Adjusted analyses included nursing home state and all resident characteristics. We 
conducted analyses restricted to those in persistent pain to provide further information on 
this vulnerable subgroup and to compare our results to prior studies.
1,3,17
 
 In supplemental analyses, we estimated the prevalence of any opioid use in those 
who were censored (excluding those who died or received hospice care) to examine 
whether and to what extent selection bias was introduced by requiring residents to have 
120 days of available follow-up in the same facility. 
RESULTS 
 The mean age of long-stay residents was 84.4 years (standard deviation [SD]: 
8.7); the majority were women (76.2%), non-Hispanic white (80.6%), with a median 
length of stay of 2.1 years (interquartile range [IQR]: 1.3–3.6; see Table 2.1). Most 
residents were moderately or severely physically and/or cognitively impaired, with higher 
prevalence of severe cognitive impairment and dementia in older age groups. More than 
40% of residents had ≥7 comorbidities, and painful comorbidities including arthritis 
(32.8%; more prevalent in older groups), anxiety (25.8%), depression (54.5%), and 
diabetes (31.6%; more prevalent in younger groups) were common. Persistent pain and 
intermittent pain occurred in 15.5% and 16.1% of residents, respectively. 
Thirty-two percent were prescribed any opioids during the 120 day follow-up 
period, with 10.4%, 6.5%, and 15.5% of all participants prescribed opioids for short-, 
medium-, and long-term (Table 2.2). The most common opioids were hydrocodone 
(52.6%; see Appendix 2.1 for further detail), tramadol (31.8%), fentanyl (12.5%) and 
oxycodone (11.8%). The majority of short-term (99.0%), medium-term (94.5%) and 
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long-term opioid users (65.7%) were prescribed short-acting opioids only. Long-term 
opioid users were prescribed more long-acting opioids (34.1% of long-term vs. 1.0% of 
short-term users) and had higher average daily doses (16.0% of long-term had average 
daily dose ≥90 mg OME/day vs. 3.3% of short-term). The majority of opioid 
prescriptions were oral formulations, though nearly one-quarter of long-term users 
received transdermal prescriptions (fentanyl). The majority of long-term users received 
scheduled analgesics (97.0%) with 29.5% receiving PRN analgesics. Scheduled analgesic 
use was lower for short-term (scheduled: 43.5%, PRN: 42.0%) and medium-term users 
(scheduled: 77.6%, PRN: 47.6%). 
The median number of unique nonopioid medications prescribed during 120 days 
was 12 in opioid users (IQR: 8-16) and 9 in non-users (IQR: 6-12). When examining 
other medications used during follow-up (Table 2.2), 16.1% of residents prescribed 
opioids had stand-alone prescription NSAIDS claims versus 8.4% of non-users. Pain 
adjuvants (32.9% of opioid users) and other medications used for pain (25.5% of opioid 
users) appeared more than twice as common in opioid users versus non-users. 
Anxiolytics/hypnotics were more common in opioid users than non-users (31.6% vs. 
17.5%), as were ≥2 psychopharmacologics (13.1% vs. 8.0%).See Appendix 2.2 for 
specific medications. 
Nine percent, 19.8%, 26.0%, and 25.4% of non-, short-term, medium-term, and 
long-term opioid users received nonpharmacological pain management, respectively. 
Women (vs. men; overall: 34.1% vs. 26.8%; long-term: 16.7% vs. 11.6%, non-
Hispanic whites (vs. non-Hispanic blacks; overall: 33.9% vs. 27.3%; long-term: 16.6% 
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vs. 11.7%), those with no/mild cognitive impairment (vs. severe impairment; overall: 
44.5 vs. 25.4%; long-term: 21.9% vs. 12.1%), and those in persistent pain (vs. no pain; 
overall: 69.8% vs. 20.5%; long-term: 35.6% vs. 9.6%) appeared to have greater overall 
opioid and long-term opioid use (Figure 2.2).  
Table 2.3 shows that resident factors associated with increased prevalence of 
long-term opioid use included being severely physically impaired (vs. no/mild 
impairment; aPR: 1.25, 95% CI: 1.22–1.28) or a woman (vs. men; aPR: 1.21, 95% CI: 
1.18–1.23). Prevalence of long-term use was lower in racial/ethnic minorities (vs. non-
Hispanic whites): non-Hispanic blacks (aPR: 0.93 95% CI: 0.90–0.95), Hispanics (aPR: 
0.84, 95% CI: 0.80–0.88), Asians (aPR: 0.69, 95% CI: 0.61–0.77), and other (aPR: 0.89, 
95% CI: 0.80–0.99). Prevalence of long-term opioid use was lower in those with 
moderate to severe cognitive impairment (severe vs. no/mild; aPR: 0.82, 95% CI: 0.79–
0.83). When restricting to residents in persistent pain, adjusted prevalence ratios were 
qualitatively similar albeit attenuated for gender and physical impairment (Appendix 
2.3).  
In supplemental analyses of opioid use in those excluded due to censoring other 
than death or hospice, overall opioid use was higher than in our analytic sample (41.8% 
vs. 32.4%). Incorporating those who were censored into our estimate of the prevalence of 
any opioid use would have shifted our results from 32.4% to 33.7%. 
DISCUSSION 
 We found that nearly one-third of long-stay residents in 2012 were prescribed 
opioids during the 120 day follow-up, with 1 in 7 residents prescribed opioids long-term. 
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We identified interesting patterns of nonopioid analgesics, adjuvants, and 
nonpharmacologic pain management use in opioid users and non-users that begin to fill 
knowledge gaps in nursing home resident pain management. Although we reported a 
lower prevalence of persistent pain than older studies,
3,92
 the extent to which this is due to 
the opioids, other medications, or methodologic differences cannot be disentangled.
1
 
Given no studies demonstrate the long-term effectiveness of opioids and concerns that 
nursing home residents may be more vulnerable to adverse side effects of opioids,
20,70,84–
86
 our findings inform discussions about improving opioid use with other pain 
management strategies in nursing homes.  
 The high prevalence of long-term opioid use in nursing homes is more than 
twofold the prescribing seen in community-dwelling older adults.
38,53
 This may be 
warranted due to residents’ pain/painful comorbidity burden and the historical 
undertreatment of pain in this care setting,
1,3,5,14,15,17
 which has distressing consequences 
including poor quality of life, decreased physical functioning, anxiety, and depression.
5,6,8
 
Similar to community-dwelling populations, most residents received only short-acting 
opioids.
93
 This may be insufficient for managing chronic pain, which may require 
scheduled, long-acting opioids for adequate pain management.
13
 However, the risks of 
opioid use are not adequately understood, as few studies of opioid effectiveness and 
safety have examined nursing home residents.
19,20
 The high frequency of fentanyl 
initiation in opioid-naïve residents also raises concerns of suboptimal opioid 
prescribing.
43,94
 In community-dwelling populations, opioids have been linked to falls, 
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fractures, overdoses, and all-cause mortality; further work is needed to characterize risks 
in nursing home residents.
20,34
    
Our findings suggest that increased use of nonopioid analgesics and 
nonpharmacologic pain management may be potential areas for improvement in nursing 
homes, though these recommendations are not without limitations.
13,34
 Nonopioid 
medications used for pain are recommended as the first line treatment for chronic 
nonmalignant pain and can be concurrently used with opioids to provide potentially 
greater benefits to residents.
34
 We found that pain adjuvants/other medications for pain 
were only prescribed to approximately half of opioid users during follow-up. Whether 
this is appropriate remains unclear because these agents also have potential risks. For 
example, NSAIDS are known to be associated with hepatic, gastrointestinal, renal, and 
cardiovascular events in older adults and may not be appropriate opioid substitutes.
13,24
 
AGS and CDC guidelines recommend nonpharmacologic pain management, which can 
be combined with opioid therapy to provide potentially greater pain relief to 
residents.
26,34
 We found that nonpharmacologic therapies were used in only one-quarter 
of opioid users. Although we could not ascertain specific nonpharmacologic interventions 
used with the MDS 3.0, common approaches in nursing homes include bio-feedback, 
applying heat/cold, massage, physical therapy, nerve block, stretching/strengthening 
exercises), and electrical stimulation.
95
 Their use – along with other nonopioid analgesics 
– are associated with short-term benefits and lower risks than opioids,
34
 but may have 
limited applicability to cognitively impaired residents and may be difficult to implement 
given nursing home staffing and reimbursement constraints.  
Chapter II 23 
 
 
 
 
 We noted several potentially modifiable risk factors for opioid prescribing, 
particularly in long-term users. Long-term users had higher daily doses than short- and 
medium-term users. Although long-term users may need higher doses due to increased 
opioid tolerance, many adverse events linked to opioids are dose-dependent,
20
 and the 
CDC prescribing guidelines recommend reassessing individual risks and benefits at doses 
≥50 OME/day and avoiding or carefully justifying doses ≥90 OME/day.
34
 Opioid users 
had a high prevalence of anxiolytic/hypnotic use. Direct measurement of benzodiazepines 
was not possible because they were not covered by Part D. Yet, before Part D, 
benzodiazepine use was more common than other anxiolytics/hypnotics in nursing 
homes.
96
 Benzodiazepines should never be co-prescribed with opioids,
34
 though further 
work is needed to evaluate this issue. Finally, 13% of opioid users received ≥2 
medications known to increase the risks of falls/fractures during follow-up 
(antipsychotics, anxiolytics, and/or hypnotics).
24
 When possible, prescribers should 
optimize concurrent psychopharmacologic use to address concerns of drug-drug 
interactions and the co-occurrence of anxiety and depression with pain, which can 
interfere with pain management.
24,34
 Although reductions in antipsychotic use have 
occurred since 2012, antipsychotics, anxiolytics and hypnotics remain commonly 
used.
97,98
  
 Findings that long-term opioid use was higher in women, non-Hispanic whites, 
those with severe physical impairment, and those with no/mild cognitive impairment are 
consistent with prior studies examining the correlates of untreated or undertreated 
persistent pain in long-stay residents.
1,17
 Contrasting with prior studies,
1,17
 we did not 
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observe a strong relationship between age and opioid use, perhaps due to the higher 
burden of certain painful comorbidities (e.g., arthritis) in those ≥85 years old, though 
caution is warranted when using opioids long-term in this population due to residents’ 
increased frailty. Identifying whether some residents are more susceptible to opioid-
related adverse events is warranted.  
 This study has several strengths and limitations. The national MDS 3.0 data 
linked to Part D claims provided national, comprehensive information on long-stay 
residents who were Medicare beneficiaries. We provided detailed information on opioid 
use not previously examined including specific opioids used, dosage strength, and length 
of opioid use over 120 days of follow-up. We characterized nonopioid pharmacologic 
alternatives for pain, nonpharmacologic pain management, and concurrent 
psychopharmacologic medication use. While the data are from 2012, they provide an 
important, more recent snapshot on opioid prescribing during the height of the opioid 
epidemic.
1,17,81
 Although we had loss to follow-up by requiring residents to be in the 
nursing home for 120 days, the sensitivity analysis suggests our estimates may be 
conservative because those lost to follow-up had higher opioid use. We recognize that 
classifying opioid use by cumulative number of days discarded important information on 
patterns of opioid use. We believe this affected our results focusing on long-term opioid 
use minimally. Operationalizing medication use through Part D claims may overestimate 
opioid use if medications were not used by residents; multiple opioid claims among those 
prescribed opioids suggest that this issue may be minimal. We cannot know from Part D 
claims how medications were administered, though data from MDS assessments show 
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that most long-term opioid users received scheduled analgesics. We have limited 
information on indications for medication use, resulting in potential misclassification 
(e.g., medications classified as pain adjuvants when they are prescribed for other 
indications). We could not evaluate over-the-counter medications from Part D (e.g., over-
the-counter NSAIDS). No information on resident or staff pain management preferences 
was available.  
 In conclusion, long-term opioid use in older nursing home residents is twice as 
prevalent than in community settings.
53
 Cautious and consistent monitoring of opioid 
doses, optimizing concurrent psychopharmacologic medications, and increasing use of 
nonopioid analgesics and adjuvants and nonpharmacologic interventions when 
appropriate may be warranted to improve the quality opioid use in nursing homes. 
Interventions to improve opioid prescribing should incorporate complex systems 
approaches that engage all providers including physicians, nurses, pharmacists, and other 
staff to improve opioid prescribing (e.g., through education, increased use of alternatives, 
and adverse event monitoring).
99
 Comparative effectiveness studies that focus on 
physical functioning, pain control, quality of life endpoints, and comparative safety 
studies of opioids in nursing homes could help healthcare providers, residents, and their 
families make informed decisions on opioid use.  
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Table 2.1: Characteristics of long-stay nursing home residents who were Medicare beneficiaries 
in 2012, overall and stratified by age (N=315,949). 
    Stratified by age in years  
 Characteristic, %
1
 
 Overall 
(N=315,949) 
 65-74 years 
(n= 50,005) 
 75-84 
years 
(n=95,297) 
 ≥85 years 
(n=170,647) 
Women  76.2  55.5  70.8  85.3 
Race/ethnicity         
   Non-Hispanic white  80.6  73.2  77.3  84.6 
   Non-Hispanic black  12.6  19.4  14.5  9.5 
   Hispanic / Latino  4.7  5.5  5.8  3.9 
   Asian  1.5  1.2  1.6  1.5 
   Other  0.6  0.8  0.8  0.5 
Married  15.7  18.6  21.1  11.8 
Length of nursing home stay         
   <1 year  17.2  17.9  18.6  16.2 
   1-2 years  31.1  31.7  32.5  30.1 
   2-3 years  19.4  18.2  19.4  19.9 
   >3 years  32.3  32.3  29.6  33.8 
Physical impairment
2
         
   Moderate  50.9  46.6  49.2  53.2 
   Severe  25.5  24.3  26.4  25.4 
Cognitive impairment
3
         
   Moderate  29.4  29.2  29.8  29.3 
   Severe  44.7  29.8  42.1  50.6 
 Comorbidities          
   Arthritis  30.5  20.6  27.6  35.0 
   Osteoporosis  19.5  11.6  16.6  23.4 
   Hip fracture  1.1  0.5  1.0  1.3 
   Other fracture  1.6  1.1  1.4  1.7 
   Diabetes  31.6  42.6  37.7  24.9 
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    Dementia  64.5  45.7  64.5  70.0 
   Parkinson’s  7.2  7.7  9.4  5.9 
   Pressure ulcers  3.0  3.2  3.0  2.9 
   Anxiety   25.8  26.9  27.0  24.7 
   Depression  54.5  57.2  56.9  52.5 
   Asthma, COPD,  chronic lung 
failure 
 18.3  22.6  19.8  16.2 
   Respiratory failure  0.6  1.3  0.6  0.3 
   Renal failure  7.8  8.0  7.8  7.8 
>8 total  comorbidities
4
  19.1  21.0  20.7  17.8 
Pain duration
5 
        
   Intermittent pain  16.1  15.7  16.0  16.2 
   Persistent pain  15.5  18.4  16.4  14.1 
Abbreviations: BIMS: Brief Interview for Mental Status; COPD: chronic obstructive pulmonary disease; CPS: Cognitive Performance 
Scale; MDS: Minimum Data Set. 
1Columns may not add up to 100% due to rounding 
2Defined using the MDS ADL Self-Performance Hierarchy Scale (range 0-7): None/mild (0-2), moderate (3-4), severe (5-6) 
3Defined using the BIMS (range 0-15) or CPS (range 0-7): no/mild impairment (BIMS 13-15 or CPS 0-2), moderate (BIMS 8-12 or CPS 
3-4), severe (BIMS 0-7 or CPS 5-6) 
4Total comorbidity burden was defined by summing all comorbidities in MDS 3.0 section I on index assessment and categorizing into 
quartiles. Only top quartile is displayed. 
5Defined as any self-reported or staff-assessed pain on both the index MDS assessment and a preceding MDS assessment (90 +/- 20 days 
before the index assessment) 
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Table 2.2: Characteristics of opioids, nonopioid pharmacologic alternatives, and potentially contraindicated 
psychopharmacologic medications prescribed during 120 days of follow-up in long-stay nursing home 
residents in 2012 (N=315,949). 
    Length of opioid use
2
 
Medication use during follow-up
1 
 No opioid use 
(n=213,652) 
 Short-term 
(n=32,841) 
 Medium-term 
(n=20,615) 
 Long-term 
(n=48,841) 
Opioid use
3
         
Median number opioid claims, 
(IQR) 
 -  1 (1-2)  5 (3-7)  6 (5-10) 
Duration of action         
   Short-acting only  -  99.0  94.5  65.7 
   Long-acting only  -  0.6  1.8  12.5 
   Short- and long-acting  -  0.4  3.6  21.8 
Average daily dose (in oral 
morphine equivalents)
4 
        
   <50 mg /day  -  78.4  77.2  68.1 
   50-89 mg /day  -  18.4  19.0  15.9 
   ≥90 mg /day  -  3.3  3.8  16.0 
Dosage form
5 
        
   Oral  -  99.5  98.8  91.5 
   Injection  -  0.2  0.1  0.1 
   Transdermal  -  0.7  3.6  24.3 
   Other  -  0.01  0.0  0.0 
Nonopioid pharmacologic alternatives          
Standalone prescription NSAIDS  8.4  15.3  17.5  16.0 
Any pain adjuvants and/or other  
medications used for pain
6
 
 23.4  41.4  50.3  50.3 
Pain adjuvants   14.9  27.6  34.7  35.7 
Anticonvulsants  9.7  19.7  25.5  25.4 
Antidepressants
 
 6.4  11.6  15.6  17.1 
 Other medications used for pain  11.0  21.8  27.4  27.2 
Corticosteroids  6.5  11.2  13.1  12.2 
Muscle relaxants  2.7  6.6  9.1  9.6 
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Transdermal Lidocaine  2.4  6.2  9.2  9.5 
Potentially contraindicated 
medication use
7
 
        
   Any anxiolytic or hypnotic use  17.5  27.6  35.5  32.7 
   ≥2 antipsychotic, anxiolytic 
and/or hypnotic
7
 
 8.0  11.5   14.8  13.5 
Abbreviations: ER: extended release; IQR: interquartile range; PRN: pro re nata; NSAIDS: nonsteroidal anti-inflammatory 
agents 
1
Numbers are percentages unless otherwise noted. Percentages may not add up to 100% due to rounding 
2
Based on MDS assessments during follow-up, prevalence of scheduled and PRN analgesics use varied by short- (scheduled: 
43.5%, PRN: 42.0%), medium- (scheduled: 77.6%, PRN: 47.6%) and long-term users (scheduled: 97.0%, PRN: 29.5%). 
3
Short-acting opioids included codeine, dihydrocodeine, hydrocodone, hydromorphone, meperidine, morphine, nalbuphine, 
oxycodone, oxymorphone, pentazocine, tapentadol, and tramadol. Long-acting opioids included buprenorphine, butorphanol, 
transdermal fentanyl, hydromorphone extended release (ER), methadone, morphine ER, oxycodone ER, oxymorphone ER, 
tapentadol ER, and tramadol ER 
4
Calculated by estimating average daily dose of each unique opioid prescription, converting each prescription to oral morphine 
equivalents, summing the oral morphine equivalents for all prescriptions, and dividing by the estimated cumulative days of 
opioid use.  
5
Percentages add up to >100% because some participants used multiple opioids with different dosage forms 
6
Antidepressents commonly used as adjuvants included desipramine, nortriptyline, amitriptyline, duloxetine, venlafaxine and 
milnacipran.
13
 Anticonvulsants included carbamazepine, gabapentin, lamotrigine, pregabalin. Corticosteroids included 
dexamethasone, prednisone, prednisolone, and methylprednisolone. Muscle relaxants included baclofen, carisoprodol, 
chlorzoxazone, cyclobenzaprine, dantrolene, metaxolone, methocarbamol, orphenadrine, and tizanidine. 
7
Defined using the Minimum Data Set during 120-day follow-up (excludes the index MDS assessment). 
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Table 2.3: Association between resident characteristics and long-term opioid use 
(N=315,949). 
Characteristic 
 Long-term 
opioid use, 
% 
 
Crude PR 
(95% CI) 
 
Adjusted PR
1
 
(95% CI) 
Age, years       
   65-74  16.5  Referent  Referent 
   75-84  15.7  0.93 (0.91–0.95)  0.97 (0.95–1.00) 
   ≥85  15.0  0.88 (0.86–0.90)  0.94 (0.92–0.97) 
Gender       
   Men  11.6  Referent  Referent 
   Women  16.7  1.40 (1.37–1.43)  1.21 (1.18–1.23) 
Race/ethnicity       
   Non-Hispanic White  16.6  Referent  Referent 
   Non-Hispanic Black  11.7  0.77 (0.75–0.80)  0.93 (0.90–0.95) 
   Hispanic/Latino  9.4  0.69 (0.66–0.73)  0.84 (0.80–0.88) 
   Asian  6.4  0.51 (0.46–0.57)  0.69 (0.61–0.77) 
   Other  12.6  0.81 (0.72–0.90)  0.89 (0.80–0.99) 
Cognitive Impairment       
   No/mild   21.9  Referent  Referent 
   Moderate  15.0  0.69 (0.68–0.71)  0.89 (0.87–0.91) 
   Severe  12.1  0.56 (0.54–0.57)  0.82 (0.79–0.83) 
Physical impairment       
   No/mild  15.8  Referent  Referent 
   Moderate  15.1  0.95 (0.93–0.97)  1.04 (1.02–1.06) 
   Severe  15.9  1.04 (1.02–1.07)  1.25 (1.22–1.28) 
Abbreviations: CI: confidence interval; PR: prevalence ratio 
1
Prevalence ratios were estimated using modified Poisson models (using generalized estimating equations to 
account for clustering within nursing homes).
91
 Models are adjusted for all resident characteristics in Table 1 
and state of residence. 
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Figure 2.1: Selection of participants into study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: CASPER, Certification and Survey Provider Enhanced Reporting; OME, oral morphine equivalents; 
SNF, skilled nursing facilities
602,122 long-stay Medicare beneficiaries 
with an assessment in the target period 
(April 1, 2012 – June 30, 2012) and 
meeting Medicare eligibility criteria 
579,559 long-stay Medicare beneficiaries 
in target period meeting study design 
criteria 
Excluded:  
54,981 <65 years old 
33,940 cancer diagnosis 
35,082 receiving hospice care 
338 comatose 
21,742 missing data  
165 
Excluded:  
20,417 no prior assessment 90 +/- 20 days 
before index assessment 
2,146 no comprehensive MDS assessment 
within 365 days of index assessment 
 
Excluded:  
11,164 living in facilities with no available 
CASPER data within 15 months of 04/01/12 
19,331 living in provider-based facilities  
4,068 living in free-standing SNFs 
313 living in small facilities (<20 beds) 
544,683 long-stay Medicare beneficiaries 
in target period meeting study design / 
facility requirements 
398,600 long-stay Medicare beneficiaries 
meeting design/facility/initial 
requirements at index  
Excluded:  
25,870 died in follow-up 
5,918 received hospice in follow-up 
42,340 discharged to hospital 
6,214 discharged to other locations 
1,926 Medicare eligibility changes 
383 implausible doses (>400 mg OME/day) 
315,949 long-stay Medicare beneficiaries 
with 120 days of available follow-up and 
in final analytic sample 
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Figure 2.2: Crude prevalence of short-, medium-, and long-term opioid use by age, 
gender, race/ethnicity, cognitive impairment, physical impairment, and pain 
duration for long stay nursing home resident in 2012 (N=315,949). 
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Chapter III: 
GEOGRAPHIC VARIATION IN THE INITIATION OF COMMONLY USED 
OPIOIDS AND DOSAGE STRENGTH IN UNITED STATES NURSING HOMES  
 
ABSTRACT 
Objectives: To examine and quantify geographic variation in the initiation of commonly 
used opioids and prescribed dosage strength among older United States nursing home 
residents. 
Methods: We merged 2011 Minimum Data Set 3.0 to Medicare claims and facility 
characteristics data to conduct a cross-sectional study among long-stay nursing home 
residents who initiated short-acting opioids commonly used in nursing homes 
(oxycodone, hydrocodone, or tramadol). We examined geographic variation in specific 
opioids initiated and potentially inappropriate doses (≥50 mg oral morphine equivalents 
[OME]/day) across hospital referral regions (HRR). Multilevel logistic models quantified 
the proportional change in between-HRR variation and associations between commonly-
initiated opioids and inappropriate doses after adjusting for resident characteristics, 
facility characteristics, and state. 
Results: Oxycodone (9.4%) was initiated less frequently than hydrocodone (56.2%) or 
tramadol (34.5%) but varied dramatically between HRRs (range: 0-74.5%; most 
frequently prescribed in HRRs within the Northeast). In total, resident/facility 
characteristics and state of residence respectively explained 84.1%, 58.2%, 59.1%, and 
46.3% of the between-HRR variation for initiating oxycodone, hydrocodone, tramadol, 
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and inappropriate doses. In all cases, state explained the largest proportion of between-
HRR variation. Initiating oxycodone vs. hydrocodone (adjusted odds ratio (aOR) =5.00, 
95% Confidence Interval (CI): 4.57-5.47) or tramadol vs. hydrocodone (aOR=0.28, 95% 
CI: 0.25-0.31) was associated with being prescribed inappropriate doses. 
Conclusions: We documented extensive geographic variation in the opioid and dose 
initiated for nursing home residents, with state explaining the largest proportion of the 
observed variation. Further work is needed to understand potential drivers of opioid 
prescribing patterns at the state level.  
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INTRODUCTION 
During the last two decades, prescription opioid use in the United States (US) – 
along with opioid misuse, abuse, and overdose – dramatically increased in younger and 
older adults.
27,28,81
 The nationwide opioid crisis may be of particular importance in 
nursing homes, where pain has traditionally been undertreated and long-term opioid use 
is two-fold the prevalence documented in older community-dwelling adults.
3,14,100
 
Nationally, extensive geographic variation in opioid prescribing and opioid-related 
mortality exists, raising concerns about inconsistent and potentially inappropriate 
prescribing dependent on place.
50–55
 However, the extent to which opioid use varies 
geographically among older adults living in US nursing homes is unknown.  
Opioids are often the preferred approach to pain management for nursing home 
residents due to the limited availability of safe, effective, and practical alternatives.
13,24
 
Despite this, little is known about the initial choice of opioids prescribed in this setting, 
and specifically whether there is a preference for short-acting formulations of oxycodone, 
hydrocodone, or tramadol, the 3 drugs that comprise 90% of short acting opioid use in the 
nursing home setting.
100
 Initial opioid selection may impact the quality of pain 
management and risk of adverse events due to differing pharmacokinetic and 
pharmacodynamic profiles (e.g., mu-opioid receptors affinity, elimination half-lives, and 
bioavailability).
56–58
 In addition, little is known about initial choice of prescribed dosage 
strength, which is important because this modulates and potentially enhances both the 
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beneficial analgesic effects and the risk of adverse opioid-related events (e.g., 
fractures).
34
  
The extent to which opioid selection and starting dose vary and potentially co-
vary may have implications for both the quality of pain management and resident safety. 
Therefore, we conducted this study to understand the overall patterns and magnitude of 
geographic variability in the initiation of commonly used opioids and prescribed dosage 
strength across states and hospital referral regions (HRRs). We then sought to quantify: 
1) the extent to which variation across HRRs could be explained by resident 
characteristics, facility characteristics, and state; 2) the strength of clustering in opioid 
prescribing practices within states versus within HRRs; and 3) whether the initial opioid 
choice was associated with differences in dosage strength in terms of oral morphine 
equivalents (OME).  
METHODS 
Study design and data sources 
 This study was approved by the University of Massachusetts Institutional Review 
Board. Using a cross-sectional study design, nursing home residents “entered” the study 
on the prescription fill date of their first opioid initiation episode (described further 
below). The data to identify and characterize residents was drawn from four data sources 
from 2011: the Minimum Data Set (MDS) 3.0, Medicare (eligibility, Part B, Part D), the 
Certification and Survey Provider Enhanced Reporting (CASPER), and Nursing Home 
Compare. The MDS is a federally-required assessment that is conducted by nurses who 
Chapter III 37 
 
 
 
 
interview residents (when possible), resident proxies (e.g., family members), and direct 
care staff to provide information on residents’ pain, cognitive and physical functioning, 
mood, comorbidities, and other measures.
76–78
 Assessments occur at admission, quarterly, 
and whenever there is a clinical change in status. Medicare Part B was used to 
operationalize painful comorbidities recorded in outpatient claims. Part D provided 
information on opioids and other prescribed medications. We used CASPER, a repository 
for federally mandated nursing home surveys, to provide information on facility 
characteristics (e.g., number of beds). Nursing Home Compare, a system developed for 
consumers to find and compare the quality of nursing homes, provided information on 
facility quality ratings.
74
 
Study sample 
 Shown in Figure 3.1, we included long-stay nursing home residents (≥90 
consecutive days in the same facility) who were ≥65 years old and initiated a commonly-
used opioid (oxycodone, hydrocodone, tramadol).
100
 We focused on long-stay residents 
because they generally require long-term assistance to manage their chronic 
comorbidities.
71
 Our cohort had to have 90 days of Medicare eligibility within 2011 (Part 
A/B/D coverage; no Medicare Advantage) before initiating a study drug to distinguish 
between incident and prevalent opioid use. Initiation was defined using Part D claims as 
being prescribed a study opioid with no opioid prescription claim in the preceding 90 
days.  
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We excluded residents who were hospitalized or received care covered by 
Medicare Part A during 2011 in the 90 days preceding initiation because medications 
received during these stays would predominantly be bundled into the Part A per diem 
rate; therefore, opioid prescriptions during this time would not appear as a Part D claim. 
We excluded: residents with no MDS assessment in the 90-day lookback period; those 
living in facilities with no recent CASPER data; residents living in standalone skilled 
nursing facilities or provider-based facilities; those with cancer or receiving hospice care 
in the year before initiation; those who were comatose; those with any missing data; those 
initiating implausibly high doses (>180 mg OME/day); and those living in small 
geographic areas (states/districts with <50 residents or hospital referral regions with <30 
residents). The final sample size was 62,889 residents. 
Opioid Use 
Commonly used opioids were short-acting, oral formulations of oxycodone 
(oxycodone, oxycodone/acetaminophen, oxycodone/nonsteroidal anti-inflammatory drug 
[NSAID]), hydrocodone (hydrocodone/acetaminophen, hydrocodone/NSAID), or 
tramadol (tramadol, tramadol/acetaminophen). These medications are used by >90% 
residents prescribed opioids and may be interchangeably used in nursing homes.
100
 From 
medications dispensed on the index date, we estimated the average daily dose in OME. 
See Appendix 3.1 for further detail on OME conversion factors and study/non-study 
opioids).
101
 We categorized residents prescribed doses ≥50 mg OME/day as receiving 
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potentially inappropriately high doses based on recommendations for opioid-naive 
patients.
34
  
Geographic Variation 
 We first examined geographic variation across US states. We then grouped 
residents into HRRs because prior studies show substantial variation within-states and 
across healthcare markets.
54,79,80
 A HRR can cross state lines and represents a regional 
healthcare market containing at least one hospital that performs neurosurgery and major 
cardiovascular procedures.
75,102
  
Resident characteristics 
 We identified the most recent 2011 MDS assessment in the 90 days preceding 
opioid initiation to characterize resident demographics (age, gender, race/ethnicity), 
cognitive impairment (none/mild, moderate, severe),
2
 physical limitations (none/mild, 
moderate, severe),
90
 pain (none, self-reported, or staff-assessed; within the five days 
preceding the MDS assessment) and dementia. 
 We used Part B claims from the 90 days preceding initiation to describe painful 
comorbidities including injuries, pressure ulcers, diagnosed chronic pain, abdominal pain, 
musculoskeletal pain, and neuropathic pain (see Appendix 3.2 for International 
Classification of Diseases, ninth revision, clinical modification codes used to classify 
these conditions); whether residents had any emergency department visits; and number of 
Part B claims. 
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 Part D claims from the 90 days before opioid initiation were used to classify any 
prescribed psychopharmacologic medications that may increase the risk of adverse events 
(antidepressants, antipsychotics) or pain adjuvants (NSAID, anticonvulsants, 
corticosteroids, muscle relaxants) that may affect type of opioid initiated.
13,34
 Because 
benzodiazepines were not covered by Part D in 2011, we used the resident’s MDS 
assessment before opioid initiation to classify receipt of any anxiolytic or hypnotic 
administered in the seven days before the assessment.   
Facility characteristics 
 Nursing home facility characteristics are associated with quality of care and may 
affect prescribing.
103,104
 Using CASPER and Nursing Home Compare, we included the 
following variables: rural location, facility size, ownership, whether the facility was part 
of a chain, occupancy, proportion of residents within the facility receiving skilled care, 
proportion of residents with facility-acquired bed sores, proportion of residents 
restrained, and quartile indicators of the number of minutes per resident day of nursing 
home staff including registered nurses, physicians, and physician extenders, and overall 
five-star rating for nursing home quality measures. See Appendix 3.3 for further detail 
on how variables were categorized. 
Analysis 
We first conducted crude and stratified descriptive analyses of resident and 
facility characteristics by opioid initiated. We then categorized the proportion of residents 
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initiating different opioids and doses ≥50 mg OME/day into quartiles and generated US 
maps to visually examine the geographic variation in prescribing by HRR.  
We were interested in understanding whether the variation in prescribing 
observed across HRRs could be explained by resident characteristics, facility 
characteristics, and state of residence. Thus, we fit multilevel logistic models for each 
commonly used opioid versus other study opioids (e.g., initiating oxycodone vs. 
hydrocodone or tramadol) and measured between-HRR variation by incorporating HRRs 
into the model as random intercepts. We then sequentially fit 4 models for each opioid 
initiated: 1) null model with only random intercepts for HRRs; 2) adjustment for resident 
characteristics; 3) adjustment for resident and facility characteristics; and 4) adjustment 
for resident characteristics, facility characteristics and state.
105
 Since HRRs can cross 
state lines (Figure 3.2), we fit cross-classified multilevel logistic models with separate 
random intercepts for HRRs and states for the final model.
106
 For adjusted models, we 
estimated the proportional change in cluster variation (PCV) to quantify the proportion of 
between-HRR variation that can be explained by covariates in the model. For example, if 
adjusting for resident characteristics resulted in a PCV of 10.0% for a specific prescribing 
practice, we would conclude that 10.0% of the geographic variation was due to 
differences in resident characteristics between HRRs. 
We estimated intraclass correlation coefficients (ICC) for all models to 
understand the strength of clustering within HRRs (ICCHRR). The ICCHRR measures the 
correlation among two persons chosen at random from within the same HRR.
105
 As the 
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ICC increases from 0 towards 1, it indicates that residents within the same HRR have an 
increased propensity to be prescribed the same opioid. For cross-classified models, we 
decomposed the variance to separately estimate ICCHRR (i.e., the ICC among persons in 
the same HRR but different states) and ICCstate, measuring the strength of clustering for 
persons in the same states but different HRRs.  
To quantify the PCV and ICCs in those initiating doses ≥50 mg OME/day versus 
lower doses, we used the same sequential multilevel modeling strategy as above. To 
additionally examine the association between specific opioids initiated and prescribed 
dosage strength, we fit a separate fully adjusted cross-classified model that included 
specific opioid initiated to estimate adjusted odds ratios (aOR) and 95% confidence 
intervals (CI). Hydrocodone was chosen as the reference because it was the most 
commonly initiated study drug. See Appendix 3.4 for an extended discussion of our 
multilevel modelling approach. 
RESULTS 
In 2011, 62,889 long-stay residents initiated opioids (oxycodone: 9.4%; 
hydrocodone: 56.2; tramadol: 34.5%). These residents lived within 12,345 nursing homes 
(median residents per home: 4, 25
th
-75
th
 percentile: 2-7) nested within 298 HRRs (of 306 
HRRs; median facilities per HRR: 29, 25
th
-75
th
 percentile: 16-49); 113 HRRs crossed 
state lines.   
Overall, 53.0% of residents were ≥85 years old, 75.8% were women, and 82.3% 
were non-Hispanic white (Table 3.1; see Appendix 3.3 for further description of resident 
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and facility characteristics). Nearly 40% and 21.5% had severe cognitive and physical 
limitations, respectively. One-third of residents had self-reported or staff-assessed pain, 
with three-quarters of residents having recorded diagnoses of painful comorbidities from 
Part B claims. Most residents lived in for-profit facilities (73.1%) with 57.4% being in 
facilities that were part of a chain. 
When stratifying by opioid initiated, those initiating tramadol were more 
commonly women and ≥85 years old compared to the other initiators. Oxycodone 
initiators had a lower prevalence of severe cognitive impairment and more self-reported 
pain on the MDS, as well as painful comorbidities documented in Part B claims than 
other initiators. Oxycodone initiators were less commonly in facilities that were rural; 
part of a chain; <80% occupancy; or in the lowest quartiles of registered nurse, physician, 
and physician extender staffing relative to other opioid initiators.   
Several patterns emerged when examining the crude proportion of specific 
opioids initiated by HRR. The top quartile of oxycodone initiating HRRs was largely 
concentrated in Northeast states, which contained 18 of the top 20 prescribing HRRs 
(Figure 2.3, Panel A). Nationally, the proportion of residents initiating oxycodone 
ranged from 0% (in 28 different HRRs) to 74.5% in Manhattan, New York (5
th
-95
th
 
percentile, 0-34.7%). Oxycodone was rarely initiated in HRRs within Texas. 
Alternatively, the top quartile of hydrocodone initiating HRRs largely extended across 
the middle of the continental US, with prescribing ranging from 3.5% (Bronx, New York) 
to 90.2% in Redding, California (5
th
-95
th
 percentile, 23.9-81.1%; Figure 2, Panel B). 
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Tramadol initiation was largely concentrated in Midwest states, Florida, Maryland, and 
northern New England states (Figure 2, Panel C), ranging from 5.8% (Alameda County, 
California) to 72.1% in Salisbury, Maryland (5
th
-95
th
 percentile, 12.0%-53.8%).   
The overall proportion of residents initially prescribed doses ≥50 mg OME/day 
was 6.7% with substantial geographic variation (Figure 3). The top quartile of initiators 
prescribed doses ≥50 mg OME/day was largely concentrated in western US states. 
However, many HRRs throughout the continental US were in the highest quartile of 
prescribing, and overall, the practice ranged from 0.0% (4 different HRRs) to 27.6% 
(Boise, Idaho; 5
th
-95
th
 percentile, 1.6-14.4%). See Appendix 3.5 for further detail on 
prescribed opioid and dosage strength by state. 
Resident and facility characteristics explained 7.8%, 1.4%, -2.4% (i.e., an increase 
in variance), and 8.6% of between-HRR variation for initiating oxycodone, hydrocodone, 
tramadol, and doses ≥50 mg OME/day, respectively (Table 3.2). For initiating 
oxycodone or doses ≥50 mg OME/day, facility characteristics explained a larger 
proportion of between-HRR variation than resident characteristics. In all cases, adjusting 
for state of residence resulted in large reductions in between-HRR variation for 
oxycodone (PCV=84.1%), hydrocodone (PCV=58.2%), tramadol (PCV=59.1%), and 
initiating doses ≥50 mg OME/day (PCV=46.3%). In fully adjusted cross-classified 
models, the propensity to initiate oxycodone was more strongly correlated among two 
residents in the same state but different HRRs (ICCstate=0.24) than among residents 
within the same HRR but different states (ICCHRR=0.06). These patterns were similar but 
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less pronounced for the propensity to initiate hydrocodone (ICCstate=0.09; ICCHRR=0.07) 
and tramadol (ICCstate=0.09; ICCHRR=0.04). For initiating doses ≥50 mg OME/day the 
ICCs were similar (ICCstate=0.03; ICCHRR=0.03). In general, resident and facility 
characteristics were weakly associated with opioid or dose initiated, with >85% of the 
adjusted odds ratios between 0.80-1.20 (See Appendix 3.6 for further detail on the 
estimated variance components). 
In fully adjusted cross-classified models that included study drug initiated, being 
prescribed oxycodone versus hydrocodone was associated with increased odds of being 
prescribed doses ≥50 mg OME/day (aOR=5.00, 95% CI: 4.57-5.47). Initiating tramadol 
versus hydrocodone was inversely associated with higher doses (aOR=0.28, 95% CI: 
0.25-0.31). 
DISCUSSION 
 We found that overall opioid initiation practices among long-stay nursing home 
residents during 2011 differed from what has been documented in community-dwelling 
populations,
107,108
 with substantial geographic variation in initiating specific opioids and 
potentially inappropriate doses. In multilevel models, state of residence explained the 
largest proportion of variation between HRRs, with most opioid prescribing practices 
more strongly clustered within state than within HRR. Most resident and facility 
characteristics were weakly associated with prescribing practices in adjusted models. 
Initiating potentially high inappropriate doses of opioids was associated with choice of 
starting oxycodone or tramadol versus hydrocodone.  
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Overall, opioids initiated in nursing homes differ from community settings. 
Although hydrocodone is initiated similarly across settings,
107,108
 tramadol was prescribed 
to 34.5% of initiators in nursing homes versus 8.7% and 20.2% of commercially insured 
and Medicare Advantage initiators, respectively.
108
 Conversely, oxycodone was 
prescribed less frequently to nursing home residents initiating opioids (9.4%) compared 
to 17-18.8% of commercially insured and 16.6% of Medicare Advantage initiators.
107,108
 
It is unclear how these differences in prescribing affect pain management and safety in 
nursing homes because most studies exclude nursing home residents and/or compare 
opioids to placebo rather than conducting head-to-head comparisons of different 
opioids.
23,58,64,109
 
That 1) clustering was stronger within states than HRRs and 2) states explained 
the majority of variation in opioid prescribing practices across HRRs suggests that factors 
unique to states and external to HRRs and nursing homes – including laws, policies, and 
regulations – are strong drivers of how opioids are initiated in this setting. Laws and 
policies that may have affected prescribing include the implementation of prescription 
drug monitoring programs, prescription limits restricting the quantity of opioids that can 
be dispensed, requirements for physician examinations before opioid prescribing, patient 
identification requirements, pain clinic regulations, and doctor shopping restrictions.
110
 
These laws drastically increased during 2010-2011
111
 and may have affected older 
nursing home residents even if they were not the primary target of such legislation, as 
most overdose deaths occur in those <65 years old.
28
 However, our results must be 
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interpreted cautiously, as it was beyond the scope of the current study to examine the role 
of specific state policies on opioid prescribing.  
We found that the proportion of opioid initiators prescribed oxycodone varied 
more widely between HRRs than other study drugs, with similar geographic patterns 
documented in younger disabled Medicare beneficiaries.
54
 This may be because 
oxycodone was the only schedule II drug during 2011 and would have been uniquely 
affected by state laws such as triplicate prescribing programs which are present in low 
oxycodone prescribing states such as Texas and California. However, there may be 
additional important state differences in the number, type, and enforcement of laws 
intended to curb opioid prescribing. For example, among younger commercially insured 
adults, rescheduling hydrocodone from schedule III to schedule II in 2014 resulted in a 
larger reduction of hydrocodone prescribing in Texas than in other states.
112
 It is unclear 
if such legislative changes had the same impact on nursing home residents.  
Differences in case-mix between HRRs explained little of the observed variation, 
suggesting that resident characteristics had limited influence on the type and dose of 
opioid initiated. We are uncertain if such observations are unique to nursing homes 
because multilevel models have not been used to quantify variation of opioid initiation in 
other studies. In some cases (being prescribed oxycodone or potentially inappropriate 
doses), facility characteristics explained a larger proportion of the observed variation than 
resident characteristics. Facility characteristics may affect prescribing directly (e.g., 
increased staffing leading to fewer residents initiating inappropriate doses due to 
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increased oversight) or indirectly through their influence on organizational culture 
including the shared behaviors, beliefs, values, and assumptions of each facility.
113,114
 
Further work is needed, but targeting facility culture may be important for improving 
opioid prescribing. 
Overall, residents initiating opioids had a relatively low prevalence of potentially 
inappropriate doses (6.7%) in nursing homes compared to commercially insured (19.9%) 
and Medicare Advantage populations (17.0%).
107
 That residents predominantly “start 
low” may be unsurprising given the high prevalence of frailty and concerns of adverse 
drug events in nursing homes.
69,115
 Dose also exhibited less clustering within HRRs and 
states compared to initiating specific opioids, suggesting that the chosen dose may be less 
regionally driven than the specific opioid initiated. However, overall geographic patterns 
of residents initiating higher doses were in many ways similar to patterns documented in 
community-dwelling adults.
50,52,54
 Within the same state and HRR, initiating oxycodone 
was strongly associated with being prescribed potentially inappropriate doses whereas 
tramadol was strongly inversely associated with higher doses. These findings may be 
driven by differences in opioid potency,
89
 though further contextualizing the relationship 
between specific opioids and doses is warranted given that many adverse opioid-related 
events are dose-dependent.
34
 
National efforts to reduce opioid prescribing must not forget that nursing homes 
have historically undertreated resident pain
3,14
 and have only recently shown potential 
improvements.
1
 In this setting, opioids may often be appropriate because older residents 
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have a high burden of painful comorbidities and lack safe and effective pharmacologic 
and non-pharmacologic alternatives.
13,100
 Further, nursing homes are medically 
supervised settings where resident access to medication is mediated through staff, which 
may limit the risk of adverse opioid-related events. Broader national policy changes must 
consider this vulnerable population so that the pendulum does not swing back towards 
undertreating pain. 
The strengths of this study include focusing on opioid initiation in an important, 
understudied population; the national, comprehensive data on facility and resident 
characteristics; and using multilevel models to examine geographic variation. There are 
also limitations. Data are from 2011, and opioid legislation is rapidly changing. However, 
we believe it is unlikely that the strong geographic variation observed in this study could 
dissipate so rapidly. We had limited data on physician characteristics and their 
contribution to prescribing variation, though we did consider physician staffing as a 
facility characteristic. Part B claims provided limited information on severity of painful 
comorbidities. Yet, we were able to supplement these measures with data from the MDS 
3.0, including any self- or staff-reported pain, which are not available in traditional 
claims-based analyses. We assumed that medications were used as prescribed. This is a 
common assumption
107,108
 but may overestimate our potentially inappropriate dose 
findings if many initiators use opioids as needed. We did not examine the effects of 
specific state policies. Given our limited follow-up and cross-sectional study design, it 
was beyond the scope of the current study to examine the influence of state policies. 
Further work is needed. 
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 Our findings call attention to the complex geographic variation observed by type 
and dose of opioid initiated in older nursing home residents. The largest driver of 
observed variation was state of residence, suggesting that state laws, policies, and 
regulations play the largest role in how opioids are initiated in this setting, though further 
work is needed to understand how specific laws may affect prescribing in nursing homes. 
Finally, although the specific opioid initiated was strongly associated with dose and 
higher doses are associated with increased risks in community dwelling adults,
34
 few 
studies have examined opioid effectiveness and safety in nursing homes, and further 
work is needed in these areas to guide clinical decision making. 
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Table 3.1: Individual characteristics of long-stay residents initiating opioids in 2011, overall and stratified 
by opioid initiated (N=62,889 residents in 12,345 facilities within 298 hospital referral regions). 
    Stratified by opioid initiated 
Characteristic
1
, % 
 Overall 
(N=62,889) 
 Oxycodone 
(n=5,891) 
 Hydrocodone 
(n=35,326) 
 Tramadol 
(n=21,672) 
Resident characteristics         
≥85 years  53.0  48.6  51.1  57.2 
Women  75.8  73.0  74.3  79.1 
Race/ethnicity         
   Non-Hispanic white  82.3  80.3  82.1  83.2 
   Non-Hispanic black  11.7  13.7  11.7  11.1 
   Hispanic/Latino  4.5  4.6  4.5  4.6 
   Other  1.5  1.4  1.7  1.1 
Physical limitations
2
         
   Moderate  50.7  52.9  50.5  50.4 
   Severe  21.5  25.3  21.9  20.0 
Cognitive impairment
3
         
   Moderate  31.5  31.5  31.5  31.5 
   Severe  39.5  34.4  40.6  39.2 
Psychopharmacologic medications
4
         
   Antidepressants  62.3  64.9  63.1  60.4 
   Antipsychotic  27.5  24.5  28.3  26.9 
   Antianxiety   21.3  20.5  22.0  20.4 
   Hypnotics  6.5  6.7  6.7  6.1 
Other medications prescribed for pain
4
         
   Anticonvulsants  15.5  19.5  15.7  13.9 
   Corticosteroids  7.2  7.8  7.1  7.1 
   Muscle relaxants  4.1  5.1  4.3  3.6 
   Nonsteroidal anti-inflammatory drugs  11.6  10.7  11.2  12.6 
Pain recorded on Minimum Data Set
5
         
   Any self-reported pain  28.8  33.4  28.6  28.0 
   Any staff-assessed pain  4.2  4.6  4.5  3.6 
Painful comorbidities
5,6
         
   Any injury
 
(excludes poisonings)  18.3  22.6  19.0  15.8 
   Pressure ulcers  7.4  11.3  7.2  6.5 
   Diagnosed chronic pain  2.7  4.0  2.5  2.6 
   Abdominal pain  5.5  7.2  5.2  5.3 
   Musculoskeletal pain  64.0  67.5  62.6  65.4 
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   Neuropathic pain  7.3  8.2  7.3  6.9 
Any emergency room use  16.2  18.0  17.7  13.3 
Facility characteristics         
Rural location  31.6  19.1  33.6  31.9 
≥200 beds  11.0  21.3  9.3  11.0 
For profit ownership  73.1  68.2  75.0  71.3 
Part of a chain  57.6  49.6  59.1  57.3 
<80% occupancy  26.4  16.0  28.4  25.9 
<10% of facility receiving skilled nursing care  35.6  34.3  37.1  35.6 
1 star nursing home compare quality rating  9.4  8.0  10.0  8.7 
≥5% of residents have facility-acquired bed sores
7
  19.2  17.4  19.7  18.8 
≥5% of residents restrained
7
  20.5  19.8  21.6  19.1 
<27.3 registered nurse minutes per resident day
7
  27.9  17.2  30.1  28.1 
<0.3 physician minutes per resident day
7
  25.9  20.1  26.5  26.4 
No physician extender minutes per resident day
7
   57.5  51.5  58.6  57.3 
1Column percentages may not add to 100% due to rounding. 
2Physical limitations were defined using the Activities of Daily Living Self-Performance Hierarchy (range: 0-6) to categorize residents as having no/mild (0-2), 
moderate (3-4), or severe limitations (5-6).  
3Cognitive impairment was defined using the Brief Interview for Mental Status (BIMS; range: 0-15) when the resident could self-report and the Cognitive Performance 
Scale (CPS; range: 0-6) otherwise: none/mild (BIMS 13-15 or CPS 0-2), moderate (BIMS 8-12 or CPS 3-4) or severe impairment (BIMS 0-7 or CPS 5-6). 
4Subcategories are not mutually exclusive and may add to >100%. 
5Derived from the most recent Minimum Data Set assessment preceding opioid initiation. 
6Based on Part B claims from the 90 days prior to opioid initiation (see Appendix 3.2 for further information on definitions used).  The total number of Part B claims 
(median and interquartile range [IQR]) varied by opioid initiated: hydrocodone (8, IQR: 5-14), oxycodone (11, IQR: 6-18), tramadol (8, IQR: 5-13). 
7Only lowest staffing quartile shown. See Appendix 3.3 for cutoffs of other quartiles. 
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Table 3.2: Measuring the proportion change in between-HRR variation explained by resident 
characteristics, facility characteristics, and state and the strength of clustering within HRRs and state for 
initiating commonly used opioids or doses ≥50 mg OME/day (N=62,889 residents in 12,345 facilities within 
298 hospital referral regions).
1 
  Characteristics included in multilevel model
2
 
  Null model  Resident  Resident + Facility   Resident + Facility + State 
Initiating oxycodone          
   PCV
3
  Referent  1.3%  7.8%  84.1% 
   ICCHRR
4
  0.37  0.36  0.35  0.06 
   ICCstate
5
  -  -  -  0.24 
Initiating hydrocodone
6
         
   PCV  Referent  -2.0%  1.4%  58.2% 
   ICCHRR  0.16  0.17  0.16  0.07 
   ICCstate  -  -  -  0.09 
Initiating tramadol
6
         
   PCV  Referent  -3.8%  -2.4%  59.1% 
   ICCHRR  0.10  0.10  0.10  0.04 
   ICCstate  -  -  -  0.09 
Initiating doses ≥50 mg OME/day         
   PCV  Referent  1.4%  8.6%  46.3% 
   ICCHRR  0.06  0.07  0.06  0.03 
   ICCstate  -  -  -  0.03 
Abbreviations: HRR, hospital referral region; ICC, Intraclass correlation coefficient; OME; oral morphine equivalent; PCV, proportional change in 
cluster variation 
1See Appendix 3.4 for further detail on multilevel model building. 
2Multilevel logistic models with a random intercept for hospital referral region were sequentially fitted using resident and facility characteristics as 
described in Appendix 3.3. The final model was a cross-classified multilevel model including a second random intercept for state.  
3PCV described the proportional change in HRR variation explained by the multilevel model and was estimated as (variance of random intercept in null 
model – variance of random intercept in adjusted model) / variance of random intercept in null model. 
4ICCHRR estimates the correlation in the propensity to initiate the same opioid or dose between two individuals randomly selected from each HRR. The 
ICCHRR for the final model is an estimate of the correlation between two persons in the same HRR but different states. 
5ICCstate was estimated using a cross-classified logistic model and estimates the correlation in the propensity to initiate the same opioid or dose between 
two individuals in the same state but different HRRs.  
6Adding resident and facility characteristics to this model increased the variance. This can occur when there is negative correlation between the opioid 
initiated and resident/facility factors within HRRs.116 
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Figure 3.1: Selection of participants into study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
923,511 long-stay nursing home residents 
who had ≥3 months of Medicare coverage 
(Part A/B/D) in 2011 
113,161 long-stay Medicare beneficiaries 
initiating a study drug 
Excluded:  
8,353 <65 years old 
5,215 cancer diagnosis 
4,490 receiving hospice care 
47 comatose 
4,912 missing data  
73 Initiating doses >180 mg OME/day 
169 residents living in 54 facilities in 
states/districts with <50 residents (Alaska, 
Washington DC) or 7 HRRs with <30 
residents 
 
Excluded:  
19,015 recent hospitalizations or skilled 
nursing facility care in 90-day lookback 
period 
3,903 no prior MDS assessment  
2,991 living in 544 provider-based facilities 
634 living in 263 freestanding SNFs 
470 living in 100 facilities with no recent 
CASPER data 
86,148 long-stay Medicare beneficiaries 
initiating study drug and meeting study 
design / facility criteria 
62,889 long-stay Medicare beneficiaries 
(in 298 HRRs) initiating study drug. 
    Hydrocodone: 35,326 
    Oxycodone: 5,891 
    Tramadol: 21,672 
Excluded:  
581,749 not prescribed opioids 
198,173 prevalent opioid use only 
28,890 initiating non-study medications1   
    -15,073 short-acting morphine 
    -6,773 schedule III/IV short-acting  opioids  
    -790 schedule II short-acting opioids 
    -6254 long-acting opioids 
1,529 initiating >1 type of opioid  
9 initiating opioids with no OME data 
Abbreviations: CASPER, Certification and Survey Provider Enhanced Reporting; HRR, hospital 
referral region; OME, oral morphine equivalents; SNF, skilled nursing facilities 
 
1Of those initiating non-study drugs, 5,387 short-acting morphine initiators, 3,995 schedule III/IV 
short-acting opioid initiators, 263 schedule II short-acting opioid initiators, and 1,682 long-acting 
opioid initiators would have met subsequent eligibility criteria 
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Figure 3.2: Visualizing the overlap between states and hospital referral regions 
(HRRs) – Massachusetts as a case study. HRRs (light grey lines) can cross state 
boundaries (thick black lines) and are therefore not nested within states. Within 
Massachusetts, there are five unique HRRs (shown in color; see legend), but two – 
Albany, New York and Providence, Rhode Island – are primarily based in neighboring 
states. Similarly, two Massachusetts HRRs (Springfield and Boston) extend into 
neighboring states. This non-nested data structure can be exploited with cross-classified 
multilevel models to measure the magnitude of clustering within states versus within 
HRRs and the extent to which variation in opioid prescribing across HRRs is driven by 
resident characteristics, facility characteristics, and state of residence. 
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Figure 3.3: Variation in the proportion of commonly used opioids initiated by 
hospital referral region (N=62,889 residents in 12,345 facilities within 298 hospital 
referral regions). Panel A, oxycodone; Panel B, hydrocodone; Panel C, tramadol.  
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Figure 3.4: Variation in the proportion of residents prescribed doses ≥50 mg 
OME/day by hospital referral region (N=62,889 residents in 12,345 facilities within 
298 hospital referral regions). 
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CHAPTER IV: 
COMMONLY INITIATED OPIOIDS AND RISK OF FRACTURE 
HOSPITALIZATIONS IN UNITED STATES NURSING HOMES 
 
ABSTRACT 
Background: Opioids are commonly initiated in United States nursing homes to manage 
nonmalignant pain, but there is limited evidence to guide clinical decision-making on 
which opioid to initiate despite concerns of differing opioid safety profiles, such as 
fracture risk. 
Methods: We conducted a new-user retrospective cohort study of long-stay nursing 
home residents initiating short-acting oxycodone, hydrocodone, or tramadol by merging 
the 2011-2013 Minimum Data Set 3.0 to Medicare hospitalization and pharmacy claims. 
Residents (≥65 years, no cancer or hospice use) contributed treatment episodes (>120 
days with no prior opioid claims) and were followed for 180 days until incident fracture 
hospitalizations (hip, femur, humerus, pelvis, radius/ulna), death (competing risk), 
treatment changes (e.g., discontinuation), or administrative censoring. Competing risks 
models were used to estimate subdistribution hazard ratios (HRSD) and 95% confidence 
intervals (CI). Inverse probability of treatment weighting was used to adjust for baseline 
confounders. 
Chapter IV 59 
 
 
 
 
Results: 110,862 residents contributed 134,432 treatment episodes: 14,373 oxycodone; 
69,182 hydrocodone; and 50,877 tramadol initiators. The incidence of fracture 
hospitalizations per 100 person-years were 9.4 (95% CI: 7.5-11.7) for oxycodone, 7.9 
(95% CI: 7.1-8.8) for hydrocodone, and 5.0 (95% CI: 4.3-5.7) for tramadol initiators. In 
weighted models, oxycodone initiators had a similar rate of fractures as hydrocodone 
initiators (HRSD=1.08, 95% CI: 0.79-1.48). Tramadol initiators had lower fractures rates 
than hydrocodone (HRSD=0.67, 95% CI: 0.56-0.80). 
Conclusions: The lower rate of fractures that we documented among tramadol initiators 
compared to hydrocodone initiators is consistent albeit attenuated compared to prior 
studies among community-dwelling older adults. However, overall fracture rates were 
lower than in community settings, potentially due to the limited risk of falling in this 
population with limited mobility. Further work is needed to broaden the evidence base on 
opioid effectiveness and safety to provide appropriate pain management in nursing 
homes. 
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INTRODUCTION 
One-third of older United States (US) nursing home residents were prescribed an 
opioid during 2011-2012 to manage their non-malignant pain.
100,117
 Fifteen percent of US 
nursing home residents were prescribed opioids long-term,
100
 more than two-fold the 
prevalence documented in community settings.
38,53
 Acute and long-term opioid use may 
be necessary in this vulnerable population given the high burden of painful comorbidities 
and concerns of the consequences of undertreating pain.
5,6,8
 Further, these practices are 
consistent with 2009 American Geriatrics Society guidelines recommending that “all 
patients with moderate to severe pain, pain-related functional impairment, or diminished 
quality of life due to pain should be considered for opioid therapy.” However, these 
strong recommendations are supported by limited evidence to guide clinical decision-
making on which opioids to initiate, particularly among older, medically-complex 
nursing home residents. 
 Short-acting formulations of oxycodone, hydrocodone, and tramadol are 
prescribed to >80% of residents initiating opioids in US nursing homes.
117
 These 
medications have varying pharmacokinetic and pharmacodynamics profiles including 
affinity for mu-opioid receptors, metabolic pathways, bio-availability, and elimination 
half-lives.
56,57,118
 Such differences may affect time to onset of effect, potency, duration of 
analgesia, and ultimately the risk of safety events such as fractures (e.g., by impairing 
cognition, coordination, and balance leading to falls). In community-dwelling older 
adults, persons initiating tramadol had lower fracture risk compared to hydrocodone 
initiators, especially in the first 30 days.
58
  Oxycodone initiators had similar fracture risk 
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to hydrocodone initiators.
58
 It is unclear if such findings extend to older nursing home 
residents due to differences in age, disease burden, polypharmacy, and overall frailty in 
comparison to community-dwelling adults.
65,84,85,115
 Yet, fractures are common and have 
devastating consequences in nursing homes. Three percent of long-stay residents will 
experience a hip fracture within two years,
119
 with survivors suffering from pressure 
ulcers and infections, functional decline, and mortality.
120–123
 Other fracture 
hospitalizations may also be devastating but have been understudied in this care setting.  
 Given the wide use of opioids in nursing homes and residents’ increased risk of 
adverse drug events including fractures, understanding the comparative safety of 
commonly used opioids in nursing homes is critical. Therefore, we conducted this study 
to evaluate the risk of major fracture hospitalizations following the initiation of short-
acting oxycodone, hydrocodone, or tramadol. 
METHODS 
The University of Massachusetts Medical School Institutional Review Board 
approved this study.  
Data Sources 
We conducted a retrospective cohort study using 2011-2013 Minimum Data Set 
(MDS) 3.0 merged to the Master Beneficiary Summary File (MBSF; contains Medicare 
enrollment and death information), Medicare Part A hospitalization claims, and Part D 
pharmacy claims (including generic drug names, fill date, days’ supply, and dosage 
strength). The Minimum Data Set 3.0 is a federally-required assessment of all US nursing 
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residents living in US Medicare- and/or Medicaid-certified nursing homes (~96% of all 
homes). Registered nurses conduct comprehensive assessments at admission, annually, 
and whenever there is a change in clinical status and at 90 day intervals (using 
condensed, quarterly assessments with a subset of items) in between comprehensive 
assessments. Nurses collect information by reviewing residents’ medical record and 
interviewing residents with validated instruments to collect information on comorbidities, 
cognitive and physical functioning, pain, mood, and other measures.
76–78
 MDS 3.0 
measures have demonstrated validity and reliability.
76
 
Study Population 
Our study cohort included Medicare beneficiaries who were long-stay nursing 
home residents (≥120 consecutive days in facility) and initiated hydrocodone, oxycodone, 
or tramadol between March 31, 2011 and December 31, 2013. These were the three most 
commonly used short-acting opioids in nursing homes during the study period.
100
 Eligible 
residents had Medicare Part A, B, and D coverage and no Medicare Advantage plan in 
the 4 months before initiating hydrocodone, oxycodone, or tramadol.  
The unit of analysis was a treatment episode (defined below). As such, residents 
could contribute multiple treatment episodes if they met our inclusion/exclusion criteria. 
We excluded treatment episodes with no MDS assessment (quarterly or comprehensive) 
in the 120 days preceding opioid initiation or no comprehensive assessment in the prior 
year; those who were recently hospitalized and/or received skilled nursing facility care 
within 120 days of opioid initiation; those living in provider-based facilities and free-
standing skilled nursing facilities; treatment episodes where the resident was <65 years 
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old at initiation or were comatose, had cancer, received hospice care, or had missing data 
on potential confounders; and those initiating unusually high opioid doses >180 mg of 
oral morphine equivalents (OME). To further increase balance of study covariates across 
treatment groups, we additionally excluded states/districts contributing <100 treatment 
episodes to the analysis (Alaska, Washington DC) and states where <2% of treatment 
episodes were oxycodone (Illinois, Michigan, Texas). See Figure 4.1 for an overview of 
our study design; see Appendix 4.1 for further detail on data sources and reasons for 
inclusion/exclusion criteria. 
Opioid Use 
Treatment Groups. Our new-user retrospective cohort study compared new 
initiators of hydrocodone, oxycodone, or tramadol. Between 2011 and 2013, oxycodone 
was a schedule II medication, hydrocodone a schedule III medication, and tramadol was 
unscheduled. New initiation was defined as initiating any oral formulation of oxycodone, 
hydrocodone, or tramadol with no prior use of any opioid in the 120 days before the 
initiating fill date (index date; see Appendix 4.2 for further information on study and 
non-study opioids). Residents were excluded if they were dispensed >1 study drug or 
both study- and non-study opioids on the index date or initiated an unusually high dose 
(>180 mg oral morphine equivalents [OME] /day).
124,125
  
Initiating Dose. Average daily dose of the oxycodone, hydrocodone, or tramadol 
prescriptions initiated on the index date was calculated by multiplying dosage strength in 
OME and quantity dispensed and then dividing by days’ supply (Appendix 4.2).
89
 Doses 
Chapter IV 64 
 
 
 
 
were categorized as <25 mg, 25-49, and ≥50 mg OME/day. Although unconventional, 
these categorizations were chosen because most residents initiate lower doses than 
community-dwelling adults. Although unconventional, these categorizations were chosen 
because most residents initiate lower doses than community-dwelling adults,
107,108,117
 and 
doses ≥50 mg OME/day are considered potentially inappropriate in persons initiating 
opioids for chronic pain.
34
 
Follow-up. We were interested in estimating the as-treated effect of commonly 
initiated opioids on fracture hospitalizations within 180 days of opioid initiation. 
Residents contributed follow-up time to analyses based on the number of days from the 
prescription fill date and the earliest of the following: experiencing the study outcome of 
interest; death (a competing event in analyses of fracture hospitalizations, described 
below); changes in opioid treatment including discontinuation, switching treatment 
groups, or initiating a non-study opioid; enrolling in Medicare Advantage; reaching end 
of follow-up (December 31, 2013); or 180 days of treatment. Residents were assumed to 
take opioids as prescribed from the fill date through the end of the prescription days’ 
supply. We allotted a seven day grace period between prescription fills (in which a 
resident was still at risk for the outcome). If a resident filled a subsequent prescription 
before the calculated end date of the previous prescription, we assumed the new 
prescription began after the calculated end date of the old prescription. Residents who 
discontinued initial treatment could reenter (and change treatment groups) if a later 
treatment episode met eligibility criteria.  
Fractures Hospitalizations  
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 The outcome of interest was fracture hospitalizations within 180 days of treatment 
initiation. We used Part A hospitalization claims using diagnosis and procedure codes to 
create a composite outcome for major fracture hospitalizations, including femur, hip, 
humerus, pelvis, or radius/ulna fractures. Although certain fractures (e.g., radius/ulna) 
may be less likely to results in hospitalization than others (e.g., hip), they are all clinically 
significant and are among the most common injuries leading to hospitalizations in older 
adults.
126
 External validation studies were used to define fractures using International 
Classification of Diseases, 9
th
 edition codes (PPV ≥ 87%; see Appendix 4.3 for specific 
definitions used).
127–129
 If during a treatment episode a resident had multiple fracture 
hospitalizations, only the first hospitalization was included in the analysis.  
Competing Risks 
 Traditional survival analysis techniques such as Kaplan-Meier curves and Cox 
proportional hazards models assume that censored study participants have the same 
survival experience as those remaining in the study.
130
 Competing risks violate this 
assumption because they are events that preclude the study outcome,
131
 and analyses that 
ignore competing risks will overestimate cumulative incidence (the complement of the 
Kaplan-Meier survival curve). Because residents who die cannot be hospitalized for 
fractures, we treated death as a competing event, measured using the date of death in the 
MBSF.  
Potential Confounders 
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 Potential confounders were primarily ascertained from Part D claims and the most 
recent MDS assessment in the 120 days preceding opioid initiation.
132
 Because certain 
chronic comorbidities (e.g., arthritis, osteoporosis) were not included on quarterly 
assessments, the most recent comprehensive assessment within 365 days preceding 
opioid initiation was used for these conditions. Prior MDS assessments provided 
information about state of residence
133
 and resident characteristics including 
demographics (age [included as a continuous variable and quadratic term], gender, 
race/ethnicity), cognitive impairment,
134
 physical functioning,
90
 self- or staff-assessed 
pain, comorbidities associated with falls or fractures, and anxiolytic and hypnotic use 
(because benzodiazepines were not covered by Medicare during 2011-2012). Part D data 
were used to identify other medications that may be associated with fractures either 
directly or as proxies for medical conditions associated with fractures. See Appendix 4.4 
for further detail on resident characteristics included as potential confounders. 
Statistical Analysis 
 We examined the distribution of potential confounders across the three treatment 
groups and calculated standardized mean differences (SMD) – first by calculating each 
pairwise treatment contrast and then averaging all 3 treatment contrasts. SMDs measure 
the differences in means/proportions between treatment groups in units of pooled 
standard deviation and are uninfluenced by sample size; covariates with SMDs >0.1 are 
generally considered meaningfully imbalanced.
135
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To adjust for potential confounders, we estimated propensity scores generalized to 
multiple treatment groups and implemented with inverse probability of treatment (IPT) 
weighting.
136,137
 A propensity score is the probability of treatment given measured 
covariates and was estimated using a multinomial model that included main terms for 
state of residence and potential resident confounders. We estimated stabilized IPT 
weights for each treatment episode by dividing the overall probability of treatment by the 
resident’s propensity of being prescribed the treatment they received.
138
 Our IPT-
weighting standardized the distribution of measured confounders within each treatment 
group to that of the entire study population.
139
 We evaluated our IPT-weights by 
comparing the propensity score distributions of initiating each study drug before and after 
weighting and comparing the SMDs of potential baseline confounder in the crude and 
weighted sample. 
135
 
 We fit Poisson models to estimate crude and weighted incidence rates of fracture 
hospitalizations per 100-person years by treatment group. We then fit Fine and Gray 
competing risks models to estimate crude and weighted cumulative risks and 
subdistribution hazards ratios (HRSD) for initiating commonly-used opioids on fracture 
hospitalization risk within 180 days of treatment initiation.
140
 For HRSD, robust 95% 
confidence intervals (CIs) were used to account for weighting and clustering of multiple 
treatment episodes within residents. We determined that the proportional subdistribution 
hazards assumption was satisfied after examining the log(-log) transformation of the 
crude and weighted nonparametric cumulative incidence function.
131
 In all analyses, 
hydrocodone was chosen as the referent treatment because it is most commonly 
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prescribed opioid in nursing homes and facilitated comparison to prior studies.
58,100
 In 
secondary analyses, we estimated HRSD and cumulative risk over progressively longer 
periods of follow-up to understand how risk may vary as length of opioid use increased 
(1-30 days, 1-60 days, 1-90 days).
141
 
 We conducted stratified analyses by prescribed dosage strength to examine 
whether the primary associations were modified by initiating dose. Because the specific 
opioid and dose are simultaneously initiated, we reweighted the data for these analyses as 
the product of the stabilized treatment IPT-weights (described above) and stabilized dose 
IPT-weights.
142
 Stabilized dose IPT-weights were estimated as the probability of being 
prescribed the specific dose initiated (<25 mg, 25-49 mg, or ≥50 mg OME/day) and the 
probability of initiating the specific dose given treatment and previously described 
confounders in the denominator. We formally tested for additive interaction by estimating 
the relative excess risk due to interaction (RERI).
143
 
 We conducted several sensitivity analyses to examine the robustness of our 
findings: 1) examining the intention-to-treat effect of initiating different opioids within 
180 days of treatment initiation; 2) restricting the outcome to hip fracture hospitalizations 
to potentially enhance the sensitivity and specificity of the outcome definition; 3) 
restricting to states where ≥10% of treatment episodes were oxycodone because study 
medications may be more exchangeable in these regions; 4) excluding residents with 
physical dependence or wheelchair use to examine fracture risk in physically mobile 
residents; 5) excluding residents with no previously documented pain on the most recent 
Chapter IV 69 
 
 
 
 
MDS assessment to mitigate concerns of confounding by pain severity; 6) excluding 
residents with osteoporosis who may be at increased risk for fractures unrelated to opioid 
use; and 7) bias analyses to examine the minimum strength an unmeasured confounder 
would need to have with exposure and outcome on the risk ratio scale to completely 
explain our primary study results.
144,145
 
Our statistical estimates will have a causal interpretation under the following 
assumptions: consistency; no unmeasured confounding, selection bias, or measurement 
error; positivity; and correct specification of the weights and outcome model. Although 
these assumptions are likely violated in practice, we believe this framework provides 
useful guidance for evaluating our results and the extent to which they can be interpreted 
causally.
146
 
RESULTS 
 We identified 110,862 long-stay residents (of 1,882,389 long-stay residents in 
total) who met inclusion criteria and contributed 134,432 treatment episodes to our 
analysis. Ten percent of initiation episodes were oxycodone, 51.4% were hydrocodone, 
and 37.9% were tramadol; see Table 4.1 for further detail on the inclusion and exclusion 
of initiation episodes by treatment group for each study criteria.  
 Table 4.2 shows selected unadjusted baseline characteristics and overall IPT-
weighted characteristics of the cohort; see Appendix 4.4 for a complete summary of 
baseline characteristics in the unweighted and IPT-weighted cohort at baseline. More 
than half (55.5%) of initiators were ≥85 years old, 47.1% had moderate or severe 
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cognitive impairment, three-quarters required extensive assistance to manage their 
activities of daily living or were physically dependent, 29.5% had self- or staff-reported 
pain at their most recent MDS assessment, and 32.1% were prescribed ≥2 psychoactive 
medications prior to opioid initiation. Before IPT-weighting, oxycodone initiators were 
on average younger, more likely to be men, with a lower burden of moderate and severe 
cognitive impairment, but more physical dependence than tramadol or hydrocodone 
initiators. IPT-weighting reduced imbalances between groups at baseline by standardizing 
the distribution of potential measured confounders to that of the entire study cohort. All 
measured confounders had SMDs ≤0.1 after IPT-weighting. See Appendix 4.5 for 
information on the distribution of propensity scores before and after IPT-weighting. See 
Appendix 4.6 for detail on SMDs of potential confounders pre- and post-weighting. 
 Table 4.3 shows the crude incidence rates of major fracture hospitalizations per 
hundred person-years were 9.4 for oxycodone initiators (77 fractures, 821 person years; 
95% CI: 7.5-11.7), 7.9 for hydrocodone initiators (336 fractures, 4,232 person years; 95% 
CI: 7.1-8.8), and 5.0 for tramadol initiators (209 fractures, 4,197 person-years; 95% CI: 
4.3-5.7). Nearly half of hospitalizations were for hip fractures. All-cause mortality during 
follow-up was common. The crude incidence rate of death among oxycodone initiators 
(60.9 per 100 person years, 95% CI: 55.7-66.8) was nearly two-fold that of hydrocodone 
(31.7 per 100 person years, 95% CI: 30.1-33.4) or tramadol initiators (29.1 per 100 
person years, 95% CI: 27.5-30.8), 9.7% of initiation episodes were within 90 days of 
death.  
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 After weighting to reduce differences in baseline confounders between treatment 
groups, the cumulative risk of fracture hospitalizations during180 days of follow-up was 
1.8, 1.6, and 1.1 for oxycodone, hydrocodone, and tramadol initiators, respectively 
(Table 4.4). The HRSD of fracture hospitalizations during 180 days of follow-up was 1.08 
for oxycodone initiation versus hydrocodone (95% CI: 0.79-1.48). HRSD estimates were 
similar when restricting follow-up to shorter time periods. Tramadol was associated with 
a lower subdistribution hazard of fractures relative to hydrocodone during 180 days of 
follow-up (HRSD=0.67, 95% CI: 0.56-0.80); these results were consistent when restricting 
follow-up to shorter time periods. 
Oxycodone initiators were more often prescribed doses ≥50 mg OME/day 
(20.2%) than hydrocodone (6.2%) or tramadol initiators (1.2%). When stratifying by 
dose, the IPT-weighted HRSD for oxycodone versus hydrocodone (<25 mg OME/day: 
HRSD=1.36, 95% CI: 0.82-2.28; 25-49 mg OME/day: HRSD=0.89, 95% CI: 0.56-1.41) 
differed qualitatively, but there was limited evidence of effect modification on the 
additive scale (RERI=0.45, 95% CI: -0.31-1.21). Dose-stratified HRSD for tramadol 
versus hydrocodone (<25 mg OME/day: HRSD=0.66, 95% CI: 0.53-0.82 ; 25-49 mg 
OME/day: HRSD= 0.81) were qualitatively similar with limited evidence of additive 
effect measure modification (RERI=-0.19, 95% CI: -0.83-0.45). We did not test for effect 
measure modification in the highest dose strata due to the low number of fracture 
hospitalizations among oxycodone and tramadol initiators. 
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 Alternative analytic approaches were largely consistent with our primary analyses 
(Table 4.5), though the HRSD between tramadol and fracture hospitalizations relative to 
hydrocodone were attenuated in the intention-to-treat analyses (HRSD=0.86; 95% CI: 
0.76-0.97). When restricting to residents who were not physically dependent or 
wheelchair users, the IPT-weighted cumulative risk and incidence rates during 180 days 
of as-treated follow-up increased relative to our primary analysis, especially among 
oxycodone initiators (cumulative risk: 4.7%; 21.3 fracture hospitalizations per 100 
person-years, 95% CI: 11.9-38.2; HRSD in comparison to hydrocodone: 1.55, 95% CI: 
0.85-2.85).  
 In sensitivity analyses examining the robustness of our primary findings to 
unmeasured confounding, we found that the HRSD between tramadol and fracture 
hospitalizations during 180 days of as-treated follow-up versus hydrocodone initiation of 
0.67 could be explained away by an unmeasured confounder associated with both 
specific opioid initiated and fracture hospitalization by a risk ratio of 2.35. See Appendix 
4.7 for a range of exposure-confounder and confounder-disease associations needed to 
explain our primary analyses.   
DISCUSSION 
Fracture risk may be important to residents and their caregivers when determining 
which opioid to initiate given their devastating sequelae including reduced quality of 
life,
122
 functional decline,
122
 and death.
122,123
 In this new-user, IPT-weighted retrospective 
cohort study, we found that long-stay nursing home residents initiating tramadol had 
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lower rates of fracture hospitalizations during 180 days of as-treated follow-up, whereas 
oxycodone initiators had a slightly elevated incidence rate of fracture hospitalizations 
compared to those initiating hydrocodone (9.6 vs. 8.1 fracture hospitalizations per 100 
person-years). These results are largely consistent with a prior study of the comparative 
safety of opioids in community-dwelling older adults.
58
 However, the reduced overall 
fracture rate that we observed among residents initiating opioids relative to community-
dwelling populations
58–60
 highlights the uniqueness of opioid use in nursing homes. We 
believe this work provides further context for weighing the risks when initiating 
commonly-used opioids, though we also note the limitations of our study and directions 
for future research. 
Our results are consistent albeit less pronounced than Solomon and colleagues’ 
study, which found that community-dwelling elders initiating tramadol had 0.32 times the 
rate of fractures as matched hydrocodone initiators, and oxycodone initiators had 1.02 
times the rate of fractures as hydrocodone initiators.
58
 Solomon et al.’s study population 
had a higher rate of fractures among hydrocodone (26 per 100 person-years), oxycodone 
(25 per 100 person-years), and tramadol initiators (7 per 100 person-years) than our study 
population. Although some of this difference may be accounted by how fractures were 
operationalized (e.g., hospitalization claims alone [current study] versus outpatient and 
hospitalization claims), the limited mobility of long-stay nursing home residents may 
lower the association between opioids and fractures,
147
 especially if the primary 
mechanism of action between opioids and fractures among older adults is through acute 
neurological effects as suggested by prior studies
58–60
 rather than hypogonadism or 
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lowering bone mineral density.
148,149
 This was supported by the heightened rates of 
fracture hospitalizations we observed in analyses restricted to residents without total 
physical dependence or wheelchair use who had fracture hospitalization rates per 100 
person-years ranging from 7.3 (tramadol; HRSD = 0.74, 95% CI: 0.57-0.99) to 21.3 
(oxycodone; HRSD versus hydrocodone = 1.55; 95% CI:0.85-2.85). Mobility may matter 
when evaluating opioid and fracture risk in nursing homes, with higher physical 
dependence inversely associated with fractures in some
132,150,151
 but not all previous 
studies.
152
  
Tramadol is commonly prescribed in nursing homes to manage pain
100,117
 and 
produces analgesia through two mechanisms – weak mu-opioid receptor affinity and 
serotonin and norepinephrine reuptake inhibition.
57
 Because of this unique dual 
mechanism of action, residents initiating tramadol may on average have lower 
somnolence, dizziness, and fall risk compared to hydrocodone or oxycodone initiators. 
However, few head-to-head trials of these commonly used opioids have been conducted 
to provide further detail on how they may influence fracture risk, particularly among 
older adults.
20,23
 Although tramadol has a similar safety profile to hydrocodone in terms 
of somnolence and dizziness in younger populations treated for acute pain,
153,154
 it is 
unclear if these findings extend to older adults with chronic pain. Further work is needed 
to elucidate potential mechanisms by which tramadol and other commonly used opioids 
may cause adverse events among older nursing home residents.  
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All opioid initiators in our study had a higher rate a higher rate of fracture 
hospitalizations (2.8 [tramadol]-3.8 [oxycodone] hip fractures per 100 person-years) than 
previously reported among long-stay nursing home residents overall (2.3 hip fractures per 
100 person-years).
119
 This is consistent with prior work in community settings and should 
be kept in mind when initiating any opioid.
155,156
 The risks of other adverse events must 
also be considered. For example, tramadol is associated with rare but potentially life-
threatening adverse drug events including serotonin syndrome and hypoglycemia.
157,158
 
Finally, nursing home residents are at increased risk of dying compared to community-
dwelling adults and may have different goals of care that mitigate concerns of fractures in 
favor of palliative care. Hydrocodone and tramadol initiators died at slower rates (29.1-
31.7 deaths per 100 person-years) than the overall long-stay nursing home population 
(37.5 per 100 person-years).
119
 However, oxycodone initiators were dying at a faster rate 
(60.9 per 100 person-years); further work is needed to understand whether oxycodone 
increases mortality risk relative to other opioids as has been documented in community 
settings.
58
  
 This study has several unique strengths. We used an active comparator, new-user 
design to compare three commonly used treatments in nursing homes. This design 
reduces concerns of confounding by indication and selection bias introduces by 
comparing incident and prevalent users.
159,160
 Compared to prior studies examining 
fracture risk in older adults,
58–60,155
 we had enhanced information from the Minimum 
Data Set 3.0 on potential confounders including pain, cognitive impairment, and physical 
functioning that are not normally available in studies relying on Medicare claims alone. 
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Using IPT-weighting, we achieved good balance of measured baseline confounders; such 
analytic strategies are not always used despite their advantages when the outcome is rare 
and there are many potential confounders.
59,156,161
 
 This study has several limitations that may limit the causal interpretation of our 
effect estimates. Although we were able to adjust for confounders not normally available 
in observational research (e.g., physical functioning), we cannot rule out unmeasured 
confounding. Further, we did not adjust for potential facility-level and other 
environmental characteristics that may affect fracture risk. In bias analyses, a measured 
confounder with a risk ratio of 2.35 with both tramadol and fracture hospitalizations 
would be needed to attenuate our primary finding. This is above and beyond the strength 
of measured resident- and facility-level confounders with opioid and fractures in this and 
other studies but is still possible.
117,132,162
 We likely undercounted fractures (i.e., reduced 
sensitivity) by focusing solely on hospitalizations. Our estimates of overall cumulative 
fracture risk are thus conservative. Our HRSD estimates are expected to be biased towards 
the null assuming nondifferential misclassification. We assumed that loss to follow-up 
was nondifferential and examined this assumption by conducting an intention-to-treat 
analysis; findings were similar albeit attenuated from our primary findings. We measured 
opioids using claims data and could not distinguish between as-needed (pro re nata) or 
scheduled use. We also assumed that propensity score models and outcome models were 
correctly specified, though we flexibly parameterized potential confounders (including 
several categories rather than dichotomizing variables, including higher-order terms for 
continuous variables) to mitigate these concerns. 
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 In conclusion, we found that initiating tramadol relative to hydrocodone was 
associated with lower fracture hospitalization risk among older adults living in nursing 
homes. This may be of particular relevance for persons at heightened risk for falls or who 
are otherwise concerned about falling. Although this finding is consistent with prior work 
among community-dwelling older adults, further work is needed to elucidate potential 
mechanisms. Further, the comparative safety of fractures following opioid initiation must 
be considered within the broader context of other adverse drug events (e.g., mortality), as 
well as the unique palliative care needs of this older population.  
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Table 4.1. Number of persons or treatment episodes meeting study eligibility criteria by study opioid
1
 
Study Criteria Hydrocodone Oxycodone Tramadol 
1. Long-stay nursing home residents. >120 consecutive days in the same nursing 
home before study drug initiation.
2
 
      1,882,389 
2. Medicare eligibility. >120 consecutive days of Medicare Part A, Part B, and Part 
D follow-up in the 120 day period preceding the index date. Simultaneously, no 
Medicare Part C (Medicare Advantage) coverage during this period.  
      1,345,693 
3. New use. No prescribed opioids in the 120 days preceding the index date. 153,695 28,943 101,147 
4. No recent SNF care / hospitalizations. No skilled nursing facility care or 
hospitalization episodes in the 120 days preceding the study index date. 
141,001 25,691 93,536 
5. Prior MDS assessments. Eligible MDS 3.0 assessment (quarterly or 
comprehensive) in the 120 day period preceding the index date, and any 
comprehensive assessment in the year preceding the index date.  
121,578 22,355 82,531 
6. Facility restrictions. Not residing in a facility with no available CASPER data, 
stand-alone skilled nursing facility, or provider-based facility on index date. 
115,428 21,310 78,943 
7. Age ≥65 years. ≥65 years old on the cohort entry date. 103,998 18,952 73,530 
8. No cancer. No evidence of cancer, as assessed on prior MDS 3.0 assessments. 97,332 17,284 69,143 
9. No hospice. No evidence of prior hospice use, as assessed on prior MDS 3.0 
assessments. 
90,388 15,673 65,571 
10. No comatose. No evidence of being comatose, as assessed on prior MDS 3.0 
assessments. 
90,338 15,667 65,553 
11. No missing data. No missing data on study covariates. 85,052 14,666 62,080 
12. Starting dose. Starting dose ≤180 mg oral morphine equivalents. 85,040 14,572 62,080 
13. No Small states contributing few residents. Living in states contributing ≥100 
treatment episodes to analysis 
85,002 14,513 62,048 
14. No states with limited oxycodone initiation. Living in states where ≥2% of 
initiators were prescribed oxycodone 
69,182 14,373 50,877 
Abbreviations: CASPER, Certification and Survey Provider Enhanced Reports; MDS, Minimum Data Set; SNF, skilled nursing 
facility. 
1
Criterion 1 and 2 are unique residents; criterion 3-12 are unique treatment episodes. 
2
Further restricted to residents with an available unique encrypted beneficiary identifier. 
Note: 110,862 residents contributed 134,432 treatment initiation episodes (17.0% of residents contributed >1 treatment episode 
[range: 2-6]). Treatment switching was uncommon: 2.4% and 0.01% of residents initiated 2 or 3 different treatments, respectively. 
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Table 4.2: Baseline characteristics of nursing home residents in the 120 days before initiating 
oxycodone, hydrocodone, or tramadol (N=110,862 residents; 134,432 treatment episodes)  
   Crude, stratified by opioid initiated  Overall,  
IPT-weighted
1
 Characteristic   Oxycodone  Hydrocodone  Tramadol  
Number of treatment episodes
2
   14,373  69,182  50,877  134,357 
Demographics          
   Age in years, mean(standard deviation)   83.7 (8.8)  84.3 (8.6)  85.5 (8.4)  84.7 (8.5) 
   Women, %   72.2  74.5  79.0  76.1 
   Non-Hispanic white, %   81.0  83.5  84.5  84.1 
Married, %   17.5  17.2  15.6  16.7 
Behavior, %          
   Rejects care   10.2  10.1  9.9  10.0 
   Wandering   5.0  6.4  6.4  6.2 
Cognitive impairment,
3
 %          
   Moderately impaired   33.6  38.1  37.2  37.0 
   Severely impaired   10.3  10.1  9.2  9.6 
Physical functioning,
4
 %          
   Requires extensive assistance   55.1  53.1  53.9  53.7 
   Physical dependence    23.8  21.2  19.5  20.7 
Pain,
5 
%          
   Any self-reported pain   28.1  25.3  25.4  26.1 
   Any staff-assessed pain   3.8  4.1  3.3  3.7 
Urinary incontinence, always %   35.0  31.9  27.7  30.5 
Bowel incontinence, always %   29.8  28.0  27.7  26.5 
Mobility devices normally used, %          
   Cane/walker   45.0  44.0  48.4  46.0 
   Wheelchair   79.4  75.6  73.9  75.4 
Comorbidities, %          
   History of falls   21.0  23.4  23.1  23.1 
   Previous fracture   3.9  2.9  2.7  3.0 
   Parkinson’s disease   6.8  7.4  7.2  7.3 
   Seizures / epilepsy   8.2  8.2  6.1  7.4 
   Osteoporosis   18.5  18.5  19.6  18.9 
   Arthritis   30.2  30.1  33.5  31.7 
   Pressure ulcers   5.5  3.9  3.3  3.9 
   Congestive Heart Failure   21.5  21.0  20.7  21.1 
   Stroke   17.6  17.6  16.7  17.2 
   Diabetes   35.0  34.5  31.5  33.5 
Number of medications prescribed, median   9 (7-13)  9 (7-13)  9 (6-12)  9 (6-13) 
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(P25-P75) 
Psychotropic medications, %           
   ≥2 psychotropic medications prescribed
6
   32.2  33.1  30.9  32.3 
   Antipsychotics   25.1  26.7  25.8  26.2 
   Antidepressants
7
   64.6  62.7  61.2  62.5 
   Anxiolytics
8
    20.1  21.3  19.6  20.7 
   Hypnotics
8
   5.6  5.7  5.1  5.6 
Pain adjuvant medications, %          
   Anticonvulsants   18.8  15.8  14.1  15.7 
   Systemic corticosteroids   8.7  7.7  7.9  8.0 
   Nonsteroidal anti-inflammatory drugs   11.7  11.9  13.1  12.5 
   Skeletal muscle relaxants   5.6  4.3  3.8  4.4 
Abbreviations: IPT; inverse probability of treatment; P25-P75: 25th to 75th percentiles; 
1Stabilized IPT-weights (mean=1.00, minimum: 0.16, maximum: 8.65) were used to standardize the distribution of potential confounders to that 
of the entire study population. See Appendix 4.4 for the IPT-weighted distribution of potential confounders by opioid initiated. See Appendix 
4.5-4.6 for further detail on the overall distribution of propensity scores and standardized mean differences before and after IPT-weighting. 
2110,862 residents contributed 134,432 treatment initiation episodes (17.0% of residents contributed >1 treatment episodes [range: 2-6]). 
Treatment switching was uncommon: 2.4% and 0.01% of residents initiated 2 or 3 different treatments, respectively.   
3Cognive impairment was defined using the Cognitive Function Scale (CFS; range 0-3): cognitively intact (0), mild impairment (1), moderate 
impairment (2), and severe impairment. 
4Physical limitations were defined using the Activities of Daily Living Self-Performance Hierarchy (range: 0-6): no/mild limitations (0-2), 
extensive limitations (3-4), and physical dependence (5-6). 
5Resident pain in the five days preceding the most recent Minimum Data Set (MDS) assessment before treatment initiation was based on self-
report when the resident was able to and staff assessment otherwise. 
6Based on antipsychotics, antidepressants, anxiolytics, and hypnotics 
7See Appendix 4.4 for further detail on specific classes of antidepressants prescribed (e.g., tricyclics) by study drug initiated. 
8Anxiolytics and hypnotics were measured in the seven days before the most recent MDS assessment because benzodiazepines were not covered 
by Part D in 2011-2012.  
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Table 4.3: Crude incidence of first major fracture hospitalizations per 100-person years among nursing home 
residents initiating oxycodone, tramadol, or hydrocodone; 180 days of as-treated follow-up (N=110,862 
residents; 134,432 treatment episodes) 
 Oxycodone  Hydrocodone  Tramadol 
 
Endpoint 
No. of 
events 
 Incidence Rate
1
 
(95% CI) 
 No. of 
events 
 Incidence Rate
1
 
(95% CI) 
 No. of 
events 
 Incidence Rate
1
 
(95% CI) 
Major fracture hospitalization
2
 77  9.4 (7.5-11.7)  336  7.9 (7.1-8.8)  209  5.0 (4.3-5.7) 
   Hip 35  4.3 (3.1-5.9)  162  3.8 (3.3-4.5)  118  2.8 (2.3-3.4) 
   Femur  16  1.9 (1.2-3.2)  59  1.4 (1.1-1.8)  30  0.7 (0.5-1.0) 
   Humerus  18  2.2 (1.4-3.5)  54  1.3 (1.0-1.7)  24  0.6 (0.4-0.9) 
   Pelvis -
3
  -
3
  48  1.1 (0.9-1.5)  30  0.7 (0.5-1.0) 
   Radius/Ulna -
3
  -
3
  26  0.6 (0.4-0.9)  15  0.4 (0.2-0.6) 
Competing risk: Death 500  60.9 (55.7-66.8)  1,343  31.7 (30.1-33.4)  1,220  29.1 (27.5-30.8) 
1Oxycodone initiators contributed 821 person-years of as-treated follow-up (median follow-up: 14 days; 25th-75th percentiles [P25-P75]: 11-21 days), 
hydrocodone initiators contributed 4,232 person-years (median: 14 days; P25-P75: 12-22 days), and tramadol initiators contributed 4,197 person-years 
(median: 15; P25-P75: 12-26). 
2The total number of specific fracture events exceeds the number of major fracture hospitalizations because 25 initiators were simultaneously hospitalized 
for ≥2 major fractures. 
3Rates are suppressed in  accordance with Centers for Medicare and Medicaid Service’s cell size suppression policy because there were <11 events 
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Table 4.4: Fracture hospitalizations by opioid initiated among older nursing home residents during as-treated follow-up 
(N=110,862 residents; 134,432 treatment episodes). 
   Crude  IPT-weighted 
Treatment group 
No. of 
episodes 
 Cumulative 
risk, % 
Incidence rate 
 (95% CI) 
HRSD  
(95% CI) 
 Cumulative 
risk, % 
Incidence rate   
(95% CI) 
HRSD  
(95% CI) 
Primary Analysis: 1-180 days          
   Hydrocodone 69,182  1.5 7.9 (7.1-8.8) Referent  1.6 8.1 (7.2-9.0) Referent 
   Oxycodone 14,373  1.7 9.4 (7.5-11.7) 1.13 (0.88-1.44)  1.8 9.6 (7.1-12.8) 1.08 (0.79-1.48) 
   Tramadol 50,877  1.1 5.0 (4.3-5.7 0.76 (0.64-0.90)  1.1 4.5 (3.9-5.2) 0.67 (0.56-0.80) 
Secondary Analyses          
Restricted follow-up: 1-30 days          
   Hydrocodone 69,182  0.6 10.1 (9.0-11.3) Referent  0.6 9.4 (8.4-10.6) Referent 
   Oxycodone 14,373  0.7 11.4 (9.0-14.4) 1.11 (0.86-1.44)  0.6 10.3 (9.6-13.9) 1.04 (0.75-1.43) 
   Tramadol 50,877  0.4 6.8 (5.9-8.0) 0.72 (0.60-0.87)  0.4 5.1 (4.4-6.0) 0.62 (0.51-0.75) 
Restricted follow-up: 1-60 days          
   Hydrocodone 69,182  0.8 9.1 (8.2-10.2) Referent  0.8 9.3 (8.3-10.5) Referent 
   Oxycodone 14,373  0.9 10.6 (8.5-13.3) 1.14 (0.88-1.46)  0.9 10.6 (7.9-14.3) 1.10 (0.80-1.51) 
   Tramadol 50,877  0.6 6.1 (5.2-7.0) 0.74 (0.62-0.88)  0.5 5.3 (4.6-6.2) 0.64 (0.53-0.77) 
Restricted follow-up: 1-90 days          
   Hydrocodone 69,182  1.0 8.7 (7.8-9.7) Referent  1.1 8.1 (7.2-9.0) Referent 
   Oxycodone 14,373  1.1 10.3 (8.2-12.9) 1.15 (0.90-1.48)  1.2 9.6 (7.1-12.8) 1.09 (0.80-1.50) 
   Tramadol 50,877  0.7 5.6 (4.9-6.5) 0.74 (0.62-0.89)  0.7 4.5 (3.9-5.2) 0.65 (0.54-0.78) 
Dose stratified: <25 mg OME/day
1
          
   Hydrocodone 36,246  1.5 6.8 (5.8-11.8) Referent  1.6 6.9 (5.9-8.0) Referent 
   Oxycodone 4,098  2.0 8.3 (5.8-11.8) 1.33 (0.91-1.95)  2.2 9.1 (5.6-14.9) 1.36 (0.82-2.28) 
   Tramadol 40,899  1.1 4.5 (5.9-7.8) 0.74 (0.60-0.91)  1.1 4.1 (3.5-4.9) 0.66 (0.53-0.82) 
Dose stratified: 25-49 mg OME/day
1
          
   Hydrocodone 28,616  1.6 10.5 (8.8-12.5) Referent  1.7 11.0 (9.1-13.3) Referent 
   Oxycodone 7,372  1.7 10.6 (7.6-14.7) 1.06 (0.73-1.53)  1.5 9.1 (6.0-13.9) 0.89 (0.56-1.41) 
   Tramadol 9,374  1.3 8.8 (6.3-12.2) 0.85 (0.58-1.23)  1.4 8.7 (6.1-14.5) 0.81 (0.54-1.21) 
Dose stratified: ≥50 mg OME/day
1
          
   Hydrocodone 4,320  0.7 9.4 (5.1-17.6) -
2  1.3 7.5 (4.2-13.3) -
2 
   Oxycodone 2,903  -
2 -2 -2  -
2 -2 -2 
   Tramadol 604  -
2 -2 -2  -
2 -2 -2 
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Abbreviations: CI: confidence interval; HRSD: subdistribution hazards ratio; IPT: inverse probability of treatment; OME: oral morphine equivalent 
1
 We found no evidence that higher doses (25-49 mg OME/day vs. <25 mg OME/day) increased the subdistribution hazard of fracture risk on the additive scale for 
hydrocodone and oxycodone (Relative Excess Risk due to Interaction [RERI]=0.45, 95% CI: -0.31-1.21) or hydrocodone and tramadol (RERI=-0.19, 95% CI: -.83-0.45). We 
did not compare those initiating doses ≥50 mg OME/day to due to the low number of fracture hospitalizations in this group.  
2Suppressed in accordance with Centers for Medicare and Medicaid Service’s cell size suppression policy because there were <11 events. 
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Table 4.5: Sensitivity Analyses.   
   Crude  IPT-Weighted 
Treatment group 
No. of 
episodes 
 Cumulative 
risk, % 
Incidence rate 
 (95% CI) 
HRSD  
(95% CI) 
 
Cumulative 
risk, % 
Incidence rate 
 (95% CI) 
HRSD  
(95% CI) 
Intention-to-treat analysis
1
          
   Hydrocodone 56,375  1.4 3.1 (2.9-3.4) Referent  1.4 3.2 (2.9-3.4) Referent 
   Oxycodone 12,273  1.5 3.6 (3.1-4.2) 1.11 (0.94-1.31)  1.6 3.8 (3.1-4.7) 1.17 (0.93-1.47) 
   Tramadol 42,214  1.2 2.8 (2.6-3.1) 0.90 (0.80-1.01)  1.2 2.7 (2.5-3.0) 0.86 (0.76-0.97) 
Restricting outcome to hip fractures           
   Hydrocodone 69,182  0.9 3.8 (3.3-4.5) Referent  1.0 3.9 (3.3-4.6) Referent 
   Oxycodone 14,373  0.9 4.3 (3.1-5.9) 1.05 (0.73-1.51)  1.0 4.6 (3.0-7.1) 1.08 (0.68-1.71) 
   Tramadol 50,877  0.7 2.8 (2.3-3.4) 0.86 (0.68-1.09)  0.7 2.5 (2.1-3.1) 0.75 (0.59-0.97) 
Excluding states where <10% of 
treatment episodes were oxycodone
2
 
         
   Hydrocodone 15,815  1.1 8.0 (6.4-9.9) Referent  1.2 7.9 (6.3-10.0) Referent 
   Oxycodone 9,298  1.3 9.4 (7.1-12.3) 1.12 (0.79-1.59)  1.4 10.0 (7.4-13.4) 1.18 (0.81-1.71) 
   Tramadol 15,782  0.9 4.9 (3.8-6.1) 0.76 (0.56-1.05)  0.9 4.5 (3.5-5.8) 0.72 (0.51-1.01) 
Excluding residents with physical 
dependence or wheelchair use 
         
   Hydrocodone 14,422  3.1 13.1 (10.9-15.7) Referent  3.1 12.5 (10.3-15.1) Referent 
   Oxycodone 2,518  4.2 19.4 (13.1-28.5) 1.36 (0.89-2.08)  4.7 21.3 (11.9-38.2) 1.55 (0.85-2.85) 
   Tramadol 11,982  2.4 8.5 (6.8-10.5) 0.76 (0.57-1.00)  2.2 8.0 (6.4-10.0) 0.74 (0.57-0.99) 
Excluding residents without 
documented pain 
         
   Hydrocodone 20,350  1.4 4.7 (3.7-6.0) Referent  1.4 4.9 (3.8-6.4) Referent 
   Oxycodone 4,593  1.6 5.7 (3.5-9.3) 1.17 (0.68-2.0)  1.6 6.8 (3.2-10.3) 1.11 (0.64-1.93) 
   Tramadol 14,619  1.1 3.5 (2.6-4.7) 0.83 (0.56-1.23)  1.1 3.3 (2.4-4.5) 0.75 (0.51-1.12) 
Excluding residents with 
osteoporosis 
         
   Hydrocodone 56,397  1.4 7.8 (6.9-8.8) Referent  1.6 8.0 (7.1-9.1) Referent 
   Oxycodone 11,718  1.7 9.6 (7.4-12.2) 1.17 (0.89-1.53)  1.8 9.8 (7.1-13.6) 1.12 (0.85-1.47) 
   Tramadol 40,918  1.1 4.9 (4.2-5.7) 0.76 (0.62-0.92)  1.1 4.5 (3.8-5.3) 0.67 (0.55-0.82) 
Abbreviations: HRSD: subdistribution hazards ratio; IPT: inverse probability of treatment 
1
The sample for the intention-to-treat analysis was restricted to the first initiation episode (n=110,862 residents) 
2
Restricted to the following states: Arizona, Colorado, Connecticut, Delaware, Massachusetts, Maryland, Maine, Minnesota, North Carolina, North Hampshire, New 
Jersey, New Mexico, Nevada, New York, Oregon, Pennsylvania Rhode Island, Vermont, Washington. 
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Figure 4.1: Study design overview. 
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CHAPTER 5: DISCUSSION AND CONCLUSIONS 
PURPOSE AND SPECIFIC STUDY QUESTIONS 
The overall purpose of this dissertation was to enhance the evidence base on 
opioid use and safety for non-malignant pain in nursing homes. Specifically, this work 
was motivated by the following multi-part research questions concerning opioid 
prescribing among older, long-stay nursing home residents: 
Aim 1. What is the prevalence of overall and long-term opioid use? 
a. How are opioids prescribed in terms of length of use (i.e., short-, medium-, or 
long-term durations), duration of action, and average daily dose? 
b. What other analgesics, pain adjuvants, and potentially contraindicated 
medications are concurrently prescribed with opioids? 
c. How does the prevalence of long-term opioid use vary by key resident factors 
including age, gender, race/ethnicity, cognitive impairment, and physical 
functioning? 
Aim 2. Does the initiation of commonly used opioids (short-acting oxycodone, 
hydrocodone, and tramadol) and prescribed dosage strength geographically vary across 
hospital referral regions? 
a. To what extent is geographic variability due to differences in resident 
characteristics, facility characteristics, and state of residence across hospital 
referral regions? 
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b. Are prescribing practices more strongly clustered within hospital referral 
regions or states? 
c. Does the strength prescribed vary by opioid initiated? 
Aim 3. Are there differences in the comparative safety of commonly used opioids and 
fracture hospitalizations? 
a. What are the rates of fracture hospitalizations per 100 person-years in the 180 
days following initiation of oxycodone, hydrocodone or tramadol? Do they 
vary by opioid initiated?  
b. Is the association between opioids and fracture hospitalizations modified by 
dose? To what extent is the association modified by particular analytic 
decisions (e.g., as-treated vs. intention-to-treat follow-up) or among subgroups 
at increased risk of fractures (e.g., residents who do not use wheelchairs or are 
physically dependent)?  
This research is especially warranted given the ongoing opioid crisis among 
younger and older adults and concerns that efforts to contain this epidemic may result in 
undertreating pain in vulnerable populations.
28,29,81,82
 Nationwide, opioid use quadrupled 
to more than 240 million prescriptions per year from 1999 to 2010.
27
 This was 
accompanied by an alarming rise of opioid misuse and abuse, addiction, and fatal and 
non-fatal overdoses.
28,29,81,82
 Yet, prior trials,
20–22
 observational studies,
39,42,45–49
 clinical 
guidelines,
33,34
 and federal campaigns
31,32
 have largely remained silent on opioid use and 
safety among older adults, especially nursing home residents. This is concerning given 
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the higher burden of pain among nursing home residents in comparison to community-
dwelling adults,
35,36
 much of which may remain undertreated or untreated.
1,3,5,14–17,19,44
 
Additionally, there are a limited number of alternative pharmacologic and 
nonpharmacologic options for this older, medically complex population.
13,24,26
 
Acetaminophen may be insufficient to manage moderate to severe pain, and nonsteroidal 
anti-inflammatory drugs (NSAIDS) are associated with cardiovascular risks among older 
adults.
13,24,26
 Nonpharmacologic options may be inadequate because of the high burden of 
cognitive impairment among residents, as well as billing and staffing constraints when 
implementing such interventions. In many cases, opioids may be the only viable 
treatment option for pain management, though their use is certainly contentious with 
some advocating
163,164
 and others opposing chronic use.
165
 For these reasons, this 
dissertation addresses an important knowledge gap in the literature and provides further 
context on use and safety of opioids in nursing homes to help guide clinical and policy 
decision-making.   
SUMMARY OF RESULTS 
 In aim 1, we conducted a cross-sectional study among older long-stay nursing 
home residents using data from 2012 to estimate the period prevalence of long-term 
opioid use and other prescribed analgesics and pain adjuvants during 120 days of follow-
up. We found that nearly one-third of long-stay residents were prescribed any opioid, 
with 1 in 7 residents prescribed opioids long-term. Among long-term opioid users, half 
were concurrently prescribed alternative analgesics (e.g., NSAIDS) and pain adjuvants, 
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and 1 in 4 received nonpharmacologic interventions for pain management. Residents who 
were women (vs. men), non-Hispanic white (vs. racial/ethnic minorities), with no/mild 
cognitive impairment (vs. those with moderate to severe limitations) or with severe 
physical limitations (vs. those with no/mild or moderate limitations) had a higher 
prevalence of long-term opioid use. 
In aim 2, we conducted a cross-sectional study among long-stay nursing home 
residents initiating commonly used short-acting opioids (identified from aim 1; includes 
short-acting formulations of oxycodone, hydrocodone, and tramadol) to examine 
geographic variation in opioid prescribing practices including choice of opioid initiated 
and whether higher doses were prescribed (≥50 mg oral morphine equivalents /day) . We 
found that more than half of residents initiated hydrocodone (56.2%), 34.5% initiated 
tramadol and 9.4% initiated oxycodone. We observed strong geographic patterns in 
opioid prescribing, with the proportion of residents initiating oxycodone being much 
higher in the Northeast, tramadol being more commonly initiated in the Midwest, and 
hydrocodone being most commonly prescribed in western US states but also banding 
across the middle of the continental United States. Seven percent of residents initiated 
higher doses; this practice was more common in western US states. In multilevel 
analyses, we found that much of the observed variation in opioid prescribing could not be 
explained by resident or facility characteristics. However, after additionally adjusting for 
state of residence, more than half of the variation in specific opioids initiated across 
hospital referral regions was explained. For higher doses, 46.3% of the variation across 
hospital referral regions was explained after additionally adjusting for state of residence. 
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The opioid initiated was strongly associated with dose; for residents within the same state 
and hospital referral region, initiating oxycodone was strongly associated with being 
prescribed higher doses in comparison to hydrocodone. Conversely, initiating tramadol 
was inversely associated with higher doses.  
In aim 3, we quantified the comparative safety of commonly-used opioids 
(oxycodone, hydrocodone, and tramadol) and fracture hospitalizations. Using a new-user 
retrospective cohort study with inverse probability of treatment weighting to balance 
baseline confounders, we examined fracture hospitalization risk during 180 days of as-
treated follow-up. The incidence rate of fracture hospitalizations was 9.4 per 100 person-
years for oxycodone initiators (95% CI: 7.5-11.7), 7.9 per 100 person-years for 
hydrocodone initiators (95% CI: 7.1-8.8), and 5.0 per 100 person-years for tramadol 
initiators (95% CI: 4.3-5.7). Using inverse probability of treatment weighted competing 
risk models, we found that oxycodone initiators had a similar rate of fracture 
hospitalizations as hydrocodone initiators (subdistribution hazard ratio [HRSD] =1.08, 
95% CI: 0.79-1.48) whereas tramadol initiators had a lower rate of fractures compared to 
hydrocodone (HRSD=0.67, 95% CI: 0.56-0.80). Restricting follow-up to shorter durations 
(1-30 days, 1-60 days, 1-90 days) showed that the majority of outcomes occurred in the 
first thirty days though HRSD were similar to the primary analysis. Results were largely 
consistent during additional sensitivity analyses, though the cumulative risk of fractures 
was higher in residents who were not wheelchair users or totally physically dependent.   
IMPLICATIONS 
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Clinical Implications. Long-term opioid use in nursing homes is twofold the 
prevalence documented in older community-dwelling adults.
38,53
 This finding from aim 1 
highlights the extensiveness of opioids for managing pain in nursing homes. Long-term 
opioid use in community settings is associated with overdose and death,
20,34
 but these 
findings may not extend to nursing homes residents because access to opioids is mediated 
through staff, and residents should (in ideal circumstances) be closely monitored by staff 
to reduce the risk or mitigate the consequences of adverse drug events. Further, long-term 
use may even be warranted given the prevalence of pain and painful comorbidities,
35,36
 
risk and consequences of undertreating pain
1,3,5,6,8,14–17,19,44
 and limited alternative 
pharmacologic and nonpharmacologic pain management options.
13,24,26
 However, we also 
documented several areas for potential improvement. Long-term opioid users were 
prescribed high daily doses that may be potentially worrisome given that the risks of 
many adverse opioid related events are typically heightened at increased doses (e.g., 
doses ≥90 mg OME/day).
34
 Many long-stay residents were also concurrently prescribed 
contraindicated psychopharmacologic medications (e.g., antipsychotics, anxiolytics) 
which may interact with opioids and increase the risk of adverse events such as 
falls/fractures.
24
 Although some of these practices may be declining in response to recent 
Centers for Medicare and Medicaid Service policies (e.g., the National Partnership to 
Improve Dementia Care in Nursing Homes and declining prevalence of antipsychotic use, 
enacted March 29, 2012),
166
 risk is nonetheless worrisome given that high 
psychopharmacologic use continues to be largely endemic in this care setting.
167,168
 
Potential interventions to improve nursing home prescribing culture
113,114
 may thus be 
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warranted and have shown some success (e.g., improving how staff interact with 
cognitively impaired residents to reduce antipsychotic use).
98
 
Our work on opioid initiation (aims 2 and 3) provided several clinical insights. 
First, our results suggest that nursing homes largely follow the geriatric maxim of “start 
low and go slow,” because most residents initiated lower doses. This is encouraging 
given the association of higher doses with adverse events such as fractures and injuries in 
community-dwelling older adults.
59,169
 Second, we found that initiating tramadol was 
associated with lower fracture hospitalization risk than hydrocodone or oxycodone. This 
finding is consistent with prior work among community-dwelling older adults that found 
tramadol to be associated with lower rates of fractures.
58
 Third, overall fracture 
hospitalization rates were lower in nursing home residents than community-dwelling 
older adults.
58–60
 This may be due to the limited mobility of residents, which should be 
considered when initiating opioids given the increased risk of fractures that we 
documented in this subset of our study population. Fourth, the risk of death in our 
population was much higher than community-dwelling elders
58,60
 (though largely similar 
to other long-stay residents)
119
 and may reduce concerns of fracture risks in favor of the 
perceived benefits of different opioids, though we note that there is also limited evidence 
to guide clinical decision making on the comparative effectiveness of commonly used 
opioids in this setting. 
Policy Implications. Only a quarter of long-term opioid users received 
nonpharmacologic interventions (e.g., biofeedback, applying heat and cold, massage, 
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physical therapy, nerve block, stretching and strengthening exercises). Although the 
efficacy of many nonpharmacologic interventions may be reduced in the presence of 
moderate to severe cognitive impairment, some therapies may still be efficacious and/or 
reduce the overall reliance on opioids (e.g., reducing the average dose to a safer range).
34
 
However, nonpharmacologic interventions are difficult to implement because of 
limitations with reimbursement, as well as staffing constraints including limited training 
in palliative care, understaffing, and high staff turnover.
103,170
 Financial 
resources/incentives may thus be needed if clinicians and policymakers seek to reduce 
opioid use in nursing homes by substituting nonpharmacologic interventions for opioid 
prescribing. These efforts may also be criticized by the limited evidence on the relative 
benefit of simultaneous pharmacologic and nonpharmacologic therapies versus 
pharmacotherapy alone among older nursing home residents. 
In aim 2, we found that much of the geographic variation in opioid prescribing 
across hospital referral regions was driven by state of residence. This suggests that state 
policies and laws have the largest influence on opioid prescribing and raises concerns that 
state efforts to curtail opioid prescribing in response to the opioid crisis may affect 
nursing home residents.
112
 As we have noted throughout this work, residents have unique 
care needs and have historically had their pain undertreated.
1,3,5,14–16,19,44
 Efforts to 
combat the opioid crisis should thus keep the unique needs of this important and oft 
forgotten population in mind. Otherwise, we risk encouraging devastating, historic norms 
that disserve some of the most vulnerable among us.   
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STRENGTHS 
 This dissertation has several strengths. For all aims, we linked the Minimum Data 
Set (MDS) 3.0 to Medicare claims. Since the MDS is federally required for all residents 
living in Medicare- or Medicaid-certified US nursing homes (>96% of all NHs), we were 
able to comprehensively look at opioid use and safety in long-stay residents across the 
United States. 
76–78
 Additionally, the revised MDS 3.0 improved on previous MDS 
versions by including self-reported measures of pain, mood, and cognitive status, as well 
as other resident-level measures not traditionally available in pharmacoepidemiologic 
studies such as physical functioning. Finally, using these national data sources resulted in 
a large sample size that allowed us to examine uncommon drug utilization patterns and 
rare outcomes such as fractures while providing sufficient precision to be relevant to 
potential stakeholders. 
 Aim 1 improved on many prior studies of pain management in nursing 
homes.
1,3,5,14–17,19,44
 We examined opioid use over a longer window of time than prior 
studies. We also did not restrict our study population to those reporting pain. We were 
thus able to provide a more comprehensive summary of how opioids are used to manage 
nonmalignant pain, which may be either present and underreported or well managed 
among residents reporting or observed to be in no pain. To our knowledge, we were the 
first study to use oral morphine equivalents to describe opioid dose in US nursing homes, 
with prior studies providing limited or no information on dose. We also included 
tramadol as an opioid in our study. Tramadol was initially approved by the Food and 
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Drug Administration in 1995 but has been excluded from many studies of pain 
management in nursing homes despite being the second most commonly used opioid in 
this work. Finally, we comprehensively measured adjuvants, potentially contraindicated 
medication use, and nonpharmacologic pain management concurrently used during 
follow-up to provide further detail on complementary and/or alternative analgesics used 
during opioid therapy, though adjuvant use has also been examined in other studies.
15,17
 
 For aim 2, we provided the first examination of geographic variation in opioid 
prescribing practices among long-stay nursing home residents. Our explicit focus on the 
initiation of commonly used opioids offered advantages when considering the role of 
facility characteristics and state of residence, which may exert more influence on 
prescribing practices at initiation rather than prevalent measures of opioid use. Further, 
comparing residents at opioid initiation may reduce bias that routinely occurs when 
comparing incident and prevalent users,
171
 as initiators and long-term users likely differ 
in many important and unmeasurable ways by being at different points in their therapy. 
Finally, we implemented cross-classified multilevel models,
106,172
 which allowed us to 
leverage the non-nested data structure of states and hospital referral regions to examine 1) 
how resident characteristics, facility characteristics, and state of residence explained 
geographic variation in opioid prescribing practices across hospital referral regions; 2) 
the relative strength of clustering of prescribing practices between states and hospital 
referral regions; and 3) the association between opioids and dose initiated. To our 
knowledge, this approach has never been applied to studies of geographic variation in 
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nursing home medication use and offered a unique look at how states may influence 
prescribing in comparison to healthcare markets. 
 For aim 3, we used a new-user, active comparator cohort study. Such a design 
should reduce confounding by indication and selection bias introduced by comparing 
incident and prevalent users (“prevalent user bias”).
159,160
 In comparison to prior studies 
of opioid safety in older adults,
58–60
 we were able to incorporate a richer set of potential 
confounders based on the MDS 3.0. Using inverse probability of treatment weighting, we 
efficiently adjusted for a large number of potential confounders, which was particularly 
relevant given the high dimensionality of our data and the rarity of our study outcome.
161
 
We also conducted multiple secondary, sensitivity, and bias analyses
145,173
 to examine 
how our results may have been affected by different analytic decisions, which provided 
further support for our primary study findings.  
LIMITATIONS 
 This dissertation is not without limitations. Data are from 2011-2013, and recent 
laws and policy changes are likely affecting opioid prescribing in nursing homes,
174
 such 
as the rescheduling of hydrocodone from schedule III to schedule II.
112
 Additionally, 
aims 1 (2012 only) and 2 (2011 only; the only year that we had Part B outpatient claims 
available) used only one year of data. They provide no information on how the overall 
prevalence of long-term opioid use or geographic variation in initiation may be changing 
over time. Although we are skeptical that these policy changes would drastically modify 
the main conclusions of our work, we recognize that our results may not accurately 
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reflect current prescribing practices in nursing homes, which are likely shifting in 
response to rapidly evolving policies aimed at slowing the opioid epidemic. 
Throughout, we assumed that opioids were used as prescribed. Violations of this 
assumption could have resulted in outcome misclassification when examining the 
prevalence of long-term opioid use (aim 1) or opioid initiation patterns (aim 2) if 
residents prescribed opioids never used their medications. If such practices were 
pervasive, we likely overestimated prevalent and incident opioid use. However, the 
majority of residents classified as long-term opioid users had documentation on the MDS 
3.0 stating that they were administered analgesics (>90%; this measure is however not 
specific to opioids). We further doubt that the practice of filling but not using opioids is 
common for long-stay nursing homes residents, as these opioids cannot be easily 
prescribed in many states,
175
 and fills likely represent efforts to alleviate acute and 
chronic pain and not simply as a precautionary measure for future pain. For our 
comparative safety study (aim 3), following persons who were prescribed but not actually 
using a study drug could have resulted in exposure misclassification.
176
 Assuming opioids 
do increase the risk of fractures, this misclassification (classifying non-users as users) 
would have attenuated our cumulative risk estimates and biased our subdistribution 
hazard ratios towards or away from the null depending on the extent to which such 
misclassification was differential by opioid initiated.  
 In our work comparing the initiation and safety of commonly used opioids (aims 
2-3), confounding by indication cannot be ruled out, as these medications have different 
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potencies and may be used differentially within nursing homes. For aim 2, if confounding 
by indication were present and not sufficiently adjusted for in multilevel models, we 
would have underestimated the extent to which resident characteristics explained 
variation between hospital referral region practices in opioid initiation practices. Such 
confounding may to some extent be present, as outpatient claims provide limited 
information on pain severity which may influence initiating higher doses or 
oxycodone.
177
 However, we find it unlikely that such patterns could geographically vary 
to the extent needed to fully explain our results (e.g., one would have to imagine that 
Texas nursing home residents are so fundamentally different from all other residents as a 
potential reason for why they were almost never prescribed oxycodone). For aim 3, we 
tried to address confounding by indication with the new-user, active comparator design 
and a rich set of potential confounders. However, we also performed subgroup analyses 
and bias analyses to quantify the strength an unmeasured confounder would need to be to 
completely attenuate our primary results.
145,173
 Alternative analytic approaches may be 
needed to further address confounding by indication (see FUTURE RESEARCH 
DIRECTIONS), though we believe our study design, coupled with the results from aim 
2 (that resident characteristics were minimally associated with or explained patterns of 
geographic variation in opioid initiated) mitigate some of these concerns.  
 Throughout, we focused on residents who were “long-stay” and modified this 
definition depending on the demands of our study design including medication washout 
and covariate lookback periods. This study criteria requiring a study participant to reside 
in the same facility for 90-120 days with no recent hospitalizations or skilled nursing 
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facilities could introduce selection bias if our sample deviated substantially from our 
conceptual population of interest – older persons receiving care to manage their chronic 
comorbidities and/or declining functioning that is intended to be long-term.
71,178,179
 
Despite this, we believe our study design increased the internal validity of our results and 
were nonetheless worth these potential limitations.   
 Selection bias could have additionally been introduced by loss to follow-up (aims 
1 and 3). In aim 1, we specifically looked at residents discharged from the nursing home 
to understand how loss to follow-up may have affected our estimates of opioid use. 
Although opioid use was higher in those who were lost to follow-up, accounting for these 
residents in our estimate of overall opioid use had minimal impact on our conclusions 
(32.4% vs. 33.7% overall opioid use). In our comparative safety work, we considered 
alternative durations of follow-up and analytic approaches that were similar to our 
primary findings, potentially mitigating loss to follow-up concerns. 
 Although the MDS 3.0 merged to Medicare claims provides data not normally 
available in pharmacoepidemiologic studies, we lacked information on certain 
confounders including end-of-life preferences and measures of terminal illness. These 
measures may have some impact on the types and doses of opioids used and initiated. For 
our work on geographic variation, these sources of unmeasured confounding may have 
underestimated the proportion of variation explained by resident characteristics if such 
preferences also geographically varied. We note that prior studies suggest that patient 
end-of-life care preferences have limited effect on geographic variability in end-of-life 
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healthcare intensity,
180
 which may reduce concerns of these confounders affecting our 
analyses if such results extend to preferences on medications received in nursing homes. 
For our comparative safety work, we conducted bias analyses for unmeasured 
confounding, but more detailed and complete data on potential confounders would be 
preferable.  
Previous work has raised concerns on the validity of the MDS to accurately 
measure resident characteristics.
181
 Although this prior work focused on the MDS 2.0 and 
concluded that the MDS is still a suitable source of information for research, it naturally 
raises concerns on the quality of MDS 3.0 data. We note that recent studies suggest that 
the MDS 3.0 can more accurately measure resident characteristics and clinical events in 
comparison to previous versions of the MDS.
76,182–184
 It is unclear to what extent 
limitations in data quality could affect this work and other studies relying on these data to 
study medication use and safety in nursing homes.  
Acetaminophen and over-the-counter NSAIDS were not measurable with Part D 
claims.
185
 Thus, we were limited in our abilities to describe nonopioid analgesics and 
could only capture prescribed NSAIDS and opioid combination products (e.g., 
hydrocodone/acetaminophen).Given that the primary purpose of this research was to 
describe opioid use and safety, we believe this limited the interpretation of our results 
minimally but must nonetheless be kept in mind. To our knowledge, NSAIDS and 
acetaminophen are not thought to increase fall of fracture risk, especially when compared 
to opioids.
59,60
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FUTURE RESEARCH DIRECTIONS 
 Our work raises a number of interesting questions for further research. As 
mentioned above, aims 1 and 2 used only one year of data. Given rapid changes in policy, 
further work to understand how the prevalence of long-term opioid use and geographic 
variation in opioid use are changing over time is needed. Additionally, examining how 
trends in the prevalence of pain may be changing in association with opioid prescribing 
patterns over time may provide further context and insights on the role of opioids in pain 
management, though such designs may be limited in their ability to disentangle the 
relationship between opioids and measured pain and also be limited by unmeasured 
confounding, measurement error, and selection bias.  
Although aim 1 documented a number of opioid prescribing practices associated 
with overdose and death in community settings, the extent to which opioid initiation and 
use are associated with overdose hospitalizations and overdose-related death in nursing 
homes is unknown. This may be a valuable direction for future research to provide 
insight on the safety of using opioids in this medically supervised setting, particularly in 
comparison to noninstitutionalized populations. If overdose events are rare, examining 
naloxone prescribing may be a reasonable proxy endpoint that may conceptually capture 
concern and precautions against overdose, or alternatively as actual use to manage and 
reverse an opioid overdose.
186
 This is particularly relevant given the systematic exclusion 
of nursing home residents from studies of overdose risk.
45–49
 
 102 
 
 
 
 
Aim 2 raises questions on specific state laws and policies that may affect opioid 
prescribing among nursing home residents. These laws and policies (e.g., hydrocodone 
rescheduling)
112
 could potentially relax assumptions on unmeasured confounding and 
represent natural experiments lending themselves to quasi-experimental approaches.
187,188
 
Notably, beyond just examining changes in medication use, these policy changes could 
be used to examine opioid effectiveness and safety if they were strong predictors of the 
opioid a resident is prescribed. 
Our comparative safety work only examined one safety endpoint. Additional 
work is needed to 1) understand the comparative safety of commonly used opioids on 
other safety outcomes (e.g., cardiovascular disease); 2) explore the potentially mediating 
pathways that may explain differential risks such as fracture; and 3) extend our 
comparative safety work to also examine other endpoints of interest to clinicians, 
residents, and their families such as comparative effectiveness. Alternative treatment 
contrasts – such as initiating different opioid doses – also require evaluation to further 
understand the risk of opioids in nursing homes. 
Future studies of medication use and safety in nursing homes should also consider 
alternative strategies to better address unmeasured confounding, measurement error, and 
selection bias. Such work would be responsive to calls for “triangulating” evidence in 
etiological epidemiology.
189,190
 Triangulation refers to the process of integrating the 
results of several different epidemiologic approaches applied to the same causal question, 
with each approach having different and unrelated biases. Although our work represents a 
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first step in this direction by focusing on nursing home residents, who may have differing 
confounding structures than community-dwelling adults (i.e., a cross-cohort 
comparison),
191
 this dissertation and the prior work by Solomon and colleagues
58
 require 
the strong assumptions of no unmeasured confounding, measurement error, and selection 
bias to hold for our conclusions to be valid. In the spirit of triangulation, future studies 
addressing this study question could apply alternative analytic approaches that have 
different, unrelated biases including natural experiments (e.g., state policy changes, 
highlighted above),
187
 instrumental variables,
192,193
 and negative control exposures and/or 
outcomes.
194,195
 Adapting these approaches could provide further context for the 
comparative safety of commonly used opioids and fracture hospitalizations and are 
particularly relevant given how underrepresented nursing home residents are in clinical 
research. 
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APPENDICES FOR CHAPTER II 
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Appendix 2.1: Specific opioid medications prescribed to study participants during the 120 day follow-up window 
(N=315,949). 
      Stratified by length of opioid use 
Medication Used (%)
1 
 Overall 
(N=315,949) 
 Any opioid 
use 
(n=102,297) 
 Short-term 
(n=31,252) 
 Medium-term 
(n=19,724) 
 Long-term 
(n=46,744) 
Any Opioid  32.4         
   Short-acting opioids
2
  30.3  93.5  99.4  98.2  87.5 
      Codeine / acetaminophen  1.1  3.3  4.9  3.0  2.4 
      Hydrocodone / acetaminophen  16.9  52.5  53.7  59.8  48.9 
      Hydrocodone / NSAID  0.0  0.1  0.1  0.1  0.2 
      Hydromorphone  0.2  0.7  0.3  0.8  0.8 
      Morphine   0.7  2.1  2.7  1.9  1.9 
      Oxycodone  1.4  4.3  2.9  4.7  5.0 
      Oxycodone / acetaminophen  2.5  7.8  6.8  8.9  8.0 
      Tramadol  9.9  30.4  31.3  29.1  30.4 
      Tramadol / acetaminophen  0.5  1.5  1.4  1.5  1.6 
   Long-acting opioids
3
  5.8  17.8  1.0  5.5  34.3 
      Buprenorphine  0.0  0.1  0.0  0.1  0.2 
      Fentanyl  4.0  12.5  0.7  3.4  23.9 
      Methadone  0.3  1.0  0.1  0.4  1.9 
      Morphine extended release  0.9  2.7  0.1  0.8  5.3 
      Oxycodone extended release  0.6  1.9  0.1  0.8  3.6 
      Tramadol extended release  0.0  0.1  0.1  0.1  0.2 
1Columns do not add up to 100% because some participants received more than one type of opioid. 
2Short-acting opioids (single-agents and/or combinations) used by <0.1% of all opioid users were not presented but include: codeine (as a single agent), 
dihydrocodeine, meperidine, nalbuphine, oxycodone/NSAID, oxymorphone, pentazocine, and tapentadol. 
3Long-acting opioids used by <0.1% of all opioid users were not presented but include: butorphanol, hydromorphone extended release, oxymorphone extended 
release, and tapentadol extended release.
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Appendix 2.2: Specific NSAIDS, pain adjuvants, and other medications used for pain and prescribed to study participants 
(overall and stratified by any opioid use and length of opioid use) during the 120 day follow-up window. (N=315,949). 
    Stratified by any opioid use  Stratified by length of opioid use 
Medication Used (%)
1 
 Overall 
(N=315,949) 
 
No use 
(n=213,652) 
 
Any use 
(n=102,297) 
 
Short-term 
(n=32,841) 
 
Medium-term 
(n=20,615) 
 
Long-term 
(n=48,841) 
NSAID prescriptions
2
  10.9  8.4  16.1  15.3  17.5  16.0 
   Celecoxib  1.5  1.0  2.4  2.0  2.7  2.5 
   Diclofenac  1.9  1.1  3.6  2.8  3.9  4.0 
   Etodolac  0.1  0.1  0.2  0.1  0.2  0.2 
   Ibuprofen  2.6  2.3  3.0  3.5  3.0  2.7 
   Indomethacin  0.2  0.2  0.3  0.4  0.3  0.3 
   Ketorolac  0.1  0.0  0.2  0.1  0.2  0.2 
   Meloxicam  3.6  2.6  5.6  5.4  6.5  5.4 
   Nabumetone  0.3  0.3  0.5  0.4  0.4  0.5 
   Naproxen  1.3  1.1  1.8  1.9  1.9  1.6 
   Sulindac  0.1  0.1  0.1  0.1  0.1  0.1 
Pain Adjuvants  20.7  14.9  32.9  27.6  34.7  35.7 
   Anticonvulsants  14.2  9.7  23.6  19.7  25.5  25.4 
      Carbamazepine  1.2  1.2  1.3  1.4  1.1  1.3 
      Gabapentin  10.9  7.0  19.0  15.5  20.8  20.5 
      Lamotrigine  1.1  1.0  1.2  1.2  1.3  1.2 
      Pregabalin  1.7  0.9  3.4  2.7  3.7  3.8 
   Antidepressants
3 
 9.2  6.4  15.0  11.6  15.6  17.1 
      Tricyclics
4
  1.4  1.0  2.4  1.8  2.5  2.7 
         Amitriptyline  0.9  0.6  1.6  1.2  1.8  1.8 
         Nortriptyline  0.5  0.4  0.8  0.6  0.7  0.9 
      SNRIs
 5
  8.0  5.5  13.0  10.0  13.4  14.9 
         Duloxetine  4.8  2.8  9.1  6.4  9.6  10.7 
         Venlafaxine   3.2  2.8  4.1  3.7  4.0  4.3 
Other medications used for pain  15.7  11.0  25.5  21.8  27.4  27.2 
   Corticosteroids
6 
 8.3  6.4  12.1  11.2  13.1  12.2 
      Dexamethasone  0.4  0.3  0.7  0.7  0.8  0.7 
      Prednisone  6.4  5.0  9.2  8.4  9.9  9.4 
      Methylprednisolone  2.1  1.6  3.1  3.1  3.4  2.9 
   Muscle relaxants
7
  4.6  2.7  8.5  6.6  9.1  9.6 
      Baclofen  2.2  1.6  3.6  2.8  3.5  4.1 
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      Carisoprodol  0.2  0.1  0.4  0.2  0.4  0.4 
      Cyclobenzaprine  1.5  0.7  3.2  2.6  3.7  3.5 
      Metaxolone  0.1  0.1  0.2  0.2  0.2  0.2 
      Methocarbamol  0.4  0.2  0.9  0.7  0.9  1.0 
      Tizanidine  0.6  0.3  1.2  0.8  1.3  1.4 
   Transdermal lidocaine  4.3  2.4  8.4  6.2  9.2  9.5 
Potentially contraindicated 
psychopharmacologics
8
 
            
   Antipsychotics  26.3  26.9  25.1  25.1  25.7  24.8 
   Anxiolytics  19.0  15.4  26.7  23.0  29.7  27.9 
   Hypnotics  4.8  3.1  8.4  7.3  10.1  8.5 
Abbreviations: NSAID: nonsteroidal anti-inflammatory drug ;SNRI: serotonin-norepinephrine reuptake inhibitor 
1Columns do not add up to 100% because some participants received more than one type of opioid. 
2NSAIDS prescribed to <0.1% of the total population were not presented but include: choline magnesium salicylate, diflunisal, fenoprofen, flurbiprofen, ketoprofen, 
oxaprozin, piroxicam, salsalate, and tolmetin 
3Limited to antidepressants commonly used as pain adjuvants as defined in the 2009 American Geriatrics Society persistent pain guidelines.23 
4Tricyclics used by <0.1% of the total population were not presented but include: desipramine 
5SNRIs used by <0.1% of the total population were not presented but include: milnacipran 
6Corticosteroids used by <0.1% of the total population were not presented but include: prednisolone 
7Muscle relaxants used by <0.1% of the total population were not presented but include: chlorzoxazone, dantrolene, orphenadrine 
8Defined using the Minimum Data Set during 120-day follow-up (excludes the index MDS assessment). 
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Appendix 2.3: Association between resident characteristics and long-term opioid 
use, restricted to residents in persistent pain (n=48,922) 
Characteristic 
 
Long-term 
opioid use, 
% 
 
Crude PR 
(95% CI) 
 
Adjusted PR
1
 
(95% CI) 
Age, years       
   65-74  37.7  Referent  Referent 
   75-84  36.7  0.97 (0.94–1.00)  0.98 (0.95–1.01) 
   ≥85  34.1  0.91 (0.88–0.94)  0.90 (0.87–0.93) 
Gender       
   Men  31.8  Referent  Referent 
   Women  36.5  1.14 (1.10–1.18)  1.09 (1.05–1.12) 
Race/ethnicity       
   Non-Hispanic White  36.6  Referent  Referent 
   Non-Hispanic Black  29.8  0.82 (0.78–0.86)  0.88 (0.84–0.93) 
   Hispanic/Latino  28.4  0.79 (0.73–0.85)  0.87 (0.80–0.95) 
   Asian  22.6  0.65 (0.52–0.79)  0.71 (0.57–0.80) 
   Other  28.6  0.80 (0.66–0.96)  0.82 (0.68–0.98) 
Cognitive Impairment       
   No/mild   38.7  Referent  Referent 
   Moderate  34.1  0.89 (0.86–0.91)  0.92 (0.89–0.95) 
   Severe  31.1  0.81 (0.78–0.83)  0.86 (0.83–0.89) 
Physical impairment       
   No/mild  36.8  Referent  Referent 
   Moderate  34.6  0.94 (0.91–0.96)  0.97 (0.95–1.00) 
   Severe  36.5  1.00 (0.97–1.03)  1.07 (1.03–1.11) 
Abbreviations: CI: confidence interval; PR: prevalence ratio 
1Prevalence ratios were estimated using modified Poisson models (using generalized estimating 
equations to account for clustering within nursing homes).91 Models are adjusted for all resident 
characteristics in Table 1 and state of residence. 
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Appendix 3.1: Study and non-study opioids and OME conversion factors 
Opioid 
OME conversion factor 
(study drugs only)
1
 
Study opioids (short-acting, oral formulations only)  
Hydrocodone (hydrocodone/acetaminophen, 
hydrocodone/NSAID)
2
 
1.0 
Oxycodone (oxycodone, oxycodone/acetaminophen, 
oxycodone/NSAID) 
1.5 
Tramadol (tramadol, tramadol/acetaminophen) 0.1 
Non-study opioids (including both short- and long-acting 
formulations when applicable; also includes oral, 
injection, transdermal, and other formulations [e.g., 
nasal] when applicable) 
 
Buprenorphine - 
Butorphanol - 
Codeine - 
Dihydrocodeine - 
Fentanyl - 
Hydromorphone  - 
Levorphanol - 
Meperidine - 
Methadone - 
Morphine - 
Nalbuphine - 
Oxycodone, parenteral - 
Oxymorphone - 
Pentazocine - 
Tapentadol - 
Abbreviations: NSAID, nonsteroidal anti-inflammatory drug; OME, oral morphine 
equivalent 
1
Based on Center for Disease Control and Prevention recommendations.
101
  
2
excludes cough preparations 
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Appendix 3.2: International Classification of Disease, Ninth Revision, Clinical Modification 
codes used to define painful comorbidities reported on Medicare Part B claims
1
 
Comorbidity  Definition 
Injuries (excludes poisonings)   
   Fracture  733.1x, 800.xx - 829.xx 
   Dislocations  830.xx – 839.x 
   Sprains  840.xx-848.xx 
   Intracranial injury  850.xx-854.xx 
   Internal injury of thorax, abdomen, 
pelvis 
 860.xx-869.xx 
   Open wounds  870.xx-897.xx 
   Blood vessel injuries  900.xx-904.xx 
   Superficial injuries  910.xx-919.xx 
   Contusions  920.xx-924.xx 
   Crushing injury  925.xx-929.xx 
   Foreign body entering through orifice  930.xx-939.xx 
   Burns  940.xx-949.xx 
   Traumatic complications / unspecified   958.xx-959.xx 
   External cause of injury  E800.x–E849.x; E880.x–E909.x; E916.x–E928.x; 
E953.x–E968.x; E970.x–E976.x; E983.x–E999.x 
Chronic pain  338.0, 338.2x, 338.4, 780.96 
Abdominal pain  789.0x 
Musculoskeletal pain   
   Back/neck pain  720.xx-224.xx 
   Limb pain  354.4, 355.71, 729.5 
   Arthritis/rheumatism/joint 
pain/myalgia 
 710.xx-719.xx, 725.xx-729.xx (excluding 729.5) 
Neuropathic pain  53.1x, 250.6x, 336.9, 337.1, 337.2x, 340, 341.9, 
350.x, 351.x, 353.x, 354.x, 355.x, 356.x, 357.81, 
729.2, 951.4, 952.xx, 953.4, 955.5, 955.6, 955.7 
1
Diagnoses were primarily defined using Davis et al., 2011;
196
 Caplan et al., 2010;
197
 Narayana et 
al., 2015;
198
 and Mack et al., 2015.
199
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Appendix 3.3: Complete resident and facility characteristics of long-stay residents initiating opioids in 2011, overall and 
stratified by opioid and dosage strength initiated (N=62,889 residents in 12,345 facilities within 298 hospital referral 
regions). 
    Stratified by opioid initiated  Stratified by dose initiated / day 
Characteristic1, % 
 Overall 
(N=62,889) 
 Oxycodone 
(n=5,891) 
 Hydrocodone 
(n=35,326) 
 Tramadol 
(n=21,672) 
 ≥50 mg OME 
(n=4,232) 
 <50 mg OME 
(n=58,657) 
Resident characteristics             
Age, years             
   65-74  15.9  19.1  17.2  12.9  22.0  15.4 
   75-84  31.2  32.3  31.7  29.9  34.1  30.9 
   ≥85   53.0  48.6  51.1  57.2  44.0  53.6 
Women  75.8  73.0  74.3  79.1  69.9  76.2 
Race/ethnicity             
   Non-Hispanic white  82.3  80.3  82.1  83.2  82.2  82.3 
   Non-Hispanic black  11.7  13.7  11.7  11.1  11.8  11.7 
   Hispanic/Latino  4.5  4.6  4.5  4.6  4.7  4.5 
   Other  1.5  1.4  1.7  1.1  1.3  1.5 
Physical limitations2             
   None/mild  27.8  21.8  27.6  29.7  26.5  27.8 
   Moderate  50.7  52.9  50.5  50.4  54.1  50.5 
   Severe  21.5  25.3  21.9  20.0  19.4  21.7 
Cognitive impairment3             
   None  29.0  34.1  27.9  29.3  32.0  28.8 
   Moderate  31.5  31.5  31.5  31.5  32.6  31.4 
   Severe  39.5  34.4  40.6  39.2  35.4  39.8 
Dementia  59.4  53.9  59.4  60.7  53.9  59.8 
Psychopharmacologic Medications4             
   Antidepressants  62.3  64.9  63.1  60.4  64.2  62.2 
   Antipsychotic  27.5  24.5  28.3  26.9  26.5  27.5 
   Antianxiety   21.3  20.5  22.0  20.4  19.4  21.4 
   Hypnotics  6.5  6.7  6.7  6.1  7.2  6.4 
Other medications prescribed for pain4             
   Anticonvulsants  15.5  19.5  15.7  13.9  18.4  15.2 
   Corticosteroids  7.2  7.8  7.1  7.1  7.3  7.2 
   Muscle relaxants  4.1  5.1  4.3  3.6  5.7  4.0 
   NSAIDS  11.6  10.7  11.2  12.6  10.8  11.7 
Pain recorded on MDS5             
   None  66.9  62.0  66.9  68.3  63.3  67.2 
   Any self-reported pain  28.8  33.4  28.6  28.0  33.0  28.5 
   Any staff-assessed pain  4.2  4.6  4.5  3.6  3.7  4.3 
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Painful comorbidities5,6             
   Any injury (excludes poisonings)  18.3  22.6  19.0  15.8  21.2  18.0 
   Pressure ulcers  7.4  11.3  7.2  6.5  8.8  7.3 
   Diagnosed chronic pain  2.7  4.0  2.5  2.6  3.3  2.7 
   Abdominal pain  5.5  7.2  5.2  5.3  6.5  5.4 
   Musculoskeletal pain  64.0  67.5  62.6  65.4  62.2  64.1 
   Neuropathic pain  7.3  8.2  7.3  6.9  9.1  7.1 
Any emergency room use  16.2  18.0  17.7  13.3  18.8  16.0 
Total number of Part B claims             
   <5  21.9  14.0  22.1  23.7  18.7  22.1 
   5-9  33.2  28.4  33.4  34.1  29.2  33.5 
  10-14  20.3  22.5  20.3  19.6  21.1  20.2 
  ≥15   24.7  35.1  24.2  22.6  31.0  24.2 
Facility characteristics             
Rural location  31.6  19.1  33.6  31.9  28.0  31.9 
Size, number of beds             
   <100   30.5  22.2  32.5  29.4  29.6  30.5 
   100-199  58.6  56.5  58.2  59.6  60.7  58.4 
   ≥200   11.0  21.3  9.3  11.0  9.7  11.1 
Ownership             
   For profit  73.1  68.2  75.0  71.3  77.3  72.8 
   Government  5.7  6.0  5.3  6.1  4.3  5.8 
   Non profit   21.3  25.8  19.7  22.6  18.3  21.5 
Part of a chain  57.6  49.6  59.1  57.3  61.7  57.3 
Occupancy, %             
   <80  26.4  16.0  28.4  25.9  29.2  26.2 
   80-89  29.8  28.2  30.1  29.8  30.2  29.8 
   90-94  23.3  27.3  22.5  23.3  22.7  23.3 
   ≥95  20.5  28.5  18.9  20.9  17.9  20.7 
Residents in facility receiving skilled 
nursing care, % 
            
   <10   35.6  34.3  37.1  35.6  33.3  36.6 
   10-19  46.5  46.6  46.2  47.0  47.0  46.5 
   ≥20  17.1  19.1  16.7  17.3  19.7  16.9 
Nursing home compare quality rating, 
stars 
            
   1  9.4  8.0  10.0  8.7  10.4  9.3 
   2  19.0  17.4  19.1  19.0  18.9  19.0 
   3  25.6  25.5  25.4  26.0  25.6  25.6 
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   4  32.2  33.6  31.8  32.5  33.0  32.2 
   5  13.9  15.4  13.7  13.7  12.1  14.0 
Residents with facility-acquired bed 
sores, % 
            
   0  15.7  13.2  15.7  16.4  15.0  15.8 
   0.1-2.4  34.6  37.8  34.2  34.4  35.8  34.5 
   2.5-4.9  30.5  31.6  30.4  30.3  30.6  30.5 
   ≥5%  19.2  17.4  19.7  18.8  18.5  19.2 
Residents restrained, %             
   0  38.9  37.3  38.3  40.4  41.6  38.7 
   0.1-1.9  18.8  22.5  18.1  19.0  18.1  18.9 
   2.0-4.9  21.7  20.5  22.0  21.6  20.6  21.8 
   ≥5  20.5  19.8  21.6  19.1  19.7  20.6 
Registered nurse staffing, minutes per 
resident day 
            
   <27.3  27.9  17.2  30.1  28.1  26.5  28.0 
   27.4-36.8  26.7  25.3  27.3  26.4  25.7  26.7 
   36.9-48.3  24.5  29.9  23.5  25.2  24.6  24.5 
   ≥48.4  21.0  27.5  19.1  20.3  23.3  20.8 
Physician staffing,  minutes per 
resident day 
            
   <0.3  25.9  20.1  26.5  26.4  24.1  26.0 
   0.3-0.6  26.4  24.0  26.9  26.8  27.6  26.4 
   0.7 -1.1  24.5  25.9  24.5  24.5  25.5  24.5 
   ≥1.2  23.2  30.0  22.1  22.3  22.8  23.2 
Physician extender staffing, minutes 
per resident day  
            
   0  57.5  51.5  58.6  57.3  55.6  57.6 
   0.1-0.6  16.6  14.9  16.7  16.9  16.3  16.6 
   ≥0.7  25.9  33.7  24.8  25.7  28.1  25.8 
Abbreviations: MDS, Minimum Data Set; NSAIDS, nonsteroidal anti-inflammatory drugs; OME, oral morphine equivalents 
1Column percentages may not add to 100% due to rounding. 
2Physical limitations were defined using the Activities of Daily Living Self-Performance Hierarchy (range: 0-6) to categorize residents as having no/mild (0-2), 
moderate (3-4), or severe limitations (5-6).  
3Cognitive impairment was defined using the Brief Interview for Mental Status (BIMS; range: 0-15) when the resident could self-report and the Cognitive 
Performance Scale (CPS; range: 0-6) otherwise: none/mild (BIMS 13-15 or CPS 0-2), moderate (BIMS 8-12 or CPS 3-4) or severe impairment (BIMS 0-7 or 
CPS 5-6). 
4Subcategories are not mutually exclusive and may add to >100%. 
5Derived from the most recent Minimum Data Set assessment preceding opioid initiation. 
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6Based on Part B claims from the 90 days prior to opioid initiation (see Appendix 3.2 for further information on definitions used). The total number of Part B 
claims (median and interquartile range [IQR]) varied by opioid initiated: hydrocodone (8, IQR: 5-14), oxycodone (11, IQR: 6-18), tramadol (8, IQR: 5-13). 
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Appendix 3.4: Further details on multilevel modelling. 
Overview. We were interested in quantifying geographic variation in opioid 
prescribing practices to examine 1) the extent to which variation in opioid prescribing 
between hospital referral regions (HRR) could be explained by differences in resident 
characteristics, facility characteristics, and state of residence; and 2) the correlation in the 
propensity of persons within similar geographic areas – including HRRs and state of 
residence – to initiate similar opioids or doses. To accomplish these aims, we fit a series 
of multilevel logistic models to explicitly model geographic variation with random 
intercepts and progressively adjusting for resident characteristics, facility characteristics, 
and state.
105,200,201
  
Outcomes. Opioid prescribing practices of interest included initiating specific 
commonly-used opioids (e.g., initiating hydrocodone vs. initiating oxycodone or 
tramadol) or doses ≥50 mg oral morphine equivalents (OME) per day versus doses <50 
mg OME/day. Outcomes were dichotomized to enhance clinical interpretability and 
because we were conceptually interested in measuring the variation of particular 
prescribing practices versus all other common practices and not with respect to a specific 
referent medication (i.e., as one would estimate with a multinomial model).   
Model Building. For each outcome, we sequentially fit a series of 4 models that 
progressively adjusted for resident characteristics, facility characteristics, and state of 
residence while measuring the variance parameters of interest. Models were sequentially 
fit so that we could examine the extent to which differences in resident characteristics, 
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facility characteristics, and state contributed to any observed geographic variation 
between HRRs. The models included: 
Model 1. Null multilevel logistic model including random intercepts for HRRs: 
 logit (𝑃(𝑌𝑖𝑗 = 1|𝛼𝑜𝑗)) =  𝛽0 + 𝛼0𝑗, (1) 
where the outcome 𝑌𝑖𝑗=1 if resident 𝑖 within HRR 𝑗 initiated the study opioid or dose of 
interest and 𝑌𝑖𝑗=0 otherwise, 𝛽0 is the log-odds of the proportion of initiators initiating 
the study opioid or dose at the average HRR, and 𝛼0𝑗 is the HRR-specific random 
intercept measuring variation in the proportion of initiators prescribed specific opioids or 
dose on the logistic scale, assumed to be normally distributed with mean 0 and variance 
𝜎𝐻𝑅𝑅
2, 𝛼0𝑗~𝑁(0, 𝜎𝐻𝑅𝑅
2 ). The variance of the random intercepts for HRRs (𝜎𝐻𝑅𝑅
2) from 
model 1 provide a crude (unadjusted) estimate of between-HRR variation on the logistic 
scale.   
Model 2. Multilevel logistic model adjusting for resident characteristics and including 
random intercepts for HRRs: 
 logit (𝑃(𝑌𝑖𝑗 = 1|𝛼𝑜𝑗 , 𝑿𝑖𝑗
𝑟 )) = 𝛽0 + 𝜷𝒓𝒆𝒔𝑿𝒊𝒋
𝒓 + 𝛼0𝑗, (2) 
where 𝑌𝑖𝑗, 𝛽0 , 𝛼0𝑗 are as described in equation 1 but we additionally adjusted for a vector 
of resident characteristics 𝑿𝑖𝑗
𝑟  included in the model as fixed effects (see Appendix 3.3 
for specific resident characteristics included). The variance of the random intercepts for 
HRRs (𝜎𝐻𝑅𝑅
2) from model 2 estimates between-HRR variation on the logistic scale after 
adjusting for measured resident characteristics.    
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Model 3. Multilevel logistic model adjusting for resident and facility characteristics and 
including random intercepts for HRRs: 
 logit (𝑃(𝑌𝑖𝑗 = 1|𝛼𝑜𝑗 , 𝑿𝑖𝑗
𝑟 , 𝑿𝑖𝑗
𝑓
)) = 𝛽0 + 𝜷𝒓𝒆𝒔𝑿𝑖𝑗
𝑟 + 𝜷𝒇𝒂𝒄𝑿𝑖𝑗
𝑓
+𝛼0𝑗, (3) 
with all previously defined variables in equations 1-2 and additionally adjusted for a 
vector of facility characteristics 𝑿𝑖𝑗
𝑓
 included as fixed effects (see Appendix 3.3). Note 
that because most facilities included few study participants, we did not adjust for 
clustering within facilities using random intercepts due to concerns of increasing bias 
when estimating variance components.
202
 The variance of the random intercepts for 
HRRs from model 3 provides an adjusted estimate of between-HRR variation on the 
logistic scale after accounting for measured resident and facility characteristics. 
Model 4. Cross-classified logistic model adjusting for resident and facility characteristics 
and including random intercepts for HRRs and state: 
logit (𝑃(𝑌𝑖𝑗𝑘 = 1|𝛼𝑜𝑗, 𝛼0𝑘, 𝑿𝑖𝑗𝑘
𝑟 , 𝑿𝑖𝑗𝑘
𝑓
)) = 𝛽0 + 𝜷𝒓𝒆𝒔𝑿𝑖𝑗𝑘
𝑟 + 𝜷𝒇𝒂𝒄𝑿𝑖𝑗𝑘
𝑓
+𝛼0𝑗 +𝛼0𝑘, (4) 
with all previously described variables (equations 1-3, but with a subscript for state 𝑘 
added to the vectors of resident and facility characteristics) and an additional random 
intercept for state of residence with mean 0 and variance 𝜎𝑆𝑡𝑎𝑡𝑒
2 , 𝛼0𝑘~𝑁(0, 𝜎𝑆𝑡𝑎𝑡𝑒
2 ) to 
separately estimate the contributions of state and HRRs to variation in opioid prescribing. 
Cross-classified models were used to account for the non-nested data structure (see 
Figure 1). This model was used to 1) estimate the between-HRR variation adjusted for 
resident and facility characteristics and state of residence (random effect 𝛼0𝑘); 2) 
separately compare clustering within states and within HRRs, as defined below.  
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 Measuring proportional change in between HRR variation. To achieve our 
aim to understand the extent that between-HRR variation of initiating specific opioids or 
doses could be explained by resident characteristics, facility characteristics, and state of 
residence, we estimated the proportional change in between-HRR variation (PCV). The 
PCV is a percentage reflecting the between-HRR variation explained by the multilevel 
model and is defined separately for models 2-4 in reference to model 1 as: 
    ?̂?𝐻𝑅𝑅
2
(𝑚𝑜𝑑𝑒𝑙 1)− ?̂?𝐻𝑅𝑅
2
(𝑚𝑜𝑑𝑒𝑙 𝑥)
?̂?𝐻𝑅𝑅
2
(𝑚𝑜𝑑𝑒𝑙 1)
× 100, (5) 
where ?̂?𝐻𝑅𝑅
2
(𝑚𝑜𝑑𝑒𝑙 1)
 is the estimated variance of the random intercepts for HRRs from 
model 1 and ?̂?𝐻𝑅𝑅
2
(𝑚𝑜𝑑𝑒𝑙 𝑥)
 is the estimated variance of the random intercepts for HRRs 
from any model 2-4. The PCV can increase or decrease (i.e., negative percentages 
because adding covariates increased the variance of the distribution of the random effects 
for HRRs)
105,116
 with the addition of resident and facility characteristics.  
 Measuring the strength of clustering within HRRs versus within states. To 
understand clustering of opioid prescribing practices within similar geographic areas, we 
estimated intraclass correlation coefficients (ICC) for models 1-4. The ICC measures the 
correlation in the propensity to either initiate the same opioid or similar doses among two 
persons chosen at random from the same geographic area. As the ICC increases from 0 to 
1, it indicates that residents within the same area are more likely to be prescribed the 
same opioid (i.e., they are more similar to each other, and conversely more different from 
persons in other areas). The ICC was estimated using the latent response formulation of 
the logistic model. For models 1-3, we estimated the ICC within HRRs (ICCHRR) as: 
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𝐼𝐶𝐶𝐻𝑅𝑅(𝑚𝑜𝑑𝑒𝑙 𝑥) =
?̂?𝐻𝑅𝑅
2
(𝑚𝑜𝑑𝑒𝑙 𝑥)
?̂?𝐻𝑅𝑅
2
(𝑚𝑜𝑑𝑒𝑙 𝑥)+ 
𝜋2
3
 , (6) 
In which ?̂?𝐻𝑅𝑅
2
(𝑚𝑜𝑑𝑒𝑙 𝑥)
 is the estimated variance of the random intercepts for HRRs for 
models 1-3 and 
𝜋2
3
 represents the between-resident variance, which is held constant across 
multilevel logistic models.
105,201
 For cross-classified models (model 4), we estimated 
ICCHRR after partitioning out state variation (i.e., examining the ICC between persons in 
the same HRR but different states) as: 
 
𝐼𝐶𝐶𝐻𝑅𝑅(𝑚𝑜𝑑𝑒𝑙 4) =
?̂?𝐻𝑅𝑅
2
(𝑚𝑜𝑑𝑒𝑙 4)
?̂?𝐻𝑅𝑅
2
(𝑚𝑜𝑑𝑒𝑙 4)+?̂?𝑆𝑡𝑎𝑡𝑒
2
(𝑚𝑜𝑑𝑒𝑙 4)+ 
𝜋2
3
 , (6) 
where ?̂?𝐻𝑅𝑅
2
(𝑚𝑜𝑑𝑒𝑙 4)
 is the estimated variance of the random intercepts for HRRs, 
?̂?𝑆𝑡𝑎𝑡𝑒
2
(𝑚𝑜𝑑𝑒𝑙 4)
 is the estimated variance of the random intercepts for states, and 
𝜋2
3
 is 
between-resident variance. For model 4, we additionally estimated the ICC within states 
after partitioning out HRR variation (ICCstate; examines the ICC between persons in the 
same state but different HRRs) as: 
 
𝐼𝐶𝐶𝑆𝑡𝑎𝑡𝑒(𝑚𝑜𝑑𝑒𝑙 4) =
?̂?𝑆𝑡𝑎𝑡𝑒
2
(𝑚𝑜𝑑𝑒𝑙 4)
?̂?𝐻𝑅𝑅
2
(𝑚𝑜𝑑𝑒𝑙 4)+?̂?𝑆𝑡𝑎𝑡𝑒
2
(𝑚𝑜𝑑𝑒𝑙 4)+ 
𝜋2
3
 , (7) 
with all parameters previously defined in equation 6. 
Statistical Software. All multilevel logistic models were estimated with ‘proc 
glimmix’ and the Laplace method using SAS 9.4 (SAS Institute, Cary, NC, USA). 
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Appendix 3.5: Summary of the proportion and absolute number of residents 
initiating oxycodone, hydrocodone, tramadol, or doses ≥50 mg OME/day by state 
(N=62,889) 
Proportion of residents initiating opioids that were prescribed short-acting 
formulations of oxycodone, hydrocodone, or tramadol by state. 
 
Absolute number of residents initiating oxycodone, hydrocodone, or tramadol by 
state. 
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Proportion of residents initiating opioids that were prescribed doses ≥50 mg 
OME/day by state.
 
Absolute number of long-stay residents initiating opioids and prescribed ≥50 mg 
OME/day by state.
 
 
 
 
 
 
 
1
2
3
 
Appendix 3.6: Model variance components; measures of between-HRR variation explained by resident characteristics, facility 
characteristics, and state; and the magnitude of clustering within geographic areas for commonly initiated opioids and initiating doses ≥50 
mg OME/day (N=62,889 residents in 12,345 facilities within 298 hospital referral regions). 
  Characteristics included in multilevel model
1
 
  Null model  Resident  Resident + Facility   Resident + Facility + State  
Initiating oxycodone         
   τ
2
 for HRR  1.8972  1.8718  1.7491  0.3024 
   τ
2
 for state  -  -  -  1.1415 
   PCV
2
  Referent  1.3%  7.8%  84.1% 
   ICCHRR
3
  0.37  0.36  0.35  0.06 
   ICCstate
3
  -  -  -  0.24 
Initiating hydrocodone
4
         
   τ
2
 for HRR  0.6400  0.6529  0.6391  0.2676 
   τ
2
 for state  -  -  -  0.3395 
   PCV  Referent  -2.0%  1.4%  58.2% 
   ICCHRR  0.16  0.17  0.16  0.07 
   ICCstate  -  -  -  0.09 
Initiating tramadol
4
          
   τ
2
 for HRR  0.3585  0.3721  0.3673  0.1466 
   τ
2
 for state  -  -  -  0.2116 
   PCV  Referent  -3.8%  -2.4%  59.1% 
   ICCHRR  0.10  0.10  0.10  0.04 
   ICCstate  -  -  -  0.09 
Initiating doses ≥50 mg OME/day         
   τ
2
 for HRR  0.2256  0.2288  0.2061  0.1211 
   τ
2
 for state  -  -  -  0.09463 
   PCV  Referent  -1.4%  8.6%  46.3% 
   ICCHRR  0.06  0.07  0.06  0.03 
   ICCstate  -  -  -  0.03 
Abbreviations: τ2, variance of the random intercept; HRR, hospital referral region, ICC, intraclass correlation coefficient; OME, oral morphine equivalent; PCV, proportional change in 
between hospital referral region variation explained by the model 
1Multilevel logistic models with a random intercept for hospital referral region were sequentially fitted using resident and facility characteristics listed in Appendix 3.3. The final model 
was a cross-classified multilevel model including a second random intercept for state.  
2PCV describes the proportional change in HRR variation explained by the multilevel model and was estimated as (variance of random intercept in null model – variance of random 
intercept in adjusted model) / variance of random intercept in null model. 
3ICC estimates the correlation between two individuals randomly selected from each HRR and was estimated based on the latent response formulation of the multilevel logistic model.105 
The cross-classified model was used to estimate the correlation between two persons in the same HRR but different states (ICCHRR) and the same states but different HRRs (ICCstate). 
4Adding resident and facility characteristics to this model increased the variance. This can occur when there is negative correlation between the opioid initiated and resident factors 
within HRRs.116 
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Appendix 4.1:  
Data sources used in this study included the Minimum Data Set 3.0 merged to the 
Medicare enrollment (Master Beneficiary Summary File), pharmacy (Medicare Part D), 
and hospitalization files (Medicare Part A). Resident data were linked using a unique 
encrypted beneficiary identifier. 
The cohort included residents newly initiating short-acting oral formulations of 
hydrocodone, oxycodone, or tramadol during the period of 05/01/2011 to 12/31/2013. 
Residents had to meet all inclusion/exclusion criteria on the day the prescription was 
filled. The number of eligible participants and final number of initiation episodes are 
shown in Table 4.1; see Figure 4.1 for an overview of the study design. 
Criterion 1 and 2 limited the study population to Medicare-eligible long-stay nursing 
home residents, defined as residents with >120 day stay in the same nursing home facility 
with 4 months of Medicare Part A, Part B, and Part D coverage. We excluded residents 
with Part C (Medicare Advantage) coverage because their claims may be incomplete. We 
included only long-stay nursing home residents because they require long-term assistance 
to manage chronic disabilities and are different from short-stay residents.
71
 Although 
many prior studies of nursing home residents define “long-stays” using shorter time 
periods (e.g. ≥90 days or >100 days),
71,133,203,204
 we used a more conservative definition 
to ensure that we had a 4-month washout period (for defining new use) and to assess 
covariates. 
Criterion 3 limited the sample to new episodes of initiating oral formulations of short-
acting hydrocodone, oxycodone, or tramadol.
159
 Long-acting formulations were excluded. 
Residents prescribed multiple study drugs on the index date were not included. 
Criterion 4 excluded initiation episodes that were preceded by any SNF care or 
hospitalizations in the prior 120 days because these services – including medications used 
in this period – are paid for by Medicare Part A and represent ‘immeasurable time’
205
 
when we could not assess medication use with Part D claims. 
Criterion 5 restricted the sample to episodes with any MDS 3.0 assessment (quarterly or 
comprehensive) in prior 120 days AND a comprehensive assessment in the prior 365 
days. Quarterly assessments are condensed and do not collect information on many 
chronic comorbidities (e.g., cancer, arthritis, osteoporosis). Therefore, we used prior 
comprehensive assessments to assess medical comorbidities that were not recorded on the 
condensed quarterly assessments. 
Criterion 6 excluded episodes of care in provider-based facilities or free-standing SNFs 
because these facilities provide more extensive services and primarily serve different 
patient populations.
206
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Criterion 7 excluded residents <65 years because we were primarily interested in older 
residents who may be clinically different from younger Medicare beneficiaries (e.g., they 
may be covered because they are disabled). Criterion 8-9 excluded those with cancer or 
receiving hospice care because pain management guidelines are different for these 
populations. Criterion 10 excluded comatose residents. Criterion 11 excluded residents 
with any missing data.  
Criterion 12 excluded treatment episodes with unusually high starting doses (>180 mg 
oral morphine equivalents).
124,125
  
Criterion 13 excluded residents from states/districts contributing <100 treatment episodes 
to the analysis (Alaska, Washington DC). Criterion 14 excluded residents from states 
where <2% of treatment episodes were oxycodone (Illinois, Michigan, Texas). We 
implemented these criteria to increase covariate balance between treatment groups. 
Unique residents could contribute multiple opioid initiation episodes if they met 
eligibility criteria. 
  
 127 
 
 
 
 
Appendix 4.2: Study and non-study opioids 
Study opioids and oral morphine equivalent (OME) conversion factors.
101
 
Drug
1,2
 OME Conversion Factor
3
 
Hydrocodone (hydrocodone/acetaminophen, 
hydrocodone/NSAID)
4
 
1.0 
Oxycodone (oxycodone, oxycodone/acetaminophen, 
oxycodone/NSAID) 
1.5 
Tramadol (tramadol, tramadol/acetaminophen) 0.1 
1
We combined single agent and combination products (e.g., tramadol included both 
tramadol only tablets and tramadol/acetaminophen combination products).
 
2
Does not include parenteral formulations. Only short-acting formulations were included. 
3
Conversion factors are to convert from mg/day of study drug to mg/day of oral morphine 
4
Does not include hydrocodone in cough preparations.
 
 
Non-study opioids
1,2
 
Buprenorphine 
Butorphanol 
Codeine 
Dihydrocodeine 
Fentanyl 
Hydromorphone  
Levorphanol 
Meperidine 
Methadone 
Morphine 
Nalbuphine 
Oxycodone, parenteral 
Oxymorphone 
Pentazocine 
Propoxyphene 
Tapentadol 
1
Non-study drug could not be prescribed in the washout period and were censoring events 
when prescribed during follow-up  
2
Includes both short- and long-acting formulations when applicable. Formulations 
considered included oral, injection, transdermal, and other less common formulations 
(e.g., nasal, suppository). 
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Appendix 4.3: Operationalizing fracture hospitalizations 
Outcome
 
(PPV)
1
 Definition 
Fracture
 
composite endpoint (Includes all outcomes defined below) 
   Femur 
   (PPV: 87%)
127
 
 
Hospitalization with ICD-9 CM femoral fracture diagnosis 
(821.XX) 
   Hip 
   (PPV range: 86%-98%)
128
 
Hospitalization with hip fracture diagnosis (ICD-9 CM: 
820.XX) AND one of the following procedure codes during 
same hospitalization (ICD-9 CM: 78.55, 79.05, 79.15, 79.25, 
79.35, 79.65; CPT: 27230-27248). 
   Humerus 
   (PPV: 95%)
127
 
Hospitalization with ICD-9 CM humerus fracture diagnosis 
(812.XX) 
   Pelvis 
   (PPV: 93%)
127
 
 
Hospitalization with ICD-9 CM pelvic fracture diagnosis 
(808.XX). 
   Radius/ulna 
   (PPV: 96%)
127
 
Hospitalization with ICD-9 CM radius fracture diagnosis 
(813.XX). 
Abbreviation: PPV, positive predictive value 
1
The following studies guided our operationalization of fracture hospitalizations.
127–129
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Appendix 4.4: Crude and IPT-weighted baseline resident characteristics of nursing home residents in the 120 days 
before initiating oxycodone, hydrocodone, or tramadol (N=110,862 residents; 134,432 treatment episodes). 
 Crude (Unweighted)  IPT-weighted
1
 
Characteristic Oxycodone Hydrocodone Tramadol SMD
2
  Oxycodone Hydrocodone Tramadol SMD
2
 
Number of treatment episodes
3
 14,373 69,182 50,877 -  14,339.7 69101.0 50,915.9 - 
Demographics          
   Age in years, mean(SD) 83.7 (8.8) 84.3 (8.6) 85.5 (8.4) 0.13  84.7 (8.5) 84.7 (8.5) 84.7 (8.5) <0.01 
   Women, % 72.2 74.5 79.0 0.11  76.4 76.0 76.1 0.01 
   Race, %    0.08     0.03 
   Non-Hispanic white 81.0 83.5 84.5   85.3 84.1 83.9  
   Non-Hispanic black 12.9 11.2 11.3   10.4 11.2 11.3  
   Hispanic/Latino 4.5 3.3 3.0   2.8 3.2 3.2  
   Other 1.6 1.9 1.2   1.5 1.6 1.6  
Married, % 17.5 17.2 15.6 0.03  16.9 16.7 16.6 0.01 
Behavior, %          
   Rejects care 10.2 10.1 9.9 0.01  9.9 10.1 10.0 <0.01 
   Wandering 5.0 6.4 6.4 0.04  6.1 6.2 6.3 0.01 
Cognitive impairment,
4
 %    0.08     0.02 
   No impairment 32.4 28.3 29.5   30.2 29.4 29.4  
   Mildly impaired 23.7 23.6 24.0   24.6 23.8 23.8  
   Moderately impaired 33.6 38.1 37.2   36.2 37.1 37.1  
   Severely impaired 10.3 10.1 9.2   9.0 9.7 9.7  
Inattention, %    0.04     0.02 
   None 82.2 79,9 80.2   81.6 80.4 80.4  
   Intermittently present 10.0 11.0 11.2   10.5 10.9 10.9  
   Continuously present 7.8 9.0 8.6   8.0 8.7 8.7  
Disorganized thinking, %    0.04     0.02 
   None 83.5 81.5 81.6   82.4 81.8 81.9  
   Intermittently present 9.5 10.6 10.8   10.6 10.6 10.4  
   Continuously present 7.0 7.9 7.6   7.0 7.6 7.6  
Overall Physical functioning,
5
 %    0.10     0.01 
   No/minimal assistance 21.1 25.7 26.6   25.7 25.7 25.6  
   Requires extensive assistance 55.1 53.1 53.9   54.0 53.6 53.6  
   Physical dependence  23.8 21.2 19.5   20.3 20.7 20.8  
Physical functioning – transfers,%    0.11     0.02 
   Independent 11.5 13.5 14.5   14.1 13.7 13.7  
   Supervision required 8.5 9.6 10.1   9.3 9.7 9.7  
   Limited assistance required 14.1 15.1 15.7   15.6 15.3 15.3  
   Extensive assistance required 47.6 45.0 45.6   45.5 45.5 45.5  
   Total dependence 18.4 16.8 14.1   15.4 `15.8 15.9  
Physical functioning – locomotion on unit    0.08     0.02 
 
 
 
 
 
1
3
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   Independent 19.5 21.0 21.4   21.5 21.1 21.0  
   Supervision required 16.6 17.3 18.2   16.9 17.6 17.6  
   Limited assistance required 14.3 15.4 15.6   15.4 15.3 15.3  
   Extensive assistance required 26.8 26.1 26.2   26.8 26.3 26.2  
   Total dependence 22.8 20.2 18.6   19.4 19.7 19.9  
Physical functioning – locomotion off unit    0.10     0.03 
   Independent 14.8 16.9 16.8   17.4 16.8 16.6  
   Supervision required 14.1 15.7 16.1   14.5 15.7 15.7  
   Limited assistance required 12.1 13.7 13.6   13.7 13.5 13.5  
   Extensive assistance required 22.8 24.0 23.7   24.2 23.8 23.7  
   Total dependence 36.2 29.7 29.9   30.2 30.3 30.4  
Pain,
6 
%    0.06     0.02 
   No self-reported or staff-assessed pain 68.0 70.6 71.3   69.3 70.3 70.3  
   Any self-reported pain 28.1 25.3 25.4   27.0 26.0 26.0  
   Any staff-assessed pain 3.8 4.1 3.3   3.73.7 3.8 3.7  
Urinary incontinence, %    0.11     0.01 
   Always continent 21.8 22.2 24.0   22.9 22.9 22.9  
   Occasionally incontinent 15.1 17.0 18.2   17.3 17.3 17.3  
   Frequently incontinent 28.2 28.9 30.1   29.9 29.4 29.3  
   Always incontinent 35.0 31.9 27.7   29.8 30.5 30.6  
Bowel incontinence, %    0.09     0.02 
   Always continent 40.1 42.3 45.4   43.7 43.4 43.3  
   Occasionally incontinent 12.0 12.5 12.8   13.1 12.6 12.6  
   Frequently incontinent 18.1 17.2 17.6   17.7 17.4 17.4  
   Always incontinent 29.8 28.0 27.7   25.6 26.5 27.7  
Mobility devices normally used, %          
   Cane/walker 45.0 44.0 48.4 0.06  46.9 45.9 45.8 0.01 
   Wheelchair 79.4 75.6 73.9 0.09  76.6 75.3 75.2 0.02 
Oxygen use, % 9.4 9.2 8.4 0.02  9.5 9.0 9.0 0.01 
Unplanned weight loss, % 4.6 4.5 4.3 0.01  4.8 4.4 4.4 0.01 
Comorbidities, %          
   Dementia 56.2 59.6 60.6 0.06  58.1 59.4 59.5 0.02 
   History of falls 21.0 23.4 23.1 0.04  23.3 23.1 23.1 <0.01 
   Previous fracture 3.9 2.9 2.7 0.04  3.2 3.0 3.0 0.01 
   Parkinson’s disease 6.8 7.4 7.2 0.02  7.3 7.2 7.3 <0.01 
   Seizures / epilepsy 8.2 8.2 6.1 0.05  7.4 7.4 7.3 <0.01 
   Paralysis 10.8 9.8 8.1 0.06  9.5 9.2 9.3 0.01 
   Osteoporosis 18.5 18.5 19.6 0.02  18.8 18.9 19.0 <0.01 
   Arthritis 30.2 30.1 33.5 0.05  32.0 31.7 31.6 0.01 
 
 
 
 
 
1
3
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   Pressure ulcers 5.5 3.9 3.3 0.07  3.7 3.8 3.9 0.01 
   Hypertension 77.7 77.3 78.0 0.01  77.0 77.5 77.5 0.01 
   Congestive heart failure 21.5 21.0 20.7 0.01  21.4 21.0 21.0 0.01 
   Coronary artery disease 22.8 18.9 20.8 0.06  20.0 20.2 20.2 <0.01 
   Peripheral vascular disease 11.7 9.2 9.8 0.06  9.8 9.7 9.6 <0.01 
   Dysrhythmia 18.3 16.6 17.3 0.03  18.0 17.2 17.1 0.02 
   Stroke 17.6 17.6 16.7 0.02  17.6 17.2 17.2 0.01 
   Diabetes 35.0 34.5 31.5 0.05  33.4 33.4 33.5 <0.01 
   Hyperlipidemia 38.2 36.8 37.1 0.02  37.2 37.0 37.1 <0.01 
   Thyroid disorder 20.1 21.3 22.2 0.03  22.6 21.7 21.7 0.02 
   Renal insufficiency/renal failure/ESRD 10.3 8.9 8.9 0.03  9.2 9.1 9.1 <0.01 
   Asthma/COPD/chronic lung failure 20.9 19.6 19.2 0.03  20.4 19.7 19.8 0.01 
   Shortness of breath 10.0 10.2 9.7 0.01  10.5 10.1 10.2 0.01 
   Anxiety 25.7 28.0 27.5 0.03  28.4 27.8 27.7 0.01 
   Depression 57.2 56.6 55.2 0.03  56.8 56.4 56.3 0.01 
Number of medications prescribed, 
median (P25-P75) 
9 (7-13) 9 (7-13) 9 (6-12) 0.04  9 (7-13) 9 (6-13) 9 (6-13) 0.02 
Psychotropic medications, %           
   ≥2 psychotropic medications prescribed
7
 32.2 33.1 30.9 0.03  32.5 32.3 32.3 <0.01 
   Antipsychotics 25.1 26.7 25.8 0.02  25.5 26.2 26.2 0.01 
   Antidepressants          
SSRI 42.6 42.8 40.6 0.04  42.6 42.2 42.2 0.01 
SNRI 8.7 8.1 7.1 0.03  8.1 7.8 7.8 0.01 
Tricyclics 2.0 2.2 1.9 0.01  1.9 2.1 2.1 0.01 
Other 26.7 22.9 25.1 0.06  24.7 24.1 24.0 0.01 
   Anxiolytics
8
 20.1 21.3 19.6   21.0 20.7 20.6 0.01 
   Hypnotics
8
 5.6 5.7 5.1   6.0 5.5 5.5 0.01 
Pain adjuvant medications, %          
   Anticonvulsants 18.8 15.8 14.1 0.09  15.9 15.6 15.7 0.01 
   Systemic corticosteroids 8.7 7.7 7.9 0.02  8.2 7.9 7.9 0.01 
   Nonsteroidal anti-inflammatory drugs 11.7 11.9 13.1 0.03  12.3 12.4 12.7 0.01 
   Skeletal muscle relaxants 5.6 4.3 3.8 0.06  4.7 4.3 4.4 0.01 
Other medications associated with falls or 
fractures 
         
   Anticonvulsants (not used as adjuvants) 9.5 9.1 6.8 0.06  8.4 8.3 8.2 <0.01 
   Antimuscarinics (for urinary retention) 9.2 10.3 10.4 0.03  11.2 10.3 10.3 0.02 
   Cardiovascular medications          
   Alpha blockers 5.7 6.2 5.4 0.02  6.2 5.9 5.9 0.01 
   Antiarrhythmics 3.3 3.6 3.7 0.01  3.5 3.6 3.6 <0.01 
 
 
 
 
 
1
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   Anticoagulants 15.3 13.4 13.3 0.04  13.5 13.6 13.6 <0.01 
   Antiplatelets 10.4 11.0 10.7 0.01  11.0 10.9 10.9 <0.01 
   ACE inhibitors 5.5 6.7 6.3 0.03  6.2 6.4 6.4 <0.01 
   ARB 10.0 10.6 11.2 0.03  10.5 10.8 10.9 0.01 
   Beta blockers 45.3 40.4 42.1 0.07  42.5 41.7 41.6 0.01 
   Calcium channel blockers 28.4 27.4 28.7 0.02  28.2 28.0 28.0 <0.01 
   Digoxin 5.9 6.3 6.2 0.01  6.4 6.2 6.2 0.01 
   Loop diuretics 35.3 36.8 36.9 0.01  37.9 36.9 36.9 0.02 
   Potassium sparing diuretics 5.1 5.5 5.5 0.01  5.3 5.4 5.5 0.01 
   Thiazide diuretics 8.7 9.8 10.1 0.03  9.4 9.8 9.8 0.01 
   Statins 37.5 35.2 35.2 0.03  35.2 35.4 35.5 <0.01 
   Nitrate 10.2 10.2 10.0 0.01  10.5 10.2 10.2 0.01 
   Diabetic medications          
Insulin or other injected 
hypoglycemics 
20.6 20.1 16.9 0.06  19.4 18.9 19.0 0.01 
Sulfonylureas 8.0 8.9 8.7 0.02  8.4 8.8 8.8 0.01 
Other oral diabetic medications 11.4 12.2 11.6 0.02  11.3 11.9 12.0 0.01 
   Gastric medications          
       H2 antagonists 6.8 6.5 5.9 0.02  6.6 6.4 6.3 0.01 
       Proton pump inhibitors 29.7 31.7 30.5 0.03  32.5 31.2 31.2 0.02 
   Dementia medications          
      Memantine 13.6 18.1 18.1 0.08  16.9 17.6 17.6 0.01 
      Cholinesterase inhibitors 22.9 28.4 28.9 0.09  27.5 28.0 27.9 0.01 
   Osteoporosis medications 8.3 8.9 9.0 0.02  9.4 8.9 8.9 0.01 
   Parkinson’s medications 9.6 10.7 10.0 0.02  10.5 10.4 10.5 <0.01 
Abbreviations: ACE: Angiotensin converting enzyme inhibitors; ARB: Angiotensin II receptor blocker; COPD: congestive obstructive pulmonary disease; ESRD: end-
stage renal disease; P25-P75: 25th to 75th percentile; IPT: inverse probability of treatment; SD: standard deviation; SMD: standardized mean difference; SNRI: selective 
norepinephrine reuptake inhibitors; SSRI: selective serotonin reuptake inhibitor. 
1The mean of the stabilized IPT-weights was 1.00 (minimum: 0.16 , maximum: 8.65) 
2SMDs were summarized by averaging the pairwise differences between treatment groups. See Appendix 4.6 for further detail on pairwise SMDs before and after IPT-
weighting. 
3110,862 residents contributed 134,432 treatment initiation episodes (17.0% of residents contributed >1 treatment episodes [range: 2-6]). Treatment switching was 
uncommon: 2.4% and 0.01% of residents initiated 2 or 3 different treatments, respectively.   
4Cognive impairment was defined using the Cognitive Function Scale (CFS; range 0-3):134 cognitively intact (0), mild impairment (1), moderate impairment (2), and 
severe impairment. 
5Physical limitations were defined using the Activities of Daily Living Self-Performance Hierarchy (range: 0-6):90 no/mild limitations (0-2), extensive limitations (3-4), 
and physical dependence (5-6). 
6Resident pain in the five days preceding the most recent Minimum Data Set (MDS) assessment before treatment initiation was based on self-report when the resident 
was able to and staff assessment otherwise. 
7Based on antipsychotics, antidepressants, anxiolytics, and hypnotics 
 
 
 
 
 
1
3
3
 
8Anxiolytics and hypnotics were measured in the seven days before the most recent MDS assessment because benzodiazepines were not covered by Part D in 2011-
2012. 
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Appendix 4.5: Distributions of propensity scorers for each study drug before and 
after inverse probability of treatment weighting. 
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Appendix. 4.6: Overall and pairwise standardized mean differences of baseline 
resident characteristics before and after inverse probability of treatment weighting. 
 
Overall: 
  
 
 
 
 
 
1
3
6
 
Pairwise: 
Oxycodone and Hydrocodone Tramadol and Hydrocodone Oxycodone and Tramadol
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Appendix 4.7: Bias analysis for unmeasured confounder 
 
 
The minimum strength an unmeasured confounder would have to be on the risk 
ratio scale to attenuate the observed association of tramadol and fracture 
hospitalizations (subdistribution hazard ratio=0.67 in primary as-treated analysis) 
to 1.0. Note: an unmeasured confounder with a risk ratio of 1.81 could move the 
upper 95% confidence interval of 0.80 to 1.0. 
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The minimum strength an unmeasured confounder would have to be to attenuate 
the observed association of tramadol and fracture hospitalizations (subdistribution 
hazards ratio=1.08 in primary as-treated analysis) to 1.0. Note: lower confidence 
interval crosses one in primary analysis. 
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